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(i) 
ABSTRACT 
The formarnidine, amitraz, is used as an acaricide wash for dogs and side 
effects, although rare, have been reported. These include CNS depression, 
ataxia, vomiting and, in more severe cases, hypothermia, bradycardia, hyper­
ventilation and tachycardia. 
The unexplained side effects, particularly the unusual biphasic heart rate 
responses, prompted this pharmacological study of the actions of amitraz on 
the cardiovascular and respiratory systems. Methods for reversal of the 
toxic effects of amitraz may emerge from these studies. 
Studies were made using mongrel dogs anaesthetised with thiopentone and 
methoxyflurane. Initial investigations showed that IV amitraz (1, 2 and 5 
mg kg-
1) increased mean arterial pressure, lowered heart rate and depressed
tidal volume. Respiratory rate, tidal volume and respiratory minute volume 
were all markedly depressed immediately after injection but respiratory 
rate then showed a dose-related increase and minute volume showed little 
change from the control. Bradycardia was less after higher doses. 
Cumulative doses of IV arnitraz were given after cardiovascular antagonists. 
Phentolamine antagonised the amitraz-induced hypertension, the effects of 
atropine and hexamethonium suggested that initial bradycardia was a reflex 
response and propranolol had no obvious effect on arnitraz responses. The 
rise in blood pressure elicited by amitraz appeared to follow peripheral 
a-adrenoceptor stimulation. A peripheral vascular effect was supported by
the concurrent dose-related rise in total peripheral resistance and blood 
pressure. Cardiac output remained unchanged 5 minutes after injection 
following an immediate transient fall. 
Blood pressure responses to tyrarnine were increased by amitraz but a possible 
(ii) 
indirect sympathomirnetic effect is unlikely since desipramine failed to alter 
amitraz responses. The effects of acetylcholine and DMPP on mean arterial 
pressure were depressed by amitraz; the reduced DMPP response was attributed 
to a
2
-adrenoceptor stimulation. Responses to noradrenaline, isoprenaline and 
histamine remained unchanged. 
Blood pressure and heart rate responses to bilateral carotid artery occlusion 
-1 were depressed by amitraz (threshold doses 2 µg kg intracisternally [ICM]
-1 and 60 µg kg IV), an effect antagonised by ICM yohimbine but not ICM
prazosin. The baroreceptor-heart rate reflex was enhanced by 75 and 275
-1 -1 µg kg of amitraz IV but inhibited by 0.5, 2 and 5 mg kg , effects
attributed to a2 - and a1-adrenoceptor stimulation, respectively.
-1 Blood· pressure and heart rate were lowered by 0.5 µg kg of amitraz ICM and
between 40 and 60 µg kg-l IV. ICM yohimbine antagonised the hypotensive
effects while ICM yohimbine and ICM prazosin, in separate experiments, each
partly inhibited the bradycardia. Amitraz stimulated both a1- and a2 -
adrenoceptors in the peripheral vasculature. 
The a2-adrenoceptor agonist action of amitraz was confirmed using rat 
isolated vas deferens preparations. 
Ami traz has been shown to be an a2 --adrenoceptor agonist with some action at 
the a1-subtype. Its central effects are hypotension, bradycardia and inter­
ference with cardiovascular reflexes while its peripheral actions increase 
blood pressure and produce a transient reflex bradycardia. 
(iii) 
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The formamidines are a relatively new group of compounds that share a common 
structural nucleus (Figure 1.1). Two important formamidine compounds are 
available commercially and they are, chlordimeform, which is used as an 
agricultural spray to control mites on crops and fruit trees, and amitraz, 
which is used to treat ticks on cattle and mites on pigs and dogs. Two 
breakdown products from chlordimeform and one from amitraz also have the 
formamidine structure and it is these five formamidine compounds which have 
real importance for agricultural and veterinary use. However, several other 
formamidines and related compounds with similar properties to chlordimeform 
and amitraz, including insecticidal actions, do exist (Aziz and Knowles, 
1973; Knowles and Roulston, 1973; Robinson, 1979; Johnson and Knowles, 1982). 
The formamidines are unlike other pesticides structurally (Hollingworth and 
Yim, 1980) and their action is novel and varied. A few reports have recently 
appeared about the metabolism and mechanisms of action of both chlordimeform 




Chlordimeform, a lipid soluble compound, (N -[4-chloro-o-tolyl]N, 
N-dimethylformamidine, Figure 1.1) has acaricidal, larvacidal and ovicidal
properties and is effective against some mites that are resistant to other 
pesticides (Abo�Khatwa and Hollingworth, 1973). 
Figure 1.1 Molecular structure for the formamidine nucleus, 








Actions of Chlordimeform in Animals 
When chlordimeform was given to rats and mice at doses between 50 and 200 
-1 mg kg IP, periods of sedation were seen after low doses and marked
excitement and muscle tremors after higher doses. The duration of the
excitement was dose related (Beeman and Matsumura, 1973; Matsumura and Beeman,
1976). These investigations also showed that chlordimeform elevated
5-hydroxytryptamine and noradrenaline levels, inhibited the enzyme monoamine
oxidase (MAO) and established that a cholinomimetic effect was unlikely.
Similar behavioural changes were noted in rats given chlordimeform at doses 
-1 from 1 to 200 mg kg IP by Hollingworth and Yim (1980) but they were unable
to reproduce the same hyperactivity by injections of 5-hydroxytryptamine
into the lateral ventricles of the brain. Furthermore, pretreatment with
either cinanserin or methysergide, specific antagonists of 5-hydroxytryptamine,
did not prevent · changes . ; due to the formamidine and, therefore, the
authors questioned whether excitement was caused by serotonin release.
-1 Doses of chlordimeform from 1-30 mg kg IV administered to dogs and cats 
anaesthet�sed with pentobarbitone caused an initial depression of blood 
pressure, heart rate and cardiac contractility followed shortly after by a 
rise in all three variables (Lund et al, 1978; Hollingworth and Yim, 1980). 
In addition, the changes in blood pressure paralleled the discharge 
frequency of cervical sympathetic nerves. Propranolol and hexamethonium 
blocked the increase in cardiac contractility while phentolamine and 
hexamethonium blocked the hypertension. These cardiovascular responses, 
which were blocked by hexamethonium, suggested that chlordimeform had a 
sympathetic action, either direct or reflex. 
In rabbits, 200 mg kg-l of chlordimeform IV caused a fall in blood pressure 
of up to 50% (Matsumura and Beeman, 1976). 
Injections of chlordimeform into the femoral artery of dogs resulted in a 
4. 
non-specific relaxation of vascular smooth muscle and was not dependant on 
the blockade of cholinergic, histaminergic, S-adrenergic or a-adrenergic 
receptors. Consequently the vasodilation was considered to be a local 
anaesthetic - like action (Lund et al, 1978; Hollingworth and Yim, 1980). 
Respiratory function was depressed in animals given chlordimeform but deaths 
resulted from depression of cardiac function and the loss of vascular tone 
(Lund et al, 1978; Hollingworth and Yim, 1980). 
Lund et al (1980) noted that lightly anaesthetised dogs hyperventilated, 
showed muscle tremors and convulsed during the transition from the depressor 
to the pressor stage. 
Metabolism 
Using mouse liver homogenates Hollingworth and Yim (1980) found that 
chlordimeform is broken down by mixed function oxidases in the microsomes. 
Initially, a methyl group is removed from the terminal nitrogen atom to form 
demethylchlordimeform and this is followed by removal of the other methyl 
group to form didemethylchlordimeform. Although other compounds are formed 
in the breakdown process it is only the parent compound and its first two 
metabolites that have the formamidine nucleus and possess toxic actions. 
Microsomes from the lung and brain showed no activity in degrading 
chlordimeform. 
Dogs, goats and rats given oral doses of chlordimeform labelled with 
14
c
showed that in excess of 85% of the radioactive material was excreted in the 
urine as free compounds and conjugates while less than 5% was excreted in 
the bile (Sen Gupta and Knowles, 1970). 
The compounds chlordimeform, demethylchlordimeform and didemethylchlordime­
form had an increasing order of toxicity following oral administration to 
mice however, chlordimeform had the longest survival time. Hollingworth and 
5. 
Yim (1980) stated that all three compounds can activate a-adrenoceptors and 
octopamine receptors but they have different potencies. Demethylchlordime­
form was most potent and chlordimeform least potent in stimulating octopamine 
receptors in invertebrates. Demethylchlordimeform had a more powerful 
contractile effect on the central ear artery of the rabbit than the parent 
compound and this action was blocked by phentolamine (Robinson and Bittle, 
1979). 
Specific Actions of Chlordimeform and its Metabolites 
Chlordimeform has important uses in agriculture and an understanding of the 
mechanisms underlying their toxic actions is appropriate. A number of 
aspects have been studied. 
(i) Monoamine Oxidase Inhibition Chlordimeform and demethylchlordimeform
inhibit MAO activity in rat liver (Aziz and Knowles, 1973; Matsumura and 
Beeman
., 
1976; Rieger et al, 1980; Bailey et al, 1982), rat brain (Benezet 
and Knowles
., 
1976; Benezet and Knowles, 1980; Rieger et al, 1980; Bailey et 
al, 1982; Johnson and Knowles, 1983), rat lung (Rieger et al, 1980), mouse 
liver, brain and small intestine (Hollingworth and Yim, 1980) and in ticks 
(Atkinson et al, 1974). Demethylchlordimeform was a more potent inhibitor 
of the enzyme than chlordimeform (Aziz and Knowles, 1973; Atkinson et al, 
1974) although, Hollingworth and Yim (1980), who also compared didemethyl­
chlordimeform with the other two compounds, found that all three compounds 
had a similar potency in the mouse liver, brain and small intestine. 
Mitochrondrial MAO exists in several forms characterised by the responses to 
inhibitors and activation at different temperatures and by different sub­
strates. The inhibiting effect of formamidines on two types of MAO has been 
investigated, type A where 5-hydroxytryptamine, octopamine and noradrenaline 
are preferred substrates and type B where S-phenylethylamine and benzylamine 
are the preferred substrates. Bailey et al (1982) found that type B MAO was 
most likely inhibited in rats which had received chlordimeform orally and 
6. 
Hollingworth and Yim (1980) found that although selectivity was low, type A 
MAO was most likely inhibited in mice. Levels of type A and type B MAO vary 
between species and tissues within species. Benezet and Knowles (1980) found 
that the formamidines were not selective inhibitors of MAO in rat brain in 
vitro. Although Matsumura and Beeman {1976) reported that chlordimeform 
inhibited MAO in rat liver in vitro, they concluded that the innnediate onset 
of hyperactivity and irritability in vivo could not be attributed to an 
effect on the enzyme, rather it could be due to a direct action on amine 
receptors. 
Chlordimeform given subcutaneously to rats caused hyperexcitement which may 
be due to altered brain amine levels because plasma levels of noradrenaline, 
5-hydroxytryptamine, tyramine and S-phenethylamine were all reduced
(Johnson and Knowles, 1983). 
-1
Intraperitoneal injections of 200 mg kg of 
chlordimeform produced an increase in 5-hydroxytryptamine and, to a lesser 
extent, noradrenaline in the brain of rats (Matsumura and Beeman, 1976). 
Hollingworth and Yim (1980) also noted a rapid onset of excitement, tremors 
and convulsions in mice given chlordimeform and its metabolites. Because one 
of the metabolites, N-formyl-4-chloro-o-toluidine, was a more potent inhibitor 
of MAO and is not considered to be toxic, these authors believed that 
enzyme inhibition is not the primary lethal factor of chlordimeform, an 
opinion also shared by Atkinson et al (1974) and Benezet and Knowles (1976). 
Chlordimeform, demethylchlordimeform and didemethylchlordimeform, in 
increasing order, were shown to inhibit the uptake of 5-hydroxytryptamine by 
rat platelets and to stimulate the release of the amine (Johnson and Knowles, 
1982). The study was performed in an attempt to find a mechanism of action 
of the formamidines on serotonergic presynaptic neurones. By comparison 
with other inhibitors of 5-hydroxytryptamine, these authors considered that 
the formamidines had an intracellular action perhaps at the site of vesicle 
storage. 
7. 
(ii) Octopamine Receptor Stimulation Octopamine is a naturally occurring 
biogenic amine found in nervous tissue of many invertebrates and in 
sympathetic nerve terminals and central nervous tissue of mammals including 
man. The possible role of octopamine as a synaptic transmitter has been 
reviewed recently (Hicks, 1977). Octopamine is synthesised from tyrosine 
(Figure 1.2) in neurones where it is then stored in vesicles. Brain 
phenolamines, tyramine and octopamine, accumulated in neurones in nanogram 
quantities whereas dopamine and noradrenaline are usually present in micro­
gram quantities. 
Breakdown of octopamine is by deamination to glycols. Conversion of 
octopamine to noradrenaline has been shown in rat brain in vitro but there is 
some doubt as to its fate in man. 
Specific receptors for octopamine have been found in invertebrates but in 
mammals there is no clear cut evidence. Hicks (1977) has reported strong 
excitatory actions to octopamine in areas of the rat central nervous system 
and Hicks and McLennan (1978) have reported that specific receptors in 
neurones of the cerebral cortex of the rat, distinct from noradrenaline and 
dopamine receptors, responded to octopamine application. Stimulation of 
octopamine receptors leads to activation of the enzyme adenylate cyclase to 
produce cylic 3', 5'- adenosine mortophosphate which mediates the responses. 
Phentolamine antagonises the stimulatory response to octopamine but not that 
to serotonin or dopamine in the mollusc (Dougan and Wade, 1978). These 
authors later (Dougan and Wade, 1981) reported that octopamine receptors in 
invertebrates probably have different pharmacological specificity to those in 
the rat brain and spinal cord. 
In animals, MAO inhibitors allow octopamine to accumulate in significant 
amounts in sympathetic nerve endings. By this mechanism octopamine has some­
times been called a false transmitter� Low concentrations of octopamine are 
Figure 1.2 Pathways for octopamine synthesis. 
8. 
Phenylalanine. 
Tyrosine Tyramine Octopamine 
DOPA ------------> Dopamine --------> Noradrenaline
Heavy arrows show major pathways. 
normally found in mammalian nervous tissue and questions do arise as to its 
regulatory function, however, much care is required to separate octopamine 
responses in the sympathetic nervous system from those of noradrenaline which 
is considered to be the major neurotransmitter. 
Both chlordimeform and demethylchlordimeform have been shown to mimic the 
action of octopamine in the locust (Evans and Gee, 1980; Orchard et al, 1982), 
the American cockroach nerve cord (Gale et al, 1983) and the light organ of 
the firefly (Hollingworth and Murdoch, 1980). Investigations showed that 
these formamidines increased the levels of the enzyme adenylate cyclase in 
the cockroach and firefly while Orchard et al (1982) showed that cyclic 
adenosine monophosphate was increased in the locust. Demethylchlordimeform 
was a more potent agonist at octopamine receptors than chlordimeform. 
Most of these studies showed that phentolamine and not propranolol blocked 
the action of the formamidines (Evans and Gee, 1980; Hollingworth and Murdoch, 
1980; Gale et al, 1983) while Dougan and Wade (1978) and Orchard et al (1982) 
also demonstrated antagonism by phentolamine. Cyproheptadine was also shown 
to block the responses mediated by chlordimeform and octopamine (Hollingworth 
and Murdoch, 1980; Gale et al, 1983). 
(iii) Oxidative Phosphorylation Chlordimeform uncouples oxidative 
phosphorylation in rat liver mitochrondria in vitro; the site of action and 
the potency was similar with 2, 4- dinitrophenol, a well known uncoupler 
(Abo-Khatwa and Hollingworth, 1973). In addition to its uncoupling ability, 
chlordimeform also increases mitochrondrial adenosine triphosphate breakdown 
(Abo-Khatwa and Hollingworth, 1972). 
(iv) Local Anaesthetic-Like Action Chlordimeform given at a dose of 1 to 
-1
30 mg kg IV to dogs anaesthetised with pentobarbitone caused an immediate
and transient fall in both blood pressure and cardiac contractility followed
by an increase above pretreatment levels. Within an hour the variables had
10. 
returned to control levels (Lund et al, 1978). These changes were similar 
to those produced by lignocaine. 
The similarity between the chemical structure of chlordimeform and the local 
anaesthetic drugs phenacaine and guanicaine has been noted (Pfister et al, 
1978a). These authors used frog sciatic nerve preparations in which 
chlordimeform and demethylchlordimeform reduced the amplitude and conduction 
velocity of electrically induced action potentials while threshold voltages 
and refractory periods were increased; all changes that were seen with 
lignocaine, procaine and holocaine. 
The toxic signs seen with chlordimeform (100 mg kg-l IP) in mice were similar 
to those for lignocaine: clonic convulsions, respiratory depression, cardio­
vascular collapse and death. The death rate in these mice was reduced by both 
diazepam and pentobarbitone but only pentobarbitone reduced the incidence of 
convulsions. As both of these drugs reduce the incidence of convulsions 
seen with lignocaine toxicity, chlordimeform may have additional excitatory 
actions not shared by local anaesthetics. 
(v) Central Actions Injections of 3 to 4 mg of either lignocaine or
chlordimeform into the cerebral ventricles of different groups of rats
resulted in clonic limb movements, increased electrical activity of the
amygdala, blood pressure oscillations and seizure-like activity. Diazepam 
-1at a dose of 1 mg kg IV antagonised the seizures by both compounds (Chinn
et al, 1977), a finding different from that made by Pfister et al (1978a)
where 15 to 30 mg diazepam IP failed to prevent seizures in mice given 100
mg kg-l of chlordimeform IP. It is difficult to make a comparison between
these experiments since the doses of drugs and the routes of administration
differ.
The hypertension following initial hypotension after chlordimeform 
administration and the antagonism of the hypertension by hexamethonium 
11 . 
suggests a central sympathomimetic action (Lund et al, 1978; Hollingworth and 
Yim, 1980). 
(vi) Prostaglandin Synthesis Chlordimeform had antipyretic and anti-
inflammatory properties in rats and inhibition of prostaglandin E 2 
synthesis from arachidonic acid was demonstrated. These properties were
similar to those of aspirin (Yim et al, 1978).
(vii) Muscle Fibre Chlordimeform, applied to frog nerve-muscle preparations
in vitro, produced a reduction in the sensitivity of the end-plate membrane
to acetylcholine primarily and an inhibition of the depolarisation­
contraction process of muscle (Wang et al, 1975). Watanabe et al (1975) also
found that this formamidine depressed the excitability of muscle cell membrane
without interfering with the sarcoplasmic reticulum or the contractile
protein.
(viii) Appetite Stimulant Low doses of chlordimeform (6 to 20 mg kg-l
IP) increased food intake in rats while doses in excess of 60 mg kg-l
produced anorexia (Pfister and Yim, 1977; Pfister et al, 1978b).
Chlordimeform and its two active metabolites have been shown to share 
similar properties and a number of studies have been performed to determine 
their mechanisms of action. A few aspects have been studied in some detail, 
namely the inhibition of MAO, uncoupling of oxidative phosphorylation, 
blockade of neuromuscular transmission and activation of octopamine 
receptors. Despite these studies no individual action has been shown con­




The other commercially important formamidine is amitraz [N-methyl-N1-2, 
12. 
4-xylyl-N-(N-2� 4-xylylformimidyl) formamidine, also known as (1,5-di
(2, 4-dimethylphenyl) -3- methyl-1, 3, 5-triazapenta-1, 4-diene), Figure 
1.1], a compound that is structurally related to chlordimeform. 
Amitraz has been used to control rust mites, European red mites and psylla 
in orchards (Muller, 1983). 
The veterinary use of amitraz, its most important, is the treatment of 
sarcoptic and demodectic mange in dogs (Folz et al, 1978; Bussieras, 1979; 
Farmer and Seawright, 1980; Harrison and Palmer, 1981; Muller, 1983; 
Seawright, 1982; Folz, 1983; Folz et al, 1984; Kwochka et al, 1985), ticks 
on cattle, sheep and goats and mange in pigs (Harrison and Palmer, 1982). 
This formamidine is formulated as an emulsifiable concentrate or a wettable 
powder which is then diluted with water to make a concentration of 0.025% 
to 0.05% (W/V) suitable for use on animals. Commercially, amitraz was re­
leased in Australia as "Taktic" (F and B Chemicals, Eastwood, N.S.W.) in 
1975 for the control of the cattle tick, Boophilus microplus,and as "Ectodex" 
(F and B Chemicals, Eastwood, N.S.W.) in 1980 for use in dogs. The compound 
was also shown to be toxic to B. microplus eggs and larvae on grazing pasture 
(Harrison and Palmer, 1981). "Taktic" is also available for treating sar­
coptic mange in pigs. 
When used at the recommended concentrations of 0.025 to 0.05% amitraz did not 
show any side effects in dogs (Bussieras, 1979; Farmer and Seawright, 1980). 
Similarly, Folz et al (1978) reported the absence of side effects when 
concentrations of up to 0.2% were used, but only four dogs were treated with 
each of 0.1 and 0.2% solutions. 
It is recommended that calcium hydroxide be added to amitraz in cattle dips 
to make the solution alkaline (pH 11 to 12) for better stability of the 
compound and to control bacterial growth. 
13. 
One extensive study has investigated tissue levels of amitraz and its 
metabolites in cattle. Tissue levels of amitraz and its metabolites were 
-1 less than 0.02 mg kg in steers slaughtered 24 to 48 hours post dipping and
-1 6 hourly milk samples from dipped cows had less than 0.01 mg kg . However,
butterfat samples from cows 6 hours post dipping contained a maximum residue 
of 0.17 mg kg-l of the formamidines. Only the butterfat residues exceeded 
-1the recommended minimum residue level of 0.1 mg kg (McDougall et al, 1979).
Side Effects of Amitraz in Animals 
Despite reports of the absence of side effects in animals following the use 
of amitraz, there are others which describe complications. Although a 0.05% 
solution of amitraz was safe in dogs, Bussieras (1979) reported signs of 
depression, anorexia and vomiting lasting 12 to 36 hours in some animals that 
were washed in a 0.1% solution. Similar signs were also seen in 20 out of 
245 dogs washed.in a 0.05% solution of amitraz (Muller, 1982) while in 
another survey of 1721 animals, 158 dogs became sedated and pruritic (Folz 
et al, 1984). Chihuahuas, one of the small breeds of dog, have died after a 
single wash in 0.05% amitraz (Gunaratnam et al, 1983). 
In another study 4 dogs in each of two groups of 9 animals (one group was 
washed in a 0.03% and the other in a 0.06% solution of amitraz) showed 
general depression, polyuria, polydipsia and ataxia. One dog that was washed 
in the 0.06% solution died soon after washing, however, the exact cause of 
death was not established (Kwochka et al, 1985). 
-1The acute oral LD,5 0 for amitraz in dogs is 100 mg kg The clinical signs 
of dogs poisoned by amitraz are central nervous system depression, ataxia, 
hypothermia and bradycardia, signs that usually last 48 to 72 hours. Severe 
intoxication resulted in intermittent hyperexcitability, hyperventilation, 
tachycardia, tongue protrusion and mydriasis (Seawright, 1982). 
The side effects following amitraz dipping of cattle are mild transient 
14. 
tranquillisation in young calves (Seawright, 1982). 
Horses washed with amitraz have shown incoordination, depression and reduced 
or absent intestinal sounds. In some animals, the intestinal atony has 
resulted in impaction of the large intestine, which later ruptured causing 
peritonitis and death (Roberts and Seawright, 1979; Seawright, 1982; Roberts 
and Seawright, 1983; Auer et al, 1984). 
Cats are more susceptible to amitraz toxicity than dogs. Cats washed in 
0.0125, 0.025 and 0.05% solutions of amitraz showed signs of transient 
anorexia, diarrhoea and sedation, the severity and duration of the signs were 
proportional to the concentration of the wash. Substantial oral ingestion 
combined with some percutaneous absorption gave higher blood levels in the 
catsthan the dogs (Gunaratnam et al, 1983). 
In toxicity studies using rats one group received amitraz orally at a dose of 
-1
600 mg kg . A second group received amitraz, 20% in 75% xylene, orally
-1
(the commercial product for dogs) at a dose of 1700 to 2050 mg kg of
product, the oral 1D 80 in females and males respectively. The amitraz/
xylene-dosed rats showed signs of tranquillisation, some episodes of increased
activity, hypothermia and general debilitation earlier than the rats that
received only amitraz. These side effects lasted up to eight days. Some
animals were treated with diuretics, urinary acidifiers, phentolamine,
nikethamide and an increase in body temperature. None of these treatments
consistently altered the duration of side effects or the mortality (Turnbull,
1983).
Low doses of amitraz in rats caused hyperactivity and aggression while 
higher doses caused depression, tranquillisation, bradycardia, respiratory 
depression and hypothermia. Death was thought to be due to respiratory 
depression. Other signs including hypotension, hyperglycaemia and 
haemoconcentration, probably due to reduced water intake, have been noted. 
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The variation in the responses seen is likely to be due to the dose of 
amitraz and the species receiving it (Bonsall and Turnbull, 1983). Similar 
signs were also seen in mice when the LD.50 of BTS 27271, the major 
metabolite of amitraz, was given subcutaneously (Ravikumar and Rieger, 1983). 
Four cases have been reported of humans either ingesting or coming into 
contact with amitraz (Bonsall and Turnbull, 1983) but exact details of the 
effects of the formamidine were either unavailable or were masked by the 
presence of other pathological problems. 
Contraindications for Amitraz Because of undesirable side effects and 
fatalities amitraz is not recommended for use in horses, cats or 
Chihuahua dogs. 
Metabolism 
Amitraz is broken down by rats (Knowles and Benezet, 1981), B. microplus 
larvae (Schunter and Thompson, 1978), corn-borer (Knowles and Gayen, 1983) 
and bacteria (Baker and Woods, 1977; Allcock et al, 1978). 
In rats dosed with either amitraz or BTS 27271 labelled with 14c, both
compounds were broken down to a number of identifiable (Figures 1.3 and 
1.4) and several unknown substances of which only amitraz and BTS 27271 had 
the formamidine nucleus. Levels of radioactivity were measured in various 
tissues and were highest in the liver. Elimination of amitraz and BTS 27271 
was mainly by urinary excretion (77.6% and 88.7% respectively) with a small 
14 
amount excreted in faeces (8.9% and 4.1% respectively). Peak levels of C 
were found in the urine at an earlier stage for amitraz than for BTS 27271. 
Experiments with tick larvae exposed to radiolabelled amitraz showed that 
BTS 27271 was rapidly formed due to cleavage of the parent compound, however, 
these arthropods could not breakdown BTS 27271, instead, small quantities of 
compounds III and IV and several unknowns were formed, probably from the 







Compound II (BTS 27271) 
N
1
- 2, 4 - dimethylphenyl
N - methylformamidine 
Compound III 
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2, 4 - dimethylaniline 
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4 - formamino - 3 _ 
methylbenzoic acid 
Compound VI 
4 - amino - 3 - methylbenzoic 
acid 
Figure 1.4 Metabolism of amitraz in the rat. 
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cleavage product of amitraz. Only amitraz and BTS 27271 are toxic to tick 
larvae (Schunter and Thompson, 1978). These authors suggested that in ticks 
the formation of BTS 27271 may be non-enzymatic. 
Breakdown products of amitraz found in the corn-borer were BTS 27271, 
compounds III, IV, V, VI and 2-amino-5-methylbenzoic acid, a metabolite not 
previously reported (Knowles and Gayen, 1983). 
Bacteria also degraded amitraz but compound IV was thought to be the first 
breakdown product (Allcock et al, 1978). 
Evidence suggests that breakdown of amitraz to BTS 27271 may be by hydrolysis. 
In an acid environment, particularly the stomach following ingestion of 
amitraz, high levels of BTS 27271 are found (Seawright, 1982). The liver is 
the main site of amitraz and chlordimeform metabolism and breakdown products 
are excreted principally in the urine. Only those compounds in this series 
with the formamidine nucleus are toxic to mammals and insects, the other 
metabolites are considered harmless (Seawright, 1982). 
At high doses both amitraz and chlordimeform were considered to be carcinogenic 
in mice (Hollingworth and Yim, 1980). 
Specific Actions of Amitraz and Metabolites 
(i) Monoamine Oxidase Inhibition Like chlordimeform, amitraz and BTS 27271 
have been shown to inhibit MAO in rat liver (Aziz and Knowles, 1973; Rieger 
et al, 1980), rat brain (Benezet and Knowles, 1976; Rieger et al, 1980), rat 




Amitraz was a more potent inhibitor of the enzyme than BTS 27271, chlordime­
form or demethylchlordimeform (Aziz and Knowles, 1973; Atkinson et al, 1974) 
although Rieger et al (1980) commented that amitraz had only a weak action. 
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Levels of (Iso M) inhibition of rat liver MAO were chlordimeform, 1.4 x 10
-S;
-6 -5 demethylchlordimeform, 4.7 x 10 ; BTS 27271, 2.7 x 10 and amitraz,
-7 6.6 x 10 (Aziz and Knowles, 1973).
(ii) Small Intestine In Vitro and In Vivo Following the report of stasis
of the large intestine in horses and death in some of these animals after 
amitraz (Roberts and Seawright, 1979), its action was investigated using 
pig ileum in vitro (Pass and Seawright, 1982). When in contact with ileum for 
several minutes amitraz produced weak contractions but more importantly, it 
had antihistamine actions, inhibiting those contractions caused by histamine 
itself and other histamine H 1 agonists. There was no effect on contractions 
produced by acetylcholine or metacholine but there was a slight increase in 
the contractions produced by DMPP. The histamine H1 antagonist actions were 
suggested as being relevant to the mechanisms producing intestinal stasis in 
horses. 
A single dose of -1amitraz (1 mg kg IV) in ponies caused general depression, 
ataxia and penile relaxation (Sellars et al, 1982). Atony and dissociation 
of the pressure waves, measured by monometer, were present for up to 24 hours 
in the caecum and the pelvic flexure area of the colon. Dissociated 
electrical activity occurred in sections of the colon taken from animals 24 
hours after amitraz treatment and studied in vitro (Sellars et al, 1982). 
The neurotransmitter, substance P, is found in the nerve fibres and nerve cell 
bodies of the wall of the equine large colon. In an immunocytochemical study 
amitraz was shown not to have any substance P-like activity (Cummings et al, 
1984) however, in a subsequent study, 0.2 mg kg-l of yohimbine given into the
ileo-colic artery of two ponies, prevented the dissociation in the pressure 
waves in the large colon, paralytic ileus and reduction in blood flow seen 
-1after intra-arterial injections of 0.1 mg kg of amitraz (Sellars et al,
1985). The authors inferred from these results that amitraz stimulated
a2-adrenoceptors.
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In comparison, chlordimeform was shown to inhibit the twitch response to 
electrical stimulation of guinea pig ileum in vitro but this compound was 
also shown to have local anaesthetic-like properties (Hollingworth and Yim, 
1980). 
(iii) a-Adrenoceptor Agonist Properties Contraction of the rabbit central
ear artery in vitro by BTS 27271 was antagonised by phentolamine suggesting
that a-adrenoceptor stimulation was the mechanism of action (Robinson, 1979).
It was shown that a potent MAO inhibitor, iproniazid, did not cause con­
tractions of the artery strips and BTS 27271 did not alter the resting rate
of radioactive efflux from noradrenaline-loaded artery strips. The author
concluded that transmitter build-up from MAO inhibitory properties and
altered noradrenaline release were unlikely causes of arterial contraction in
the presence of BTS 27271. Contractile responses produced by noradrenaline,
histamine, serotonin and high doses of potassium salts were reduced by
-3BTS 27271 (concentration 10 M) and all actions were reversible, indicating
a transient effect.
Hsu and Kakuk (1984) showed that IV arnitraz produced bradycardia and mydriasis 
-1 -1 in rats at doses of 30 :µg kg and 100 :µg kg respectively. Both clonidine
and xylazine also produced similar responses but chlordimeform at doses from
0.03 to 10 mg kg-l IV did not cause either effect. Pretreatment with either
yohimbine or phentolarnine prevented any response to arnitraz, clonidine or
xylazine whereas prazosin had no inhibitory effect. 




Rats pretreated with reserpine and a-methyl-p-tyrosine to deplete endogenous 
monoarnines responded to arnitra:z with mydriasis but no further change in heart 
rate was found. These results suggest that postsynaptic a 2-adrenoceptors 
are activated to produce mydriasis while presynaptic a 2-adrenoceptors are 
responsible for the bradycardia (Hsu and Kakuk, 1984). Further evidence of 
the a 2-adrenoceptor activity of arnitraz was later provided when yohimbine, 
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piperoxan and tolazoline blocked the dose-dependant delay of gastrointestinal
transit in conscious mice. Additional studies using other specific 
antagonists indicated that amitraz did not have a1 or S-adrenergic,
dopaminergic, serotonergic, histaminergic, cholinergic, GABAergic or opioid 
activity at the doses studied (Hsu and Lu, 1984). 
(iv) Muscle Activity Mice given the LDso of BTS 27271 (107 mg kg-l SC)
showed signs of abnormal gait, hindlimb extension, transient hyperactivity 
followed by hypoactivity, ataxia, dyspnoea, cyanosis, convulsions and death. 
-1Lower doses of 1, 5, 10 and 20 mg kg SC impaired the ability of mice to
ride a rotating rod. In the rat phrenic nerve-hemidiaphragm preparations
where the nerve and the muscle were electrically stimulated independantly, 
-4 BTS 27271 (at 4 to 8 x 10 M) was shown to reduce the evoked responses to both
forms of stimulation (Ravikumar and Rieger, 1983). It was concluded that 
BTS 27271 interfered with neuromuscular transmission and reduced skeletal 
muscle contractility. The plasma concentration of BTS 27271 in those mice 
given 107 mg kg-l was calculated to be 5.5 x 10-4M.
Although those mice that became dyspnoeic, convulsed and died received 
sufficient formamidine to account for the signs by a peripheral action alone, 
a central effect cannot be excluded. As the maximum effect in the phrenic 
nerve hemidiaphragm preparations took about 20 minutes to develop, it was 
suggested that BTS 27271 had an intracellular action. 
(v) Prostaglandin Synthesis Amitraz, like chlordimeform, at doses of
-1S to 80 mg kg IP inhibited prostaglandin E 2 synthesis in rats, however 
chlordimeform was more potent than amitraz (1 50 for chlordimeform 34 µM and 
for amitraz 880 µM (Yim et al, 1978)). 
(vi) Appetite Stimulation Another property of the formamidines has been
reported but it is not a toxic action. Food intake in rats was increased 
three hours post-injection of amitraz (2.5 to 40 mg kg-l IP), an effect
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similar to that of chlordimeform (Pfister et al, 1978b). The formamidines 
appear to constitute a new class of appetite stimulants (Pfister et al, 1978b). 
There are a number of reports describing toxic signs of amitraz in animals. 
Although some reports describe actions of amitraz on the gastrointestinal 
tract the important systems that are involved with toxicity are the cardio­
vascular, respiratory and nervous systems. In addition, some studies have 
examined the inhibition of MAO and the actions of a-adrenoceptors in vivo by 
amitraz and its metabolite. Despite this information very -little is known 
about the mechanisms involved with amitraz toxicity. 
AIMS OF THE STUDY 
A number of studies have investigated the actions of both amitraz and 
chlordimeform using vertebrate and invertebrate preparations in vitro but 
few studies have investigated the effects of these relatively new formamidine 
compounds in vivo. 
Several actions are shared by amitraz, chlordimeform and their formamidine 
metabolites; two important ones are the inhibition of MAO and the activation 
of a-adrenoceptors. A particularly interesting finding by Hsu and Kakuk 
(1984) was the ability of amitraz, but no·t chlordimeform, to activate 
-1
a2-adrenoceptors at relatively low doses (0. 03 to 0 .. 1 mg kg IV). Despite
the available information about chlordimeform, some researchers consider that
its lethal effect in insects is unlikely to be due to one particular mechanism
of action and a definitive toxic action has not been elucidated.
Amitraz is a compound used primarily on animals and already there are contra­
indications for its use. Cats, horses and Chihuahua dogs should not be 
washed in this compound because of the danger of side effects and death. In 
other animals side effects include cardiovascular and respiratory effects. As 
yet, very few controlled studies have been made in intact animals in an 
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attempt to investigate the mechanisms of action of amitraz. 
The aim of these studies was to investigate mechanisms of action of amitraz 
in anaesthetised dogs. The lack of information on the effects of amitraz 
in vivo necessitated initial studies to characterise cardiovascular and 
respiratory actions of amitraz. With this information at hand further 
studies were made on the underlying mechanisms of action using specific 
cardiovascular agonists and antagonists. Finally, both peripheral and central 
actions of amitraz on the cardiovascular system were studied separately in 
the presence of specific adrenoceptor antagonists. 
A summary of the experimental protocol used in these studies with amitraz 
follows. 
I. Investigations for the determination of the mechanisms of action of
amitraz on the cardiovascular system were:
1. Cardiac actions - actions of amitraz alone, after intravenous
administration
.,
- interactions with a-adrenoceptor agonist and
antagonist,
- interactions with S-adrenoceptor agonist and
antagonist,
- interactions with acetylcholine and antagonist,
- interactions with histamine.
2. Vascular actions - actions of amitraz alone, after intravenous and
intra-arterial administration, 
- interactions with a-adrenoceptor agonist and
a1- and a 2-adrenoceptor antagonists,
- interactions with S-adrenoceptor agonist and
antagonist,
- interactions with acetylcholine and antagonist,
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- interactions with histamine.
3. Actions on cardiovascular nerve fibres
- interactions with ganglion stimulant,
- interactions with ganglion blocker,
- interactions with tyrarnine and antagonist.
4. Central actions - actions of arnitraz given intracisterna magna
- interactions with a1- and a2-adrenoceptor
antagonists given intracisterna magna.
5. Actions on the cardiovascular reflexes
- responses to carotid artery occlusion,
- responses to carotid artery occlusion in the
presence of a1- and a2-adrenoceptor antagonists
given centrally,
- baroreceptor-heart rate reflex.
II. Investigations into the actions of arnitraz on the respiratory system
were:
1. Direct actions on - tidal volume,
- respiratory rate,
- respiratory minute volume.






III. Definitive investigations using rat isolated vas deferens preparations
1. Effects of amitraz on evoked contractions following electrical
stimulation - alone,
- in presence of yohimbine,
- in presence of prazosin.




CARDIOVASCULAR AND RESPIRATORY ACTIONS OF AMITRAZ 
INTRODUCTION 
Amitraz, a member of the formamidine group of compounds, is used as a wash 
for dogs at concentrations of 0.025 to 0.05% for the treatment of demodectic 
mange. Occasionally dogs are susceptible to intoxication by amitraz and signs 
of sedation, bradycardia, hypotension, hypothermia, polyuria, vomiting and 
hyperglycaemia have been reported (Anon, 1977; Seawright, 1982). Tachycardia 
was a sign of severe intoxication (Seawright, 1982), however the quantity of 
amitraz required to give these signs was not reported. 
Seawright (1982) also described hyperventilation in dogs given amitraz where­
as Bonsall and Turnbull (1983) reported respiratory depression in rats. 
Bradycardia and mydriasis have been demonstrated in the rat following IV 
-1
amitraz at doses in excess of 30 to 100 µg kg respectively (Hsu and Kakuk, 
1984). 
Amitraz and its first metabolite, BTS 27271, are known to inhibit MAO and 
BTS 27271 can also activate a-adrenoceptors (see Chapter 1). 
On rare occasions small breeds of dogs, such as Chihuahuas, have died 
following a single treatment with amitraz but the cause of death was not 
elucidated (Gunaratnum et al, 1983). 
In view of the reports describing changes in blood pressure, heart rate and 
respiratory rate in dogs following amitraz, the aims of these experiments 
were to study the action of a range of doses of amitraz ·on the cardiovascular 
and respiratory systems for set periods of time. 
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METHODS 
These experiments were performed on healthy mongrel dogs of either sex 
weighing 14.6 ± 0.7 kg (mean ± SEM). 
Anaesthetic Technique 
These animals were anaesthetised with an inducing dose (about 12-15 mg kg-l
IV) of thiopentone sodium (Pentothal, Ceva Chemicals, Aust. Pty. Ltd.),
intubated and connected to a closed circle-circuit anaesthetic machine 
delivering oxygen and methoxyflurane (Metofane Co. , Pitman-Moore Inc. USA) 
from a vaporiser within the circuit. Adjustments were made to the anaesthetic 
vapour concentration to maintain an even depth of anaesthetic throughout each 
experiment. 
Measurement of MAP and HR 
The right femoral artery and vein were cannulated with about 15 cm of 
polyvinyl chloride tubing (Dural Plastics and Engineering, Dural, NSW, 
SV 65, ID 0.86 mm, OD 1.52 mm) filled with heparinised saline (15 IU heparin 
per ml, 0.9% sodium chloride). The arterial catheter was connected to a 
Gould Statham P 23 ID pressure transducer for measuring blood pressure and 
both pulsatile and mean arterial blood pressure (MAP) were recorded on a 
Grass Model 7D polygraph. 
The time interval between each peak systolic pressure (heart period, msec) 
was also continuously recorded on the polygraph. Heart rate (HR, beats per 
minute) was calculated from heart period when required. 
Measurement of Respiratory Variables 
A pneumotachograph (FlOOL flowhead, Mercury Electronics, Scotland, Ltd.) was 
placed in the inspiratory limb of the anaesthetic circuit near the animal 
and the pressure difference across the pneumotachograph screen measured with 
a M8 Electromanometer (Mercury Electronics, Scotland, Ltd.). Inspiratory 
28. 
tidal volume was obtained by electronic integration of gas flow and recorded 
on the polygraph. 
Placing the pneumotachograph on the animal end of the inspiratory limb of the 
anaesthetic circuit ensured laminar flow through the screen and avoided water 
condensation from expired gases. Both turbulent gas flow and water droplets 
on the screen can produce abnormal readings. 
Pneumotachography is based on Poiseuille's Law and the viscosity of the gas 
is an important consideration when determining flow (Grenvik et al, 1966). 
Thus the pneumotachograph was calibrated by flushing known volumes of oxygen 
and methoxyflurane, taken from the anaesthetic machine, through the flow­
head. This procedure was usually done twice during each experiment, before 
and after amitraz administration. 
Respiratory minute volume was calculated by multiplying the average inspired 
tidal volume by the number of breaths for that minute. 
Single Dose of Amitraz 
These studies were made using technical grade amitraz (supplied by Dr A.A. 
Seawright, University of Queensland), the active constituent in the commercial 
products "Ectodex" and "Taktic" (F and B Chemicals, Eastwood, NSW). 
As amitraz is insoluble in water it was dissolved in dimethylsulphoxide 
(DMSO, Ajax Chemicals Ltd.). A test dose of DMSO, the same volume needed to 
dissolve the amitraz, was injected initially to determine the effects of the 
solvent. No further injections were made until all variables had returned 
to preinjection controls. 
A single bolus injection of amitraz was given IV and flushed in with 1 ml of 
heparinised saline. MAP, HR, tidal volume and respiratory rate wer� record­
ed continuously for an hour following amitraz injection. 
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In separate experiments three different doses of amitraz, 1, 2 and 
5 mg kg-1, were given IV to anaesthetised dogs, each dog receiving only one
dose. 
Cumulative Doses of Amitraz 
Cumulative doses of amitraz were given IV to dogs. Initially, 0.5 mg kg-l of 
amitraz was given and after 5 minute intervals, additional doses were given 
to study the effects of 0.5, 1, 2, 5 and 10 mg kg-l of amitraz on MAP, HR, 
tidal volume, respiratory rate and respiratory minute volume. 
In another series of experiments, cumulative doses of amitraz were given IV 
to study the actions of 0.125, 0.25 and 0.5 mg kg-l of amitraz on MAP and HR. 
Statistical Analysis 
Control readings were taken for each variable over a 10 minute period before 
amitraz was injected and, at predetermined times following injection, changes 
from the control were calculated and averaged. 
The average standard error of the mean (SEM) at any time was calculated by: 
SEM = Error mean square 
n 
where the error mean square is determined by analysis of variance and 
n = the number of dogs (Korner
., 
1965; Snedecor and Cochran, 1967). 
Comparison of Treatment Means with a Control 
At selected times following amitraz injection the change from the pretreat­
ment control was averaged for each variable. These treatment values were 
compared with the control by using Dunnett's distribution for that 










EMS = error mean square from analysis of variance 
n = number of animals in each treatment group. 
Comparison Between Three Single Doses 
The results (change from control) obtained in the experiments following 
-1 single doses of amitraz at 1, 2 and 5 mg kg were compared at standard times
using analysis of variance. 
Apnoea Due to Amitraz 
The number of dogs that become apnoeic following a single dose of amitraz, 
at 1, 2 or 5 mg kg-land the duration of the apnoea in each case were
compared statistically using the Mann-Whitney U-test (Siegel, 1956). 
All values are expressed as mean± SEM. Values differing from the control 
at P<0.05 were considered significant. 
RESULTS 
The Effects of the Vehicle, DMSO 
The volume of DMSO was kept to a minimum by using solutions containing up to 
180 mg of amitraz per ml of DMSO. Dqgs receiving S mg kg-l of amitraz also
received the largest amount of DMSO (42.1 ± 2.3 mg). This quantity of DMSO 
produced the greatest increase in blood pressure (7.0 ± 1.05 mmHg) and the 
greatest fall in heart rate (6.3 ± 1.5 bpm). These values had returned to 
preinjection controls after 3-4 minutes. Smaller doses of DMSO were used for 
dissolving smaller doses of amitraz and there were no changes to the respiratory 
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variables at any dose level. 
As the effects of DMSO were so small in comparison to those of amitraz no 
adjustments were made for the vehicle. 
Single Doses of Amitraz 
The resting MAP and HR prior to amitraz injections are given in Table 2.1. 
All three doses of amitraz produced a significant increase in MAP which 
lasted for at least one hour, the duration of the experiments. 
Table 2.1 Average resting MAP and HR in dogs before amitraz injections. 
Values show mean ·± SEM, n=12 for each dose. 
Amitraz -1 IVmg kg 
1 2 5 
MAP 92.1 ± 4.6 87.6 ± 4.2 86.4 ± 3.8 
(mmHg) 
HR 120.2 ± 3.9 119.5 ± 4.1 113. 0 ± 4.4
(bpm) 
The greatest increase in blood pressure was seen within 2.5 minutes of 
amitraz injection and although there was then a gradual fall, particularly 
following doses of 1 and 2 mg kg-
1
, values remained in excess of the control 
(Figure 2.1). 
-1 The maximum increase in MAP was 37.5 rnrnHg with 1 mg kg , 38.7 mmHg with 
-1 -1 2 mg kg and 52.7 mmHg with 5 mg kg . These increases showed a dose
related effect which persisted throughout the recording period.
Bradycardia was the consistent heart rate effect following all doses of 
-1 -1
amitraz; the effect was greatest at 1 mg kg and least at 5 mg kg (Figure
2.2). A marked fall in the HR from the preinjection control values was seen
Figure 2.1 Effects of IV amitraz on MAP in the anaesthetised dog. Error bars indicate the SEM at any time 
(n=12 for each dose), calculated from analysis of variance. 
-1
0---0 1 mg kg 
-1
t:r-- ---ll. 2 mg kg 
-1
e----e 5 mg kg
All responses for each dose, taken at the times listed in the table below, were significantly 
different from the control (C) (P<0.01, Dunnett's t-Test). 
The significance levels for differences in the responses between the doses of amitraz at the 
following times post-amitraz (ANOVA, F-test) were as follows: 
Time p Time p Time p 
- -
(min) (min) (min) 
0.25 <0.005 3 NS 25 <0.05 
0.5 <0.005 5 NS 30 <0.05 
1 <0.005 7 NS 40 <0.005 
1.5 <0.05 10 NS 50 <0.005 
2 NS 15 NS 60 <0.005 
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Figure 2.2 Effects of IV amitraz on HR in the anaesthetised dog. Error bars indicate the SEM at any time 
(n=12 for each dose), calculated from analysis of variance. 
-1 
o�---.Q 1 mg kg 6-- - -� 
-1 2 mg kg -1e----e 5 mg kg 
All responses taken at the times listed in the table below for amitraz at doses of 1 and 2 mg kg-1,
as well as those readings taken at 0.25 and 0.5 minutes following 5 mg kg-l of amitraz, were
significantly different from the control (C) (P<0.01, Dunnett's t-Test). 
The significance levels for differences in the responses between the doses of amitraz at the 
following times post-amitraz (ANOVA, F-test) were as follows: 
Time p Time p Time p 
(min) (min) (min) 
0.25 NS 3 <0.01 25 <0.01 
0.5 NS 5 <0.05 30 <0.01 
1 <0.005 7 <0.05 40 <0.01 
1.5 <0.005 10 <0.05 50 <0.05 
2 <0.005 15 <0.05 60 <0.01 
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immediately after amitraz injection. This was followed within 2.5 minutes 
by a return towards control values, the most complete recovery seen after 
5 mg kg-l of amitraz. A second but more gradual fall was seen 15 to 25 
minutes after injection. The maximum fall in HR initially was 39.4 beats per 
-1 -1 minute after 1 mg kg , 31.8 beats per minute after 2 mg kg and 25.9 beats
per minute after 5 mg kg-l of arnitraz.
The simultaneous increase in blood pressure and decrease in heart rate is seen 
in Figure 2.3 which shows typical changes following doses of amitraz. 
All of the respiratory variables were expressed as a percentage of the control 
to enable comparisons to be made between dogs of different sizes. Tidal 
volume, respiratory rate and respiratory minute volume were all initially 
depressed by amitraz to be followed by an increase. -1After 1 mg kg of
amitraz the tidal volume returned to control values after 0.5 minutes whereas
at the higher doses of the formamidine, the tidal volume remained significantly
depressed for up to 3 minutes (Figure 2.4).
Respiratory rate was initially depressed for a period up to 3 minutes and then 
increased above control values depending on the dose given. Amitraz at 
-15 mg kg produced the greatest hyperventilation, an increase of 45% above
control values (Figure 2.5).
Figure 2.6 shows typical changes in tidal volume and respiratory rate after 
amitraz administration. 
Respiratory minute volume was significantly depressed by amitraz for 2-3 
minutes but after 20 minutes, values in excess of the control, due to in­
creased respiratory rate, were recorded (Figure 2.7). 
Amitraz produced apnoea in some dogs and details of the number affected are 
given in Table 2.2. 
Figure 2.3 Typical example of the effects of IV amitraz at 1 and 5 mg kg-l 
on BP and HR in anaesthetised dogs, initially and at 10, 20, 40 and 
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Figure 2.4 The effects of IV amitraz on the tidal volume (VT) in the anaesthetised dog. Error bar is 
the SEM at any time (n=12 for amitraz 1 and 5 mg kg-1, n=ll amitraz 2 mg kg
-1).
-1
0---0, 1 mg kg 
-1
l::r------ -� 2 mg kg -1e---e 5 mg kg 
Values that were significantly different from control (C) at P<0.01 (Dunnett's t-Test): 
amitraz 5 mg kg-l - 0.25, 0.5, 1, 1.5, 2, 2.5 and 3 min.
amitraz 2 mg kg-l - 0.25, 1 min.
amitraz 1 mg kg-l - 0.25 min.
Difference at P<0.05 were: 
amitraz 2 mg kg-l - 0.5, 1.5 min.
The significance levels for differences in the responses between the doses of amitraz at the 
following times, post-amitraz (ANOVA, F-test) were as follows: 
Time p Time p Time p 
(min) (min) (min) 
0.25 NS 3 <0.01 25 NS 
0.5 <0.005 5 NS 30 NS 
1 <0.005 7 NS 40 NS 
1.5 NS 10 NS so NS 
2 <0.05 15 NS 60 NS 
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Figure 2.5 The effects of IV amitraz on the respiratory rate (fR) in the anaesthetised dog. Error bar is 
the SEM at any time (n=12 for amitraz 1 and 5 mg kg-1, n=ll for amitraz 2 mg kg
-1), calculated
from analysis of ,variance. 
-1 Qi-----0 1 mg kg -1 1::r-- ---fj. 2 mg kg -1e-----e 5 mg kg 
Values that were significantly different from control (C) at P<0.01 (Dunnett's t-Test): 
Differences at P<0.05: 
. 5 k -l 1 · amitraz mg g - min.
-1 amitraz 2 mg kg - 1, 2, 50 min.
-1 amitraz 5 mg kg - 2, 40, 50, 60 min.
amitraz 2 mg kg-l - 3, 30, 40, 60 min.
amitraz 1 mg kg-l - 1, 2 min.
The significance levels for differences in the responses between the doses of amitraz at the 
following times post-amitraz (ANOVA, F-test) were as follows: 
Time p Time p Time p 
- -
(min) (min) (min) 
1 NS 10 NS 30 NS 
2 NS 15 NS 40 0.05 
3 NS 20 NS 50 0.05 
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Figure 2.6 Typical example of the effects of IV amitraz at 1 and 5 mg kg-
1
, on tidal 
volume and respiratory rate in anaesthetised dogs, initially and at 10, 
20, 40 and 60 minutes afte� injection. 
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Figure 2.7 The effects of IV amitraz on the respiratory minute volume (VI) in the anaesthetised dog. Error
bar is the SEM at any time (n=12 for amitraz 1 and 5 mg kg-1, n=ll for amitraz 2 mg kg
-1),
calculated for analysis of variance. 
-1 -1
.____... --- ---• 1 mg kg • • 2 mg kg 5 mg kg 
Values that were significantly different from control (C) at P<0.01 (Dunnett's t-Test): 
Differences at P<0.05: 
-1 amitraz 5 mg kg - 1, 2, 3 min.
amitraz 2 mg kg-l - 1, 2 min.
-1 amitraz 1 mg kg - 1, 2 min.
amitraz 5 mg kg-l - 40 min.
. 2 k -l 3 · am1traz mg g - min.
The significance levels for differences in the responses between the doses of amitraz at the 
following times, post-amitraz (ANOVA, F-test) were as follows: 
Time p Time p Time p 
- -
(min) (min) (min) 
1 0.05 5 NS 25 NS 
1.5 0.01 7 NS 30 NS 
2 0.05 10 NS 40 NS 
2.5 0.01 15 NS 50 NS 




















































Table 2.2 Apnoea produced by amitraz (NS= not significant).· 
No. of animals with 
apnoea 
(cf total) 






Cumulative Doses of Amitraz 
Dose of amitraz ( mg kg-1)
1 2 5
3/12 7/12 8/12 
50.3 112.1 136.5 
I I I , 
I 
U=41.5, NS U=56, NS 
U=32, P<0.05 
-1 Cumulative doses of amitraz of 0.5, 1, 2 and 5 mg kg IV at intervals of 5 
minutes produced a step wise increase in blood pressure, however, there was 
a fall when the dose level reached 10 mg kg-l (Figure 2.8). 
-1Bradycardia was seen immediately with amitraz at 0.5 mg kg IV and this 
persisted with 1 mg kg-l but subsequent doses produced a slight increase in 
heart rate in excess of the control (Figure 2.8). 
This small tachycardia occurred in the presence of hypertension. Figure 2.9 
shows typical changes in MAP and heart period (HP) following cumulative doses 
of amitraz. 
All doses of amitraz produced immediate depression of tidal volume, 
respiratory rate and respiratory minute volume (Figure 2.10). Although all 
respiratory variables returned towards control after initial depression only 
respiratory rate exceeded control values. 
As with single doses, higher doses of amitraz made some dogs apnoeic. Blood 
Figure 2.8 The effects of IV arnitraz on MAP and HR in anaesthetised dogs 
(n=6). Additional doses of amitraz given every 5 minutes. 
Error bars indicate the SEM at any dose. (� - change in). 
** P<0.01, * P<0.05, (Dunnett's t-Test on 5-minute points 

































Figure 2.9 An example of the changes in BP and HP following cumulative doses of amitraz 
given IV every 5 minutes to anaesthetised dogs. 
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Figure 2.10 The effects of IV amitraz on the tidal volume (VT), respiratory
rate (fR) and respiratory minute volume (VI) in anaesthetised
dogs (n=6) following cumulative doses of amitraz IV. 
Additional doses of amitraz given every 5 minutes. Vertical 
bars show the SEM at any time. 
** P<0.01 
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pressure fell during apnoea but showed a rise once spontaneous ventilation 
returned. 
Figure 2.11 shows typical changes in tidal volume and respiratory rate 
following cumulative doses of amitraz. 
Figure 2.12 shows readings taken at 1, 2, 3 and 5 minutes after either 
-1 single or cumulative doses of IV amitraz (1, 2 and 5 mg kg ). Similar
trends in responses are evident following both methods of administration. 
The actions of IV amitraz at doses 0.125, 0.25 and 0.5 mg kg-l on the 
cardiovascular variables are shown in Figure 2.13. These lower doses of 
amitraz acted in a similar way to the previous doses tested by producing 
hypertension and bradycardia. 
Both 0.125 and 0.5 mg kg-l of amitraz increased the MAP to ·a similar extent 
and this was not surprising as both doses are on the bottom of the dose 
response curve (Figure 2.14). It was interesting to note that 0.5 mg kg-l of 
amitraz given as the first dose in a series (Figure 2.8) produced marked 
bradycardia during the 5 minutes of recording, whereas, after two smaller 
doses (Figure 2.13) the heart rate, following the same dose of amitraz, 
returned towards control levels. An explanation for this difference cannot 
be given at this stage but one aspect that both graphs demonstrate was the 
return towards control values 10 minutes after the initial dose of amitraz. 
This may be a time related effect allowing amitraz to penetrate to the central 
nervous system. 
Dose-Response Relationship
Responses to amitraz 1 minute after its administration were plotted against 
the dose given (Figure 2.14), using data from single dose experiments or from 
the first dose in the cumulative series. Despite a dose related hypertension, 
bradycardia was seen only with lower doses of amitraz. 
Figure 2.11 An example of the changes in tidal volume and respiratory rate following cumulative doses 
of amitraz given IV every 5 minutes to anaesthetised dogs. This trace and Figure 2.9 were 
taken from the same dog. 
















Figure 2.12 Comparison of responses to arnitraz given either as a single dose 
C•-----ie•) or as a cumulative dose (■------11). All responses are 




T - tidal volume,
f
R - respiratory rate, 
v
1 
respiratory minute volume) 
-1 Columns A, Band C represent effects of 1, 2 and 5 mg kg of
arnitraz respectively. 
(MAP expressed as mmHg, HR as bpm and respiratory variables as a 
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Figure 2.13 The effects of IV amitraz on MAP and HR in the anaesthetised dog 
(n=4). Additional doses of amitraz given every 5 minutes . 
. Vertical bars show the SEM at any time. 
** P<0.01 Dunnett's t-Test used to compare 5-minute points 
immediately prior to next dose. The change in MAP 5 minutes 
-1
after 0.25 mg kg of amitraz was 31.6 mmHg. This change was 























Figure 2.14 Dose response curve in dogs given amitraz IV. Readings were taken 1 minute after 
amitraz administration and shown here as a change from the control. 
(A) - change in MAP ( • e) 
(B) - change in HR Ce e) 
(C) - percent change in tidal volume (V1) (0--0)
percent change in respiratory rate (fR) (D---o)
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In the current series of experiments all doses of amitraz increased blood 
pressure immediately after injection and in experiments where single doses 
were given, this persisted for at least an hour. There were a few 
exceptions where hypotension developed later: 2 animals (n=l2) given amitraz
at 1 mg kg-land 3 animals (n=12) given 2 mg kg-1.
Bradycardia was the initial response of all dogs given single doses of 
-1 1 amitraz, however, 2 dogs (n=12) given 1 mg kg , 1 dog (n=l2) given 2 mg kg-
-1and 5 dogs (n=12) given 5 mg kg later developed a heart rate in excess of
the control value, although this tachycardia was small.
The reason for the increase in blood pressure is unknown but possible causes 
are stimulation of the sympathetic system by either a central or ganglion 
stimulating mechanism or local constriction of the peripheral vessels. 
The hypotension that followed the initial hypertension in 5 of the dogs was 
an inconsistent finding. 
The bradycardia may be due to increased vagal tone (by either a direct central 
action or a reflex in response to hypertension), an inhibition of cardiac 
sympathetic outflow or a direct myocardial depressant action. The biphasic 
dose-related bradycardia, seen between 0.125 and 1 mg kg-l of amitraz, 
followed by a rise in heart rate at higher doses (Figure 2.14) is difficult 
to explain. It is possible that reflex bradycardia occurs in response to 
hypertension but, if so, another mechanism must account for the lack of 
bradycardia with higher doses of the formamidine when hypertension is even 
more pronounced. 
Amitraz depressed all three respiratory variables in a dose related manner 
initially. This was followed by a slight rise but it was only the respiratory 
50. 
rate that rose significantly above the control values. The increased 
respiratory rate helped overcome the depression of the tidal volume to 
maintain the respiratory minute volume. Apnoea was seen more often at higher 
doses of amitraz. Respiratory depression may be a result of a direct central 
depressant effect of amitraz or desensitisation of the carotid and aortic 
chemoreceptors. Another possible effect may be sensitisation of the stretch 
receptors in the lung to produce hyperventilation which is overpowered by 
the central depressant action seen immediately after injection. 
Elevated carbon dioxide levels are expected following apnoea seen after high 
doses of amitraz. It has been shown that elevated circulating carbon 
dioxide levels have a variable effect on the heart and circulation. The 
direct effect of hypercapnia is depression of myocardial contractility and 
heart rate and dilation of the peripheral blood vessels while there is also 
an opposing stimulant effect mediated through the sympathetic nervous 
system (Foex
> 
1980). During periods of apnoea the blood pressure fell 
markedly and the heart rate showed a lesser fall, changes which were quickly 
reversed when spontaneous ventilation recommenced. It is likely that those 
cardiovascular effects seen following a cumulative dose of 10 mg kg-l of 
amitraz were caused by the changes in blood gases due to apnoea. It should 
be pointed out that these respiratory effects were seen in dogs that were 
anaesthetised with thiopentone and methoxyflurane. While hypercapnia had to 
be expected after periods of apnoea in these dogs, hypoxia was likely to have 
been a lesser problem due to the high concentration of inspired oxygen. 
Hsu and Kakuk (1984) have classified amitraz as an a 2 -adrenoceptor agonist, 
like clonidine and xylazine, after showing that the three substances produced 
bradycardia and mydriasis in the rat. Similarities exist between the 
responses to amitraz and those to xylazine in the dog. The presser response 
and the decrease in heart rate, seen particularly at lower doses of amitraz, 
were in common with those actions reported following intravenous xylazine 
injection in dogs (Schmitt et al, 1970; Antonaccio et al, 1973; Klide et al, 
51. 
1975). Hypotension was an inconsistent finding in dogs given amitraz, 
although at some dose rates recordings were made for only 5 minutes before 
another dose was given. This response differs from xylazine where hypotension 
is seen consistently. Furthermore, the return of the heart rate towards 
control values after higher doses appears to be another unique property of 
this formamidine. 
In a review on clonidine and clonidine-like drugs, Kobinger (1978) stated 
that 5 to 500 ·.µg kg -l of clonidine given by rapid intravenous injection to 
animals produced bradycardia and transient hypertension followed by hypo­
tension. The pressor response was likely to result from peripheral 
a-adrenoceptor stimulation. Kobinger (1978) also listed other drugs,
belonging to the imidazoline, oxazoline and guanidine groups, capable of 
producing similar changes in cardiovascular variables. Four imidazolines 
known to lack a hypotensive effect when given intravenously are naphazoline, 
oxymetazoline, St91 and St66. Amitraz shows some actions similar to those 
of clonidine and related drugs but differences do exist, particularly with 
respect to its effect on blood pressure. 
Seawright (1982) described the toxic signs of amitraz in the dog as an initial 
bradycardia followed in severely intoxicated animals by tachycardia and 
hyperventilation. The responses to amitraz in the present study are 
consistent with the signs descri·bed by Seawright but he did not specify dose 
rates. From the doses of amitraz used in this study maximum bradycardia is 
expected following single doses of 0.5 to 1 mg kg-l IV and tachycardia may 
develop after 5 mg kg-l IV. Hyperventilation is expected when doses of 
amitraz in excess of 1 mg kg-l IV are given. 
In rats, ami traz produced bradycardia and respiratory depressi_on and it was
considered that respiratory depression was the lethal factor (Bonsall and 
Turnbull, 1983) . 
52. 
-1 In dogs xylazine (1.1 mg kg IV) produced no significant change in arterial
blood pH, PC0 2 and P0 2 5 minutes after injection (Klide et al, 1975). As 
PC0 2 correlates closely with respiratory minute volume (Nunn, 1979), this 
variable was unlikely to be affected by xylazine, however, the respiratory 
minute volume in the amitraz-treated dogs was still depressed after 5 minutes, 
suggesting that amitraz may have greater respiratory depressant properties 
than xylazine. 
The actions of amitraz on the cardiovascular system differs from those of the 
related formamidine, chlordimeform. Chlordimeform (1 to 30 mg kg-l IV) in
dogs anaesthetised with pentobarbitone produced an initial fall in blood 
pressure lasting 2 to 3 minutes which was followed by a pressor response that 
lasted less than an hour. The heart rate showed a similar biphasic response 
to blood pressure. In common with amitraz, chlordimeform produced hyper­
ventflation (Lund et al, 1978). The authors explained these responses by 
suggesting that chlordimeform had an initial local anaesthetic-like-action 
followed by a reflex or direct sympathomimetic effect. 
Despite the fact that both amitraz and chlordimeform are formamidine compounds, 
they appear to differ in the responses they produce in dogs. 
The hydrophobic nature of amitraz necessitated that it be mixed with DMSO 
before injecting into dogs. The test doses of vehicle given to each dog 
before amitraz showed that DMSO had minimal effect compared to the formamidine. 
The greatest quantity of DMSO needed to dissolve amitraz (42.1 ± 2.3 mg kg-1)
-1was small in comparison to the LDso in dogs (2.5 g kg IV) reported by
Rosenkrantz et al (1963). The responses to DMSO shown by dogs in the present
experiments were similar to those reported by Peterson and Robertson (1967).
Hsu and Kakuk (1984) suggested that amitraz, mixed with DMSO, may precipitate 
out immediately after injection and slow the onset of activity. While 
53. 
precipitation may occur, changes in blood pressure and heart rate were seen 
immediately following injection in these experiments. 
The anaesthetic drugs used in the present experiments may have had a minor 
effect on the cardiovascular and respiratory variables. Control readings 
before amitraz injection were taken when the circulating thiopentone levels 
were expected to be low and the methoxyflurane levels had stabilised to 
produce a steady stage of anaesthesia. 
Methoxyflurane is known to lower blood pressure and peripheral vascular 
resistance while heart rate may increase in response to the lowered blood 
pressure (Hickey and Eger, 1980). Methoxyflurane also has a depressant 
effect on the respiratory system (Larson et al, 1969). 
These experiments have provided useful information about the actions of 
amitraz on the cardiovascular and respiratory systems in the dog. In the 
light of the rise in blood pressure and bradycardia more details are 
required about the actions of amitraz to investigate its mechanisms of action. 
Aspects that need to be investigated initially are the effects of specific 




it has been shown that responses to single doses of amitraz are 
quite prolonged and are very similar to those from cumulative studies. This 
feature will allow for the use of cumulative dose response curves utilizing 




CARDIOVASCULAR AND RESPIRATORY ACTIONS OF AMITRAZ 
IN THE PRESENCE OF SPECIFIC ANTAGONISTS 
INTRODUCTION 
Administration of amitraz (IV) to the dog increased blood pressure and 
reduced heart rate, although a small tachycardia developed following higher 
doses. Hypotension was an inconsistent finding. Transient respiratory 
depression was a constant feature immediately following injection of all 
doses but dogs given single doses of the formamidine in excess of 1 mg kg-l
IV hyperventilated after the initial depression while the tidal volume and 
respiratory minute volume values were depressed. There are several possible 
explanations for these cardiorespiratory effects. 
The first metabolite of amitraz, BTS 27271, which is formed from cleavage of 
the amitraz molecule has been shown to be an a-adrenoceptor agonist 
(Robinson, 1979). Phentolamine reduced the contractions of the·rabbit ear 
artery produced by BTS 27271. Other closely related formamidine compounds, 
chlordimeform and its metabolites, have also been shown to have a-adrenoceptor 
agonist properties (Robinson and Bittle, 1979; Hollingworth and Yim, 1980). 
It is also possible that amitraz produces its cardiorespiratory effects via 
interaction with other parts of the autonomic nervous system. Thus a 
systematic investigation of the effects of specific competitive antagonists 
on the actions of amitraz was warranted. Cholinergic,.a- and S-adrenergic 
and ganglion stimulating properties of amitraz were assessed using specific 
antagonists. The antagonist drugs used were atropine, an inhibitor at post­
ganglionic cholinergic receptors of the parasympathetic nervous system; 
phentolamine, an a-adrenoceptor antagonist; propranolol, a S-adrenoceptor 
antagonist and hexamethonium, a ganglion blocker. 
55. 
METHODS 
These experiments were performed using healthy mongrel dogs of either sex 
weighing 17.6 ± 0.8 kg (mean ± SEM). The dogs were anaesthetised and 
prepared for recording cardiovascular and respiratory variables as described 
in Chapter 2. Mean arterial pressure (MAP), heart rate (HR), tidal volume 
(VT) and respiratory rate (fR) were measured and the respiratory minute
volume (VI) was calculated.
Cumulative Doses of Amitraz 
Prior to the administration of amitraz an equivalent volume of DMSO that was 
used to dissolve the highest dose of amitraz was injected intravenously to 
test responses to the vehicle. 
Amitraz, dissolved in DMSO, was injected into the femoral vein. An initial 
-1dose of 0.5 mg kg of amitraz was followed at 5-minute intervals by 
additional doses so that the effects of 0.5, 1, 2, 5 and 10 mg kg-l of 
amitraz were studied. Each dose was flushed in with 1 ml of heparinised 
saline. 
Measurements of MAP, HR, VT' fR and v1 were taken before amitraz was injected
and again every minute postinjection. Changes from the preamitraz control 
for each variable were calculated and these results .were used to compare 
with those where antagonist drugs were given. 
The Effects of Antagonist Drugs 
In order to monitor the effectiveness of the antagonists, agonist drugs were 
administered before DMSO, after DMSO and again 40 to 45 minutes after the 
antagonist to ensure that there was no interaction with DMSO and that the 
antagonist was effective. The same protocol was followed with amitraz. 
MAP and HR were expressed as raw data while tidal volume, respiratory rate 
56. 
and respiratory minute volume were expressed as per cent change of the pre­
injection control value. 
Statistical Analysis 
Responses to cardiovascular agonists before and after each antagonist were 
compared using a paired "Students" t Test (Snedecor and Cochran, 1967) and 
the standard error of the mean (SEM) at any time was calculated as described 
in Chapter 2. 
Results for the change from the preamitraz control for each variable in dogs 
given antagonists (treated group) were compared with those readings from 
untreated animals (no antagonists). This was done for readings 5 minutes after 
injection of amitraz and analysed by analysis of variance (Snedecor and 
Cochran, 1967). All 5 doses of amitraz were compared for the cardiovascular 
and respiratory variables using analysis of variance and then the results for 
the HR following amitraz at doses 0.5, 1 and 2 mg kg-l were analysed using 
the same method. 
Results that differed from the control at P<0.05 were considered significant. 
Drugs 
The amitraz used was technical grade. The agonists and doses used were: 
acetylcholine chloride (Sigma Chem. Co.) 0.25 and 1 µg kg-1; noradrenaline
hydrochloride (Sigma Chem. Co.) 0.05 and 0.2 µg kg-1; isoprenaline sulphate
(Sigma Chem. Co.) 0.05 and 0.1 µg kg-l; DMPP iodide (Sigma Chem. Co.) 9 and 
15 µg kg-1. These drugs were diluted in a solution containing 9.0 g 1-l
sodiwn dihydrogen phosphate and 3.0 g 1-l of ascorbic acid and were made up 
fresh each day. Volwnes of 0.1 ml were flushed in with 1 ml heparinised 
saline. 
The doses of the antagonists used were: atropine sulphate (Parnell Labs.) 
57. 
-1 1 0.5 mg kg phentolamine mesylate (Ciba Phann.) 1.4 mg kg- propranolol
hydrochloride (Sigma Chem. Co.) 1 mg kg-
1
; hexamethonium bromide (Sigma 
-1
Chem. Co.) 10 mg kg . 
All doses of agonists and antagonists were expressed as their total salt. 
RESULTS 
Actions of DMSO 
The effects of DMSO on blood pressure, heart rate and respiratory variables 
were minimal in comparison with those following amitraz (discussed in Chapter 
2), thus no adjustments were made for the vehicle. 
Table 3.1 shows the effect of antagonists on control readings for the cardio­
respiratory variables before amitraz was given. 
Figure 3.1 shows the cardiovascular responses to agonists before the 
respective antagonist, immediately after and then 40 to 45 minutes after the 
antagonist. These experiments were performed in the presence of an equal 
volume of DMSO required to dissolve the high dose of arnitraz. Results showed 
that antagonists inhibited the actions of their respective agonists in the 
presence of DMSO and the antagonists all had a duration of action in excess of 
40 to 45 minutes. The duration o'f effect of the antagonists was considered 
long enough to enable the actions of all doses of arnitraz to be studied in 
subsequent experiments. The heart rate values for noradrenaline and DMPP 
were not given because of the variation between an increase or decrease in 
responses among the dogs. 
Cardiovascular Responses to Amitraz Following Antagonist Drugs 
The results from the dogs that did not receive antagonist drugs, i.e., the 
untreated group, are summarised in Figure 2.8 (Chapter 2). 
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Table 3.1 Control values of MAP and HR before amitraz was given in the 
group of animals not given antagonists and changes in cardio­
respiratory variables in subsequent experiments using antagonists. 
The change due to antagonist shows the effect each drug had on 
the cardiovascular and respiratory variables. 
Figures show mean ± SEM, t - increase, + - decrease. 
Antagonist Control Values Change due to Antagonist 
MAP HR MAP HR V f 
(rnmHg) (bpm) (rnmHg) (bpm) (%} (%� (%} 
No antagonist 84.4 126.4 
n = 6 (7. 0) (11.5) 
Atropine 84.0 135.6 0.2t 23.lt 12.0t 10.2+ 0.lt
n = 5 (5. 3) (7. 7) (2.6) (9. 2) (3.6) ( 4. 0) (2. 9)
Phentolamine 82.2 111.6 4.0+ 12.7+ 0 0 0 
n = 4 (10.1) (3.7) (1.1) (4.3) 
Propranolol 102.1 119.9 5.2+ 3.4t 1.5t 0 l.5t
n = 4 (7.6) (9.6) (2. 7) (2. 2) (1.5) (1.5)
Hexamethonium 79.6 137.6 15. 7+ 17. lt 8.7t 3.9t 40.9t 
n = 4 (7.6) (3.3) (5. 8) (13.2) (8. 7) (3. 9) (40.9) 
Figures 3.2 and 3.3 summarise the changes in MAP and HR from the preamitraz 
control value, comparing results of the untreated group with those given 
antagonist drugs. 
Marked hypertension was the constant feature following amitraz in animals 
pretreated with propranolol (n=4), hexamethonium (n=4) and atropine (n=5) 
however, those dogs given phentolamine (n=4) showed only a slight increase in 
-1
MAP after 2, 5 and 10 mg kg of amitraz.
There was little difference between the blood pressure responses of the un­
treated group compared to the group given propranolol, while those animals 
-1
given hexamethonium or atropine showed greater hypertension after 0.5 mg kg 
of amitraz than the untreated group. 
-1
Five minutes after 0.5 mg kg of
Figure 3.1 The effects of cardiovascular agonists on MAP and HR: 
(a) before respective antagonist• • 
(b) immediately after antagonist a-----11
(c) 40 to 45 minutes after antagonist.•-----•
Acetylcholine, isoprenaline, noradrenaline and DMPP were 
used to monitor effects of atropine, propranolol, 
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Figure 3.2 The effects of intravenous amitraz on the MAP and HR in dogs 
without an antagonist (n=6 ,••t-----1e•), and animals: pretreated 
with either propranolol (1 mg kg -l, n=4 ,�·········.&), or 
-1phentolamine (1.4 mg kg , n=4, ■•----�■•). Error bars show the
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Figure 3.3 The effects of intravenous amitraz on the MAP and HR in 
dogs without an antagonist (n=6,.e�-�••), and animals 
-1
pretreated with either hexamethonium (10 mg kg , n=4,
-1
£ ... •· •··.& ) or atropine (0. 5 mg kg , n=S , ■ ai----■ ) . Error






























amitraz the blood pressure increased by 54.9 mmHg in the hexamethonium 
group, 60.8 mmHg in the atropine group and 24.8 mmHg in the untreated group. 
Further rises in blood pressure were recorded in these groups with increasing 
doses of amitraz; 5 minutes after 5 mg kg-l of amitraz the propranolol group 
increased by 71.1 mmHg, atropine by 71.4 mmHg, hexamethonium by 67.6 mmHg and 
the untreated group by 66.7 mmHg. In contrast those animals pretreated with 
phentolamine showed a blood pressure increase of only 12.8 mmHg at the same 
time. 
The MAP tended to fall in all groups following 10 mg kg-l of amitraz. 
Statistical analysis of the MAP changes showed that only the phentolamine 
group differed from the untreated group when all doses of amitraz were 
included in the analysis (F = 23.00, P<0.005). 
-1Bradycardia was constantly seen in those animals given 0.5, 1 and 2 mg kg 
of amitraz in the untreated group as well as the hexamethonium, propranolol 
and phentolamine groups. The exception to this was the atropine group where 
tachycardia was seen. -1For example, five minutes after 0.5 mg kg of the
formamidine the HR decreased by 9.2 beats per minute in the phentolamine
group, 15.7 in the hexamethonium group, 31.6 in the untreated group and 41.5
in the propranolol group but increased by 11.3 beats per minute in the
atropine group (Figure 3.3).
It was only the hexamethonium, propranolol and untreated groups where the HR 
-1 returned to control values after 2 mg kg of amitraz, but after the two
highest doses, a tachycardia was produced in the presence of propranolol. 
Statistical analysis of the changes in HR for all of the doses of amitraz 
showed no significant difference between the treated groups and the untreated 
group. Comparison of only three doses of amitraz (0.5, 1 and 2 mg kg-1)
showed that phentolamine (F = 4.58, P<0.05), atropine (F = 16.53, P<0.005) and 
hexamethonium (F = 4.85, P<0.05) groups were all significantly different from 
the untreated group whereas propranolol did not effect the responses. 
------------- --�- - - - - -�------� 
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The Respiratory Responses to Amitraz Following Antagonist Drugs 
The changes in tidal volume, respiratory rate and respiratory minute volume 
in all groups of animals are summarised in Figures 3.4 and 3.5. 
The tidal volume in the untreated group of dogs was depressed more than in 
those animals given antagonists. 
The phentolamine group showed an increase in tidal volume after 0.5, 1 and 
2 mg kg-l of amitraz (maximum increase of 17.3% S minutes after 2 mg kg-1)
-1while at doses of 5 and 10 mg kg the tidal volume was markedly depressed.
Although there was little change from the control in the propranolol,
hexamethonium and atropine groups at the lower doses of amitraz, greater
-1depression was apparent after 5 and 10 mg kg 
Statistically, the tidal volume changes in the phentolamine group were 
significantly different from those of the untreated group (F = 5.43, 
P<0.05). 
On most occasions all doses of amitraz depressed the respiratory rate 
immediately following injection. While readings taken 5 minutes after each 
dose of amitraz showed either little change or an increase in respiratory 
rate in the propranolol, hexamethonium, atropine and untreated groups, the 
phentolamine group consistently showed depression. 
The respiratory minute volume was depressed in all groups of dogs by each 
dose of amitraz but the greatest depression was seen immediately following 
injection of the formamidine. 
There were no significant differences between the changes in respiratory rate 
and respiratory minute volume for any groups compared with the untreated 
group. 
Figure 3.4 The effects of intravenous amitraz on the tidal volume 
(VT), respiratory rate (fR) and respiratory minute volume
(VI) in dogs without an antagonist (n
= 6, • e ) and 
-1animals pretreated with either propranolol (1 mg kg , 
-1
n=4, A·--·--:.&) or phentolamine (1. 4 mg kg , n=4, ■----�■) .
Values are expressed as per cent change from preamitraz






























PH ENTO LAMINE 
DOSE {mg.kg-I) 0·5 I 2 5 I 0 
___ ...__ __________ .....__ _ ___, 
C O 5 10 15 20 25 
TIME ( min) 
Figure 3.5 The effects of intravenous amitraz on the tidal volume 
(VT), respiratory rate (fR) and respiratory minute volume
(VI) in dogs without an antagonist (n
=6, • • ) and 
-1 animals pretreated with either hexamethonium (10 mg kg ,
n=4 ,•········•) or atropine ( 0. 5 mg kg -l, n= S ,■ •.,__--■ ) .
Values are expressed as per cent change from preamitraz 
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Phentolamine, atropine and hexarnethoniurn, but not propranolol, altered the 
cardiovascular responses to amitraz. Phentolamine prevented the marked 
hypertension and bradycardia produced by arnitraz. Bradycardia was prevented 
by atropine and reduced by hexarnethoniurn while propranolol had little 
influence on the hypertension or bradycardia produced by arnitraz but en­
hanced the high-dose tachycardia. As the hypertension following arnitraz was 
markedly reduced by the a-adrenoceptor antagonist, phentolarnine, a peripheral 
a-adrenoceptor activation by arnitraz seems likely. The possibility of a
central action on the sympathetic system to produce hypertension is unlikely 
because the ganglion blocker, hexarnethoniurn, failed to reduce amitraz­
induced hypertension. Furthermore, nicotinic receptor stimulation at the 
ganglia is unlikely because of the persistence of the hypertension following 
amitraz in the presence of hexarnethoniurn. 
The absence of bradycardia in dogs pretreated with atropine suggested that 
this effect was due to increased vagal activity. A bradycardia markedly 
reduced in the presence of hexarnethoniurn also supported this observation. 
As phentolarnine antagonised the hypertension due to arnitraz and a marked 
decrease in heart rate was not a feature in this group, it is possible that 
the bradycardia following lower doses of arnitraz (without antagonists) is a 
reflex response to the hypertension but may also be a centrally initiated 
reduction in sympathetic outflow. 
The reason for the return of the heart rate to pre-injection values after 
higher doses of arnitraz, particularly when the hypertension is maximum, still 
cannot be explained at this stage. 
The blood pressure change following low doses of arnitraz in either atropine 
or hexarnethoniurn groups was much higher than the untreated group. This may 
be attributed to the lack of compensation caused by the inhibition of 
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bradycardia. 
The effect of amitraz on the cardiovascular system is to increase blood 
pressure and reduce heart rate. Similar responses have been reported 
following the systemic administration of clonidine, xylazine and related 
-1 compounds (Kobinger, 1978). Schmitt et al (1970) showed that 2 mg kg IV
of phentolamine reduced the hypertension produced by 0.25 to 1 mg kg-l IV of 
xylazine in dogs. In addition, it was shown that bilateral vagotomy in dogs 
given xylazine reduced only the bradycardia and did not alter t�e blood 
pressure. In contrast, dogs given amitraz after high doses of atropine 
showed mild tachycardia and an increase in blood pressure. 
Klide et al (1975) reported that atropine at a dose of 0.02 mg kg-l IV had 
little effect on the bradycardia produced by 1.1 mg kg-l IV of xylazine in 
dogs but this dose of atropine is much lower than the 0.5 mg kg-l used in the 
present experiments with amitraz. Schmitt et al (1970) also showed that 
xylazine reduced sympathetic activity, an effect which may have contributed 
towards the bradycardia seen in their dogs. 
A number of drugs similar to clonidine have been shown to have a pressor 
effect from stimulation of peripheral a-adrenoceptors. The pressor action of 
oxymetazoline, naphazoline, tr_amazoline and tetryzoline as well as clonidine 
and xylazine was competitively antagonised by phentolamine in pithed rats 
(Autret et al, 1971). These drugs as well as tolonidine, flutonidine, 
thiamenidine, guanabenz and other clonidine analogues have been listed by 
Kobinger(1978) as having a-adrenoceptor agonist properties. 
Bradycardia is another action produced by some of these a-adrenoceptor 
agonists. Pretreatment with atropine or vagotomy prevented bradycardia 
following clonidine (Robson and Kaplan, 1969; Autret et al, 1971) naphazoline 
(Autret et al, 1971) and other clonidine like drugs (Kobinger, 1978). Robson 
and Kaplan (1969) demonstrated that the bradycardia produced by intravenous 
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clonidine in dogs was due to a central action decreasing sympathetic outflow 
as well as a reflex response to the initial hypertension. The present 
results with amitraz indicate that the bradycardia is a reflex response, 
however the presence of a central action needs to be examined. 
In comparison with studies of the actions of a-adrenoceptor agonists, like 
clonidine and xylazine, on the cardiovascular system very little has been 
done to investigate the actions of these drugs on the respiratory system. 
Both intravenous clonidine and guanabenz (Wy8768) reduced the respiratory rate 
in rats by up to 19% and 32% respectively (Bolme and Fuxe, 1973). A central 
inhibitory noradrenergic mechanism that controlled the respiratory rate was 
suggested to explain these results. Later, Bolme et al (1974) reported that 
rats given clonidine at a dose of 5 µg kg-l IV had a decreased respiratory 
rate (by up to 23%), an increased tidal volume (27.5%), but the respiratory 
minute volume showed little change. The changes in tidal volume and 
respiratory rate were prevented by either piperoxan -1 20 mg kg IP or 
-1yohimbine 1 mg kg IP. These responses differed from those seen with 
amitraz where all doses produced depression of the tidal volume and 
respiratory minute volume. The respiratory rate was depressed by only the 
lower doses of the formamidine or immediately· following its injection. 
Except for the small increase in the tidal volume after phentolamine, the 
presence of the antagonists appeared to have little effect on the respiratory 
function after amitraz. 
Amitraz and its first metabolite, BTS 27271, have MAO inhibiting properties, 
and of the two, the parent compound is the more potent inhibitor (discussed 
in Chapter 1). Catecholamine and 5-hydroxytryptamine response times are 
prolonged by MAO inhibitors and this effect is likely to occur at central 
neurones utilizing these transmitters. In a recent review of respiratory 
function, Mueller et al (1982) has summarised information about the central 
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neurotransmitters, particularly 5-hydroxytryptamine, noradrenaline and 
dopamine. Whereas dopamine is considered to be associated only indirectly 
with respiratory timing, both 5-hydroxytryptamine and noradrenaline have 
been shown to play more important roles. Adrenergic drugs can stimulate the 
respiratory centre in cats (Florez et al, 1972; Armijo and Florez, 1974) and 
rats (Lundberg et al, 1980), however, injections of 5-hydroxytryptamine 
(1 to 25 µg) into the cerebral ventricles of rats have shown a depressant 
effect (Lambert et al, 1978). 
Armijo and Florez (1974) also showed that tranylcypromine, a potent MAO 
inhibitor, potentiated the depressant effects of 5-hydroxytryptamine. Rieger 
et al (1980) showed that the potency of amitraz, when compared with 
tranylcypromine on rat brain homogenates. using tyramine or tryptamine as 
substrates, was 0.39 and 0.23 respectively. While these figures indicate 
that amitraz is a weaker inhibitor of MAO than tranylcypromine, the doses of 
the formamidine used in dogs in the present experiments may have been 
sufficient to alter the levels of central transmitters associated with 
respiratory function. A direct effect of amitraz on central neurones or 
peripheral receptors cannot be ruled out, particularly when considering the 
apnoea that was occasionally seen immediately after injection. However, 
elevated central 5-hydroxytryptamine levels may also account for the 
depression seen in respiratory variables. This could dominate any 
stimulatory effect due to a-adrenoceptor agonist action. 
The evidence that amitraz-induced hypertension is reduced by a-adrenoceptor 
antagonists in dogs is in agreement with other reports about this and related 
compounds. Hsu and Kakuk (1984) showed that amitraz was an a-adrenoceptor 
agonist in rats while Robinson (1979) also reported a similar action for 
BTS 27271, the first metabolite of amitraz. Chlordimeform and its 
formamidine metabolites also have a-adrenoceptor stimulating properties 
(Robinson and Bittle, 1979; Hollingworth and Yim, 1980). Intravenous 
chlordimeform in dogs produced an initial transient fall in heart rate and 
70. 
blood pressure before a rise in both variables which was later shown to be 
blocked by hexamethonium. Chlordimeform produced central stimulation of 
sympathetic activity (Lund et al, 1978; Hollingworth and Yim, 1980), a 
response that did not occur following amitraz. 
The four antagonist drugs produced some changes in the blood pressure and 
heart rate of the dogs. Propranolol produced a slight fall in blood 
pressure and this may be explained in several ways; as a direct action on 
the central nervous system, an antirenin effect, an adrenergic neurone 
blocking action, a fall in cardiac output or a resetting of the baroreceptors 
(Prichard, 1978). Any sympathetic activity on the heart is blocked by the 
B-adrenoceptor blocking action of propranolol. The enhanced tachycardia
produced by high doses of amitraz in the presence of propranolol remains 
unexplained but it is possible that propranolol unmasks a direct effect of 
amitraz on the heart. This suggestion is supported by the evidence from 
pithed rats where a positive chronotropic effect was mediated by myocardial 
a-adrenoceptors, a response that was antagonised by prazosin (Flavahan and
McGrath, 1981). 
The fall in blood pressure caused by phentolamine in these dogs was a similar 
response to that reported by Das and Parratt (1971) following intravenous 
injections in cats. This effect was probably due to vasodilation. These 
authors also reported cardiac stimulation. 
Tachycardia is the expected response following intravenous atropine and this 
is considered to be caused by the blocking of vagal activity and alteration 
of the balance between the sympathetic and parasympathetic systems (Shutt 
and Bowes, 1979). 
Hexamethonium can change the heart rate by blocking sympathetic or vagal 
activity at the ganglion level. Although the vascular resistance in 
individual organs may vary, the total systemic vascular resistance falls to 
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lower the blood pressure following this ganglion blocker (Taylor, 1980b). 
Both heart rate and blood pressure fell following hexamethonium in the 
present experiments with dogs. 
Results from this series of experiments have indicated that amitraz produces 
hypertension by an action on peripheral a-adrenoceptors and that bradycardia 
is most likely a reflex response to the increase in blood pressure. Aspects 
that need further clarification are the mechanisms by which the a-adrenoceptors 
are activated by amitraz; the type of adrenoceptor that is stimulated, either 
presynaptic or postsynaptic; the reason for the tachycardia at higher doses 
and the presence of any central actions. 
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CHAPTER 4 
THE EFFECTS OF AMITRAZ ON THE CARDIAC OUTPUT AND 
TOTAL PERIPHERAL RESISTANCE 
INTRODUCTION 
Results from previous experiments have indicated that the increase in blood 
pressure produced by intravenous amitraz was due to stimulation of peripheral 
a-adrenoceptors while the initial bradycardia was a reflex response to the
hypertension (Chapter 3). It has also been shown that there was a close 
correlation between the cardiovascular responses to amitraz given in 
cumulative doses and single doses (Chapter 2). 
Determination of the effects of amitraz on the cardiac output and total 
peripheral resistance would provide more information about the cardiac 
actions of the formamidine. A suitable technique for the measurement of 
cardiac output uses the indicator dilution method. Indicators can be dyes, 
electrolytes, acids, cold, heat or radioactive tracers (Prys-Roberts, 1969). 
The principle of this technique relates to the time-concentration curve, or 
time-temperature-change curve, of the indicator following rapid 
administration. This curve is a frequency distribution curve of the transit 
times of the indicator between injection and sampling sites. 
The thermodilution method, where volumes of cold saline or dextrose solutions 
are injected, has advantages over the dye-dilution method in that it 
permits frequent repeat determinations and rapid detection of temperature 
change without requiring blood withdrawal, the internal calibration is 
constant and the method uses physiological solutions (Warren and Ledingham, 
1974). 
Measurements of cardiac output by thermodilution are frequently compared 
with those made by the Fick or dye-dilution technique. The direct Fick 
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technique uses either oxygen or carbon dioxide as the indicator, whereas 
indocyanine green is the dye that is frequently used for dye-dilution. A 
disadvantage of the thermodilution technique is that it progressively over­
estimates the cardiac output the lower the actual cardiac output becomes 
(Sorensen et al, 1976; Runciman et al, 1981). 
The simultaneous measurement of cardiac output and blood pressure also allows 
for the calculation of total peripheral resistance so that effects on both 
heart and circulation may be assessed. 
The aim of these experiments was to determine the effect of cumulative doses 
of amitraz on the cardiac output and total peripheral resistance in dogs. 
Initially it was necessary to determine the correlation between cardiac 
output measured by thermodilution and by the Fick technique to validate the 
use of the thermodilution apparatus in the dog. 
METHODS 
1. Correlation Between the Thermodilution and.Fick Techniques
Animals and Anaesthesia 
Three healthy mongrel dogs with a weight of 17.0 ± 2.1 kg (mean ± SEM) were 
-1
anaesthetised with 25 to 30 mg kg IV of sodium pentobarbitone(Nembutal,
Ceva Chemicals Aust. Pty. Ltd.) and then intubated with a cuffed
endotracheal tube. The dogs were placed in right lateral recumbency and
breathed air spontaneously. The femoral artery was cannulated for the
measurement and recording of blood pressure and heart rate, as described in
Chapter 2.
The femoral vein was cannulated to enable additional doses of pentobarbitone 
to be given, if necessary. 
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Thermodilution Technique 
An 80 cm double lumen, flow directed thermodilution catheter with a 
thermistor tip (Gould Statham SPS00S SF, California, U.S.A.) was passed down 
the left jugular vein through the right atrium and ventricle so that the tip 
lay in the pulmonary artery. Continuous recording of the blood pressure at 
the tip of the catheter identified its location. The catheter also had a 
proximal opening to allow for the injection of cold dextrose solution just 
before the right atrium when in position. The thermistor leads were 
connected to a Gould Cardiac Index Computer SP1435 (Gould Inc., California, 
U.S.A.). A temperature probe was inserted into the injectate, a solution of 
5% dextrose at room temperature, and connected to the monitor. A single 
channel Gould Recorder SP2009 (Gould Inc., California, U.S.A.), attached to 
the monitor showed the thermodilution curve generated by the injection of 5ml 
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and not measured by the thermistor. 
By using oxygen as the indicator in the direct Fick technique pulmonary blood 
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flow was measured. Cardiac output was calculated from body oxygen con­
sumption and arteriovenous oxygen difference. 
The anaesthetised dogs breathed air from a Modular Stead-Wells Spirometer 
(Warren E. Collins Inc., Massachusetts, U.S.A.) for 3 minutes to measure 
oxygen uptake per minute and this was converted to dry gas at 0°C and
760 mmHg. 
Mixed venous blood samples were taken from the pulmonary artery_ through the 
catheter positioned for the therrnodilution measurements and arterial blood 
samples were taken from the cannula in the femoral artery. Blood samples 
were drawn into 2 ml syringes with only the deadspace containing heparin 
(1000 IU ml-1) . .  It is unlikely that this volume of heparin would influence
the oxygen levels (Hamilton et al, 1978). 
Oxygen saturation and haemoglobin concentration of the arterial and venous 
blood samples were measured immediately using an OSM 2 Hemoximeter (Radiometer 
Ltd., Copenhagen, Denmark) while additional blood samples were kept on ice 
until the partial pressure of oxygen (P0 2) was measured. The principle of 
the Hemoximeter is the absorption of light at wavelengths of 506.5 nm and 
600.0 nm to measure reduced and oxyhaemoglobin levels. Cole and Hawkins 
(1967) showed that readings from the OSM 1 Hemoximeter (light wavelengths of 
505 nm and 598 run) compared favourably with those from the Van Slyke technique 
(variation of 0.88% ± 0.83 (SD) of saturation, n= 21). 
P0 2 levels were measured by a Corning 168 pH/Blood Gas System (Corning Medical, 
Massachusetts, U.S.A.) where the oxygen electrode (Clark electrode) has a 
platinum cathode and a silver/silver chloride anode and a constant voltage of 
700 mV is maintained between them. Oxygen is reduced, silver is oxidised at 
the anode to complete the circuit and the magnitude of the current indicates 
the partial pressure of oxygen. Adjustments were made to the P0 2 readings 
according to the nomogram by Kelman and Nunn (1966), to allow for the 
76. 
difference between the body temperature of the dog and that for the blood 
gas analyser (37 ° C). 
Cardiac output was calculated using the equation: 
co 
C(a - v) 0 2 
where C(a - v)Oz = [Hb x 1.34 x S(a - v)Oz] + [0.031 x P(a - v)0 2 ] 
co cardiac output -1 = (1 min )
V0
2 oxygen uptake 
-1(ml min )
C(a - v)o 2 = arteriovenous oxygen content difference (ml Oz -1
-1)
Hb = haemoglobin concentration (g 1-1)
1.34 = oxygen haemoglobin combining factor (ml Oz per g Hb) 
S(a - v)o 2 = arteriovenous oxygen saturation difference (%)
P(a v)0 2 = arteriovenous oxygen tension difference (mmHg). 
For each cardiac output comparison measurement, cardiac output was measured 
by thermodilution 3 times while each dog was breathing air from the spirometer 
and the average value was compared with the measurement by the Fick method. 
Resting cardiac output measurements were made and then the cardiac output was 
increased by a constant infusion of noradrenaline intravenously. An intra­
-1 cisternal injection of clonidine (2 µg kg ) was used to lower the cardiac.
output. 
2. Cardiac Output in Dogs Given Amitraz
These experiments were performed on 8 healthy mongrel dogs of either sex 
weighing 14.7 ± 1.2 kg (mean ± SEM). Animals were anaesthetised and 
prepared as described in Chapter 2 for the recording of femoral artery blood 
pressure and heart rate. Pulmonary artery blood pressure was recorded from 
the double lwnen catheter with the thermistor· tip. Cardiac output by 
thermodilution was measured in each dog, as described above, on three 
occasions initially and again 1, 3 and 5 minutes following the intravenous 
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injection of an equivalent volume of DMSO required to dissolve the highest 
dose of amitraz. 
-1
An initial dose of 0.5 mg kg of technical grade amitraz
was given intravenously and after every 6 minutes additional doses were given
-1
so that the effects of 0.5, 1, 2, 5 and 10 mg kg of amitraz were studied.
Cardiac output was measured 1, 3 and 5 minutes after each dose of the
formamidine.
To reduce the variation in cardiac output between dogs with different body 
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213 (Guyton et al, 1973). 
Wiggers (1944) showed that the cardiac index is of a similar order of 
magnitude for dogs of different weights. 
The total peripheral resistance was calculated from the femoral artery blood 









referred to as "units") 
MAP = mean femoral artery pressure (mmHg) 
cardiac index (1 min 
-1 -2
CI = m ) .
Again cardiac index was used in this calculation to reduce variation between 
animals. An accurate calculation of the total peripheral resistance is made 
by dividing the difference between the mean arterial pressure and the right 
atrial pressure by the cardiac output. As the right atrial pressure is small 
and close to zero it was not used for the present calculations. 
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Results for all variables were expressed as a change from the preamitraz 
control. 
Statistical Analysis 
Values for the cardiac output measured by therrnodilution were compared to 
those from the Fick technique and linear regression was used to construct a 
line relating these measurements (Snedecor and Cochran, 1967). 
Values for the change from control for mean arterial pressure (MAP), mean 
pulmonary artery pressure (MPAP), heart rate (HR), cardiac index (CI) and 
total peripheral resistance (TPR) were analysed using Two-Way Analysis of 
Variance (Snedecor and Cochran, 1967). 
The standard error of the mean (SEM) at any time was calculated for each 
variable as described in Chapter 2. 
Values differing from the control at the level of P<0.05 were considered 
significant. 
RESULTS 
1. Correlation Between Therrnodilution and Fick Techniques for
Measuring Cardiac Ouput 
The mean value for three cardiac output measurements by thermodilution were 
compared with the simultaneous measurement by the Fick method. Thirteen 
pairs of readings were made in three dogs and the results are shown in Figure 
4.1. Linear regression analysis produced the equation: 
y = 0.83x + 0.46 
y = therrnodilution cardiac output 
X = Fick cardiac output 
r = 0.99, t = 23.28, P<0.001. 
Figure 4.1 Cardiac output measurements by thermodilution plotted 
against simultaneous measurements by the Fick method. 
The identity line (----) and the line of regression 
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2. Cardiac Index and Total Peripheral Resistance
in Dogs Given Aihitraz 
Statistical analysis of the cardiac index values in the presence of DMSO, the 
vehicle used to dissolve amitraz, showed that there was no difference from 
the control values (n=8). 
The control values (preamitraz injection) for all variables are shown in 
Table 4.1. 
Table 4.1 Mean (SEM) values for the cardiovascular variables for the 
control and after DMSO (n=S) 
Variable Control DMSO 
MAP (mmHg) 101. 7 (6.3) 105.0 (7.2) 
MPAP (mmHg) 10.5 (0.6) 10.5 (0.6) 
HR (bpm) 115.5 (8.3) 109.8 (6. 8) 
CI (1 min -1 m-2) 3.5 (0.2) 3.5 (0.2) 
TPR (units) 30.0 (3.3) 32.3 ( 4. 4)
-1 Figure 4.2 summarises the effect of 0.5, 1, 2, 5 and 10 mg kg of amitraz 
IV on MAP, MPAP, HR, CI and TPR (n=S). 
The increase in blood pressure (maximum 26.3 mmHg) and bradycardia 
(maximum 38.7 bpm) produced by 0.5 mg kg-l of amitraz was of a similar 
magnitude to that seen in previous experiments. Subsequent doses produced 
further rises in blood pressure and a heart rate that showed a gradual 
return to control values. These changes were similar to the observations 
made previously using the same doses of the formamidine. 
Results for all cardiovascular variables were analysed statistically and a 
summary of those values that were significantly different from the control are 
presented in Table 4.2. 
Figure 4.2: The effects of cumulative doses of arnitraz (0.5, 1, 2, 
-15 and 10 mg kg IV) on the mean femoral artery pressure
(MAP), mean pulmonary artery pressure (MPAP), heart 
rate (HR), cardiac index (CI) and the total peripheral 
resistance (TPR).  Vertical bars indicate the SEM at 
any time (n=8). 
* P<0.05 ** P<0.0$. Statistical analyses performed 
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Table 4.2 Statistical data of results that were significantly different 
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Orthogonal partitioning of the between-treatments swns of squares, that is, 
control, DMSO, and the five doses of arnitraz, was performed to examine the 
results in greater detail. Amitraz values were found to be significantly 
different from the control values for all variables. Analysis of the 
"within treatment" results, that is, between doses and between times, showed 
that there were differences. The relationships, either linear, quadratic or 
cubic, whe.re differences exist are listed. 
The pulmonary artery pressure increased with cumulative doses of amitraz: 
-1
0.5 mg kg produced an increase of 4.7 nunHg (3 minutes post-injection) and
-1
10 mg kg , an increase of 14.5 rnmHg (5 minutes post-injection). Whereas the 
-1
femoral artery pressure showed a slight fall in blood pressure after 10 mg kg 
of amitraz compared to the previous doses, the pulmonary artery pressure 
showed a slight rise. 
-1
After 5 mg kg of arnitraz the pulmonary artery
pressure showed an increase of 12.7 nunHg (5 minutes post-injection) while
-1
10 mg kg produced an increase of 13.1 rnmHg (1 minute post-injection).
The cardiac index was initially depressed by all doses of arnitraz. The 
-1 -2 -1 
greatest decrease was 0.9 1 min m with a dose of 0.5 mg kg . Measure-
ments taken at 3 and 5 minutes after arnitraz injection showed a return of the
cardiac index towards the control value following a statistically
significant difference between the control value and the readings taken 1
minute post-injection (df = 1, F = 6.96, P<0.005).
Amitraz produced a dose related increase in total peripheral resistance after 
doses of 0.5, 1, 2 and 5 mg kg
-1
; readings 5 minutes after each amitraz
injection were 8.2, 12.0, 17.8 and 23.8 units, respectively. 
-1
After 10 mg kg 
of arnitraz the increase in total peripheral resistance had plateaued with an 
increase from control of 23.2 units, 5 minutes post-injection. The greatest 
increase in the peripheral resistance was immediately after amitraz injection 




Correlation Between Thermodilution and Fick Techniques 
Cardiac output by thermodilution is a technique that is quick and easy to 
perform and permits frequent measurements. Measurements correlate closely 
with results from dye-dilution and the Fick method, a well recognised 
standard for measuring cardiac output, however, the thermodilution technique 
progressively over-estimates the cardiac output the smaller the actual value 
becomes. This was investigated extensively where 171 measurements were made 
in dogs by thermodilution and compared with the dye-dilution method 
(Runciman et al, 1981). Although the correlation coefficient was 0.98, 
thermodilution over-estimated dye-dilution measurements by 0.6% at 5 1 min-l
-1 and 7.5% at 2 1 min . A review of the literature by Runciman et al (1981)
showed that their results correlated well with other studies. Similar 
reports about errors associated with thermodilution measurements have been 
made in dogs,(Chapman and Baker, 1984) and pigs (Sorensen et al, 1976) and 
the present study, in which thermodilution and Fick methods are compared, 
showed a similar error when lower cardiac outputs were produced (6.25% at 
2 1 min-lover-estimate; 1.42% at 3 1 min-l underestimate).
Reasons for the error using thermodilution are heat loss of thermal 
indicator between injectate reservoir and injection site, between injection 
site and sampling site by the thermistor and inadequate response of the 
thermistor (Korner and Hilder, 1974; Runciman et al, 1981). Heat loss of 
the thermal indicator between injectate reservoir and injection site can be 
reduced by using injectate at room temperature and taking care when handling 
the syringe during injection. The Gould Cardiac Index Computer permits the 
use of injectate at room temperature and care was taken in handling the 
syringe. 
Effects of Amitraz 
Not only does intravenous amitraz increase blood pressure and produce 
bradycardia but also there is a dose related increase in the total 
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peripheral resistance. The cardiac index was reduced only transiently and 
had returned to control values 5 minutes after injection. 
-1Amitraz at 10 mg kg produced a fall in total peripheral resistance and a 
rise in cardiac index 3 minutes post-injection. In Chapter 2 it was shown 
that the respiratory minute volwne was markedly depressed by high doses of 
amitraz (Figure 2.7) causing elevation of body carbon dioxide levels. 
Elevated carbon dioxide levels produce complex changes in the body: there is 
stimulation of the sympathetic system to increase the cardiac output and con­
strict the blood vessels, however in the tissues, carbon dioxide is a potent 
vasodilator (Nunn, 1977; Prys-Roberts, 1980). Increased carbon dioxide 
levels may be the reason for the variation in cardiac index and total 
peripheral resistance seen following 10 mg kg-l of amitraz when compared to
previous doses. 
After each dose of amitraz the cardiac index showed greatest depression when 
the total peripheral resistance was at its highest level. A likely reason for 
this reduction in cardiac index is the greater aortic impedance against which 
the ventricles had to eject blood. At the same time, bradycardia may have 
contributed to the transient fall in cardiac index. Reduced end-diastolic 
pressure (preload) may also reduce cardiac output (Fletcher, 1980) but this 
is unlikely since amitraz has been shown to stimulate a-adrenoceptors 
(Chapter 3) . 
It was interesting to note that five minutes after each dose of amitraz the 
cardiac index values showed little difference from the control. Preload, 
myocardial contractility and heart rate are three important factors that 
regulate cardiac output (Prys-Roberts, 1980). When the cardiac index had 
returned towards control values at a time when the heart rate was reduced by 
amitraz, then it is reasonable to infer that the formamidine had some 
stimulating effect on one or more of the other factors that regulate cardiac 
output. Experimental evidence exists for post-junctional myocardial 
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a-adrenoceptors that mediate a positive inotropic response following
clonidine and naphazoline (Schumann and Endoh, 1976). In view of this 
information amitraz may stimulate myocardial a-adrenoceptors and increase 
myocardial contractility, thereby maintaining cardiac output when both the 
aortic impedance is increased and the heart rate is reduced. It is possible 
that higher doses of amitraz may further stimulate myocardial a-adrenoceptors 
but aortic impedance is also higher, as shown by the peripheral resistance. 
Although cardiac index values had returned to control levels 5 minutes after 
each injection of amitraz the total peripheral resistance remained elevated, 
indicating that the hypertension following amitraz was an action on the blood 
vessels. In support of this postulate, it was shown in Chapter 3 that 
phentolamine prevented amitraz-induced hypertension. As this antagonist has 
weak cardiac stimulating properties rather than depressing properties (Das 
and Parratt, 1971) it is likely that the hypertension produced by amitraz is 
associated with vascular constriction. 
Amitraz produced only a transient decrease in cardiac index which was in­
consistent in comparison to two other drugs with similar properties, xylazine 
and clonidine. -1 Xylazine (1.1 mg kg IV) depressed aortic blood flow in dogs
for 60 minutes, an effect the authors attributed to a simultaneous bradycardia
(Klide et al, 1975). The bradycardia in the dogs given xylazine (19.9% 
decrease S minutes post-injection} was similar to that seen with 0.5 mg kg-l
amitraz (23.5% decrease) and was associated with a 40% reduction in cardiac 
output. At a similar time, cardiac output in the amitraz treated dogs had 
returned to control levels. Schmitt et al (1970) showed that xylazine re­
duced sympathetic activity and this may have contributed to the fall in 
cardiac output. Similarly cardiac output showed prolonged depression for at 
least 90 to 120 minutes in dogs given clonidine at a dose of either 
-1 -1 30 µg kg IV or 1 µg kg ICM (Kobinger and Walland, 1967).
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Both xylazine (Klide et al, 1975) and clonidine (Kobinger and Walland, 1967) 
increased the total peripheral resistance in dogs during an initial stage of 
hypertension. Amitraz also increased the peripheral resistance but hypo­
tension was an inconsistent feature. 
In the present study the right atrial pressure was not measured and it was 
considered to be close to zero for the calculation of total peripheral 
resistance. If actual values were taken into account there may have been 
minor changes to the calculation particularly after the higher qoses of amitraz 
when hypertension was maximal. 
Cardiac output values were converted to cardiac index to overcome variation 
due to dog size. For this reason the cardiac index was used to calculate 
the total peripheral resistance; a transformation of data that was also 
preferred for interpatient relationships by Greenburg and Peskin (1978). 
Haddy and Campbell (1953) have also calculated the total peripheral 
resistance in dogs using cardiac index. Wiggers (1944) questioned the 
advantage of introducing body surface area into the calculation of total 
peripheral resistance because of the lack of correlation between these two 
measurements and, therefore, chose cardiac output over cardiac index. 
The control value for the cardiac index in the present study of 
. -1 -2 3.5 ± 0.2 1 min m (mean± SEM) was similar to the value of 3.55 ± 0.18
-1 -2 1 min m reported by Haddy and Campbell (1953) and 3.5 ± 0.86 by Gould et
al (1970). Other reports of the cardiac index in dogs are 2.87 ± 0.44 
. -1 -2 . -1 2 1 min m (Wiggers, 1944), 2.7 1 min m- within a range of 1.8 to 3.7
(Yarns and Tashjian, 1967) and 3.3 ± 1.1 1 min-l m-2 (Haddy et al, 1949).
The control value for the pulmonary artery pressure was 10.5 ± 0.6 mmHg which 
was lower than 16.7 ± 3.4 mmHg reported by Haddy et al (1949) and 13 mmHg, 
range 8 to 16 mmHg, by Yarns and Tashjian (1967). Due to variation in the 
way total peripheral resistance units are expressed, references using the 
same units as in this study are limited. Data provided by Haddy and Campbell 
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·(1953) allowed for the calculation of the total peripheral resistance of
41.3 ± 2.09 units which was higher than the control value of 29.9 ± 3.3 units
from the present study, however, the dogs used by Haddy and Campbell (1953)
had a higher mean femoral artery pressure (132.6 ± 4.2 mmHg).
The measurement of cardiac output using thermodilution has provided more 
information about the actions of amitraz in the dog. As well as causing 
hypertension and bradycardia, cumulative doses of amitraz also produced a 
dose related increase in the pulmonary artery pressure and the total 
peripheral resistance, however, the cardiac index was only transiently 
depressed before it returned to control values. The concurrent increase in 
blood pressure and total peripheral resistance without much change in the 
cardiac index indicated that the hypertension, at the doses given, was the 
result of a vascular action by amitraz rather than a cardiac effect. This 
finding agrees with those findings detailed in Chapter 3 that peripheral 
a-adrenoceptors are activated by amitraz.
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CHAPTER 5 
THE EFFECTS DFAMITRAZ ON THE RESPONSES TO CARDIOVASCULAR AGONISTS 
· INTRODUCTION
Previous experiments have shown that the increase in blood pressure seen in 
dogs following IV amitraz is caused by stimulation of peripheral a-adrenoceptors. 
The initial bradycardia appears to be a reflex response. In addition, cardiac 
output returned to control levels soon after injection and S-adrenoceptor 
stimulation was not apparent. 
The enzyme, MAO, is inhibited by amitraz in rat liver, brain and lung 
(Rieger et al, 1980) slowing the oxidative deamination of 5-hydroxytryptamine 
and sympathetic ·amines, which include adrenaline, noradrenaline, tyramine and 
dopamine. Most of these naturally occurring monoamines are neurotransmitters 
and if their actions are prolonged, the possibility of an effect on the 
respiratory system cannot be discounted (see Discussion, Chapter 3). 
Investigations of the mechanisms of action of amitraz at receptor sites in the 
cardiovascular system require further study. Although antagonists have been 
examined, the effect of amitraz on agonist action has not been studied. 
Actions at the ganglion and the postganglionic effectors for both the 
sympat�etic and parasympathetic systems can be investigated by comparing the 
responses of specific agonists before and after amitraz. Important agonists 
in these areas are acetylcholine, noradrenaline, i3oprenaline, 
dimethylphenylpiperazinium (DMPP) and tyramine. 
Acetylcholine is an important neurotransmitter at parasympathetic effectors 
(muscarinic actions), autonomic ganglion cells, adrenal medulla, motor end­
plates on skeletal muscle (nicotinic actions) and some synapses within the 
central nervous system. Acetylcholine is synthesized in the nerve ending by 
the acetylation of choline with acetylcoenzyme A and is rapidly destroyed by 
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cholinesterase, particularly acetylcholinesterase. 
Noradrenaline is the transmitter at sympathetic postganglionic fibres and at 
some synapses in the central nervous system. Noradrenaline is synthesized 
from the amino acid tyrosine in the nerve ending and, when released, about 
75% is taken up by the nerve ending to terminate its actions (Langer and Hicks, 
1984). Catechol-o-methyl transferase, found mainly in the effector cell, and 
MAO, found mainly in the mitochrondria of the nerve ending, metabolise 
noradrenaline. This amine activates predominantly a-adrenoceptors but also 
has some S-adrenoceptor agonist action (Weiner, 1980). 
Isoprenaline is a sympathomimetic amine that has powerful S-adrenoceptor 
agonist properties and is primarily metabolised in the liver and other tissues 
by catechol-o-methyl transferase. Only very small quantities are either 
taken up by sympathetic neurones or metabolised by MAO (Weiner, 1980). 
The indirect sympathomimetic amine, tyramine,. produces most of its responses
by displacing noradrenaline from the nerve ending and is itself metabolised by 
MAO (Weiner, 1980). Desipramine (DMI) blocks the neuronal uptake of 
noradrenaline (Langer and Raisman, 1983) and the actions of amitraz were 
tested in the presence of this antagonist to determine if the formamidine has 
an indirect sympathomimetic effect. 
DMPP is a short acting ganglion stimulant in nicotinic receptors in the 
autonomic ganglia and adrenal medulla (Chen et al, 1951). 
Histamine is synthesized from the amino acid histidine and is stored 
predominantly in granules in mast cells and basophils. Smooth muscles of 
the bronchi and gut are contracted by histamine, however, blood vessels are 
relaxed producing vasodilation. Histamine is metabolised by various enzymes 
(Douglas, 1980). 
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The aim of this investigation was to study the responses to agonists at 
ganglia and effector cells of the sympathetic and parasympathetic nervous 
systems in the presence of amitraz. Histamine was also studied in view of 
the report by Pass and Seawright (1982) that amitraz inhibited its action on 
the guinea-pig ileum in vitro. In view of its profound effects on cardio­
respiratory function, an investigation of the actions of amitraz on autonomic 
function was considered important. Agonists that activate receptor sites at 
particular segments of the autonomic nervous system were chosen for this study. 
An indirect sympathomimetic action of amitraz was investigated using tyramine 
and the antagonist, DMI. 
METHODS 
Dose Response Curves for Agonists 
Dose response curves for the agonists were determined in dogs anaesthetised 
and prepared for the recording of blood pressure and heart rate as described 
in Chaper 2. Responses to increasing doses of each agonist, given IV via a 
femoral vein cannula, were used to plot dose response curves. 
The Effects of Drug Vehicle on Agonist Responses 
Thirteen dogs of either sex, that were clinically healthy and had a mean 
weight of 15.8 ± 1.2 kg (mean ± SEM) were anaesthetised and prepared for the 
recording of blood pressure and heart rate. Agonist drugs (acetylcholine, 
noradrenaline, isoprenaline, tyramine, histamine, DMPP), giving responses on 
the linear portion of the dose response curves, were given IV before and 
after an equivalent volume of DMSO used to dissolve the high dose of amitraz. 
Maximum changes in MAP and HR from the preinjection baseline and the time 
taken for responses to return to within 10% of the baseline were then 
compared. 
Six dogs were given 0.1 ml of catecholamine vehicle solution IV, the vehicle 
-----;-
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used to dissolve the agonist drugs, and the effects on the MAP and HR were 
recorded. 
The Effects of Amitraz on Responses to Agonists 
These investigations were performed on 43 clinically healthy mongrel dogs 
of either sex (13.6 ± 0.5 kg) anaesthetised and prepared for the recording of 
MAP and HR as described in Chapter 2. 
Two doses of agonist drugs (acetylcholine, noradrenaline, isoprenaline, 
tyramine, DMPP and histamine) from the linear part of the dose response curve 
were given IV and flushed in with 1 ml of heparinised saline. Subsequent 
injections were not made until the variables had returned to preinjection 
levels and the catheter was periodically flushed with heparinised saline to 
ensure that any residual agonist drug was removed. 
Agonists were retested after amitraz injection when the MAP and HR recordings 
had stabilised. The maximum change in MAP and HR produced by each agonist 
was recorded as well as the time taken for the response to return to within 
10% of the baseline reading. Responses before and after amitraz, at doses of 
-1
1, 2 and 5 mg kg IV, were compared for each agonist. These amitraz doses
were on the linear portion of the dose-response curve (Figure 2.14).
The actions of amitraz in the presence of IV DMI were also investigated in 
this series of experiments. Responses to tyramine were studied in one group 
of dogs where cumulative doses of amitraz were administered while the 
remaining five agonists were tested in dogs given a single dose of the 
formamidine. 
Statistical Analysis 
MAP and HR responses were plotted against the dose of agonist and then 
analysed by linear regression. The correlation coefficient was calculated and 
then the t value for the slope of the line (Snedecor and Cochran, 1967). MAP 
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and HR responses for the two doses of each agonist before and after DMSO or 
amitraz were compared by symmetrical 2 + 2 parallel line assay (Colquhoun, 
1971). Statistical analysis was not done on the HR responses to 
noradrenaline, DMPP and histamine due to inconsistencies in the direction of 
change. This analysis tested for a significant shift of the line and for 
parallelism. The time taken for responses to return to within 10% of the base­
line reading before and after DMSO or amitraz was compared using the "Student's" 
t test for all drugs except tyramine, where Dunnett's t test was used 
(Snedecor, and Cochran, 1967; Dunnett, 1955). 
All values that differed from the control (the preamitraz response) at levels 
of P<0.05 were considered significant. 
Results are expressed as mean ± SEM. 
Drugs 
The agonist drugs used in these experiments were acetylcholine chloride 
(Sigma Chem. Co.; 0.25 and 1 µg kg-
1
), noradrenaline hydrochloride (Sigma 
Chem. Co.; 0.05 and 0.2 µg kg-1), isoprenaline sulphate (Sigma Chem. Co.;
0.05 and 0.1 µg kg-
1
), tyramine hydrochloride (Sigma Chem. Co.; 12.5 and 
-130 µg kg ), dimethylphenylpiperazinium iodide (DMPP; Sigma Chem. Co.; 9 and
-1 1 15 µg kg ) and histamine diphosphate (Sigma Chem. Co.; 0.5 and 2 µg kg- ). 
The doses given above are those chosen from the linear part of the full dose 
response curve obtained for each agonist. Drugs were prepared fresh each day 
-1and dissolved in catecholamine vehicle (9.0 g 1 sodium chloride,
1 -10.19 g 1- sodium dihydrogen phosphate, 30 mg 1 ascorbic acid). Volumes of 
0.1 ml were flushed in with heparinised saline. 
Desipramine hydrochloride (DMI; Ciba-Geigy; 1 mg kg
-1) was prepared in 0.9%
sodium chloride solution. 
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Technical grade amitraz was dissolved in dimethyl �ulphoxide (DMSO; 
1.08 g ml-
1
; Ajax Chemical Labs.). 
The weights of all drugs were expressed as the total salt. 
RESULTS 
Dose Response Curves for Agonists 
Dose response curves of the mean change in MAP and HR were plotted for each 
agonist (Figures 5.1 and 5.2). Tables 5.1 and 5.2 show details of the 
statistical analysis of MAP and HR changes. 
The heart rate changes produced by histamine and DMPP were not considered 
because of variations between dogs. DMPP produced a biphasic change in MAP 
and calculations were performed on both peaks. 
The Effects of Drug Vehicle on Cardiovascular Responses 
There was no change in the MAP and HR following 0.1 ml of catecholamine 
vehicle IV. 
Statistical analysis of the agonist responses and the time taken for the 
return to control levels before and after DMSO showed that there was no 
significant difference. Consequently, the small effects of DMSO were not 
taken into account when analysing data from arnitraz experiments. 
The Effects of Amitraz on Agonist Responses 
Examples of typical changes in MAP and HR produced by the agonists before 
and after amitraz are shown in Figures 5.3, 5.4 and S.S. 
-1
The responses to acetylcholine (0.25 and 1 µg kg IV; n=6) are swnmarised in 
Figure 5.6. The decrease in MAP caused by acetylcholine was antagonised by 
amitraz but this did not appear to be dose related. Analysis of the data 
Figure 5.1 Dose response curves for changes in MAP and HR produced 
by acetylcholine (n=4), noradrenaline (n=4) and 
isoprenaline (n�4). The symbols represent the mean change 
and bars the SEM. Statistical analysis of these curves 
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Figure 5.2 Dose response curves for changes in MAP and HR produced 
by tyramine (n=4), DMPP (n=S) and histamine (n=4). For 
DMPP, dose response lines were plotted for each phase of 
the rise in :MAP. Symbols represent the mean change and 
the bars the SEM. Statistical analysis of these curves 
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Table 5.1 Statistical analysis of the points for the MAP in the agonist 
dose response curves. The t and P values represent a test of 
significance of the correlation coefficient. 
Agonist No. of Correlation 
t value p 
Dogs Coefficient 
Acetylcholine 4 0.996 19.81 <0.001 
Noradrenaline 4 0.988 11.17 <0.01 
Isoprenaline 4 0.962 5.01 <0.05 
Tyramine 4 0.946 5.08 <0.05 
DMPP (first peak) 8 0.993 14.26 <0.001 
(second peak) 8 0.950 5.30 <0. 05 
Histamine 4 0.997 21.27 <0.001 
Table 5.2 Statistical analysis of the points for the HR in the agonist dose 
response'curves. The t and P values represent a test of 
significance of the correlation coefficient. 
Agonist No. of Correlation t value 
Dogs Coefficient 
Acetylcholine 4 0.972 14.31 <0.001 
Noradrenaline 4 0.979 8.38 <0.01 
Isoprenaline 4 0.965 5.17 <0.05 
Tyramine 4 0.983 9.27 <0.01 
Figure 5.3 Examples of responses to acetylcholine, noradrenaline 
and isoprenaline before (control) and after amitraz at 
-1
a dose of 2 mg kg IV. Upper trace shows BP and lower
trace shows HP. 
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Figure 5.4 Examples of responses to DMPP and histamine before 
-1
(control) and after amitraz at a dose of 2 mg kg IV. 
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Figure 5.5 Examples of responses to tyramine before (control) and 
-1
after ami traz at a dose of 2 mg kg . For each panel
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Figure 5.6 Effects of 1, 2 and 5 mg 
-1
of amitraz kg on responses to 
acetylcholine (0.25 and 1 µg 
-1
kg ; n=6) Histograms 
show the time taken for the response to return to within 
10% of the baseline. Symbols show the mean and vertical 
bars the SEM. 
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showed that the acetylcholine dose response line in the presence of amitraz 
was parallel to the control line but significantly shifted to the right. 
The times taken for the return of the responses were reduced by all doses of 
amitraz and although the difference between control and amitraz (5 mg kg-
1)
times were not significant statistically, t values were close to 
significance. 
-1
(acetylcholine, 0.25 µg kg , t = 1.99, d.f. = S;
-1acetylcholine, 1 µg kg , t = 2.28, d.f. = S; value�£or t zt P<0.05 � 2.57).
The HR responses and the time taken for them to return following acetyl­
choline were reduced in the presence of arnitraz. The dose response line after 
-1amitraz at 1 mg kg was not parallel to the control (F = 2.09; P = 0.05).
-1 -1After amitraz at 2 mg kg and 5 mg kg there was no difference between the
control and post
-amitraz dose response lines.
The responses to noradrenaline (0.05 and 0.2 µg kg-1; n=6) are shown in
Figure 5.7. Analysis of the results for the increase in MAP before and after 
amitraz showed that there was no significant difference between any of the 
control and post
-
amitraz lines. Statistically, there was no difference 
between the times for return of responses for the control and arnitraz groups. 
However, times were increased for the two lowerarnitraz doses and t values were 
-1 -1close to significance after arnitraz at 2 mg kg (noradrenaline, 0.05 µg kg ,
-1t = 2.-02, d.f. = 5; noradrenaline, 0.2 µg kg , t = 2.46, d.f. = 5, value for
t at P<0.05 = 2.57).
The changes in HR following noradrenaline before and after arnitraz are shown 
in Table 5.3. These results show that in most groups the mean increase in 
heart rate elicited by noradrenaline was greater after arnitraz than before. 
Furthermore, fewer animals showed heart rate decreases after the forrnamidine. 
Results of the effects of arnitraz on the responses to isoprenaline (0.05 and 
0.1 µg kg-
1
; n=6) are swnrnarised in Figure 5.8. Statistical analysis of the 
Figure 5.7 
-1
Effects of 1, 2 and 5 mg kg of amitraz on responses to noradrenaline (0.05 and 
0.2 µg kg-
1
; n=6). Histograms show the time taken for the response to return 
to within 10% of the baseline. Symbols show the mean and vertical bars the SEM. 
A - amitraz 
• • Response before ami traz
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Table 5.3 Changes in HR (bpm) produced by noradrena-line comparing the 
effects before amitraz (control, C) with those after 1, 2 and 
5 mg kg-1 (Al, A2, AS). Figures show mean (SEM). The number 
of dogs in each group showing HR changes in the direction 
indicated are given in italics. Some dogs showed a biphasic 
change. 
Direction of C Al C A2 C AS 
HR change 
Noradrenaline Increase - 4.5 1.3 1.6 1.9 13.7 
0.05 µg kg 
-1
(0. 9) (1.3) (0.4) (0. 4) (6. 2) 
4/6 1/6 5/6 2/6 5/6 
---------------- -----------------------------------------------
Decrease 18.4 10.4 11.6 8.8 12.4 6.9 
(3.4) (1. 3) (2.5) (2.9) (3.9) (1. 4) 
6/6 4/6 6/6 3/6 6/6 3/6 
Noradrenaline Increase 16.9 15.1 29.0 8.6 15.9 24.0 
0.2 µg kg
-1
(14.1) (4.1) (17.1) (1. 9) (3.3) (9. 0) 
2/6 4/6 3/6 6/6 5/6 6/6 
---------------------------------------------------------------
Decrease 31.7 15.7 26.3 11.4 21.1 14.9 
(5.3) (2. 8) (5. 3) (1.8) (4.5) (5. 6) 
6/6 5/6 6/6 6/6 6/6 3/6 
Figure 5.8 
-1
Effects of 1, 2 and 5 mg kg of amitraz on responses to 
-1
isoprenaline (0.05 and 0.1 µg kg ; n=6). Histograms 
show the time taken for the response to return to within 
10% of the baseline. Symbols show the mean and vertical 
bars the SEM. 
A amitraz 
• ..,_ __ ___. •• Response before amitraz 
0------0 Response after amitraz 
* P<0.05
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isoprenaline dose response lines for blood pressure before and after amitraz 
showed no significant difference between them. Lines were parallel for 
· 1 · 1 d 5 mg kg-l of am1·traz. an1ma s given an The times for the return of blood
-1 pressure responses were increased after amitraz at 1 mg kg (isoprenaline,
0.1 µg kg-1, t = 2.58, d.f. = 5, P<0.05) and 2 mg kg-l (isoprenaline,
-1 0.1 µg kg , t = 3.30, d.f. = 5, P<0.05). The prolonged time taken for the
return of responses decreased with higher doses of amitraz. There was also
a change in the shape of the MAP response to isoprenaline in the presence of
amitraz as shown in Figure 5.3. The increase in HR and the time taken for
return of the responses to isoprenaline after amitraz showed no significant
difference from the control.
The effects of cumulative doses of amitraz on the responses to tyramine 
-1 (12.5 and 30 µg kg ; n=4) are summarised in Figure 5.9. While mean values 
for tyramine-induced rises in blood pressure increased with the dose of 
-1amitr�z, a statistically significant shift occurred· only after 5 mg kg
(F = 11.89, P<0.05). All lines were parallel. The only response time that 
was significantly different from the control was that for tyramine at 
-1 -1 30 µg kg (control, 111.0 ± 24.8 seconds; amitraz 5 mg kg , 387.0 ± 108.7
second; P<0.01). Conversely the HR changes produced by tyramine were
decreased after amitraz. The only dose response line that showed a
-1 significant shift was after 5 mg kg of amitraz (F = 10.07, P<0.05). This
line did not show a parallel shift. The time for return of the responses
decreased with increasing doses of amitraz. The only time significantly
different from the control with 30 -1 tyramine was in theµg kg of presence 
of 5 -1 of amitraz (control, 174 ± 8.1 seconds; amitraz 5 mg -1 mg kg kg , 
12.0 ± 6.9 seconds; P<0.05). 
-1 The increases in rvtA.P produced by DMPP (9 and 15 µg kg ; n=8) before and after
amitraz are shown in Figure 5.10. While amitraz consistently reduced the 
blood pressure responses to DMPP, the only dose response line that was 
significantly different from the control was that after 2 mg kg-l of amitraz. 
Figure 5.9 Effects of 1, 2 and 5 mg kg 
-1
of amitraz on responses 
tyramine (12.5 and 30 µg 
-1
kg ; n=4). Histograms show 
time taken for the response to return to within 10% of 
baseline. Symbols show the mean and vertical bars the 
SEM. 
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Effects of 1, 2 and 5 mg kg of amitraz on responses to 
-1
DMPP (9 and 15 µg kg ; n=8). Histograms show the time
taken for the response to return to within 10% of the
baseline. Symbols show the mean and vertical bars the
SEM.
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Blood pressure responses to 15 µg kg-l of DMPP (second peak) were
-1 significantly reduced by 1 and 2 mg kg of amitraz (paired t test; amitraz
-1 -1 1 mg kg , t = 2.57, d.f. = 7, P<0.05; amitraz 2 mg kg , t = 2.39, d.f. = 7, 
P<0.05). Times for return of responses varied; figures for the two 
significant differences are shown helow: 
DMPP Control Amitraz (Dose) t·value d.f.
Dose Time (sec) Time (sec) 
9 µg kg -1 64.0 ± 16.0 -1 (5 mg kg ) 3.18 7 
5.7 ± 3.7 
15 µg kg -1 179.0 ± 43.4 -1 (1 mg kg ) 2.44 7 
83.5 ± 36.2 
<0.05 
<0.05 
-1 The decreases in MAP following histamine (0.5 and 2 µg kg ; n=6) before and 
after amitraz are shown in Figure 5.11, along with the times taken for the 
return of the responses. Statistical analysis showed that the histamine 
dose response lines after amitraz were parallel to the control lines with no 
significant shift. Table 5.4 summarizes the HR responses to histamine before 
and after amitraz. 
Three dogs were given 1 mg kg-l of desipramine IV followed by 0.5 and
-11 mg kg of amitraz, given cumulatively with 5 minutes between the doses.
The maximum MAP responses produced by amitraz in the presence of the
noradrenaline-uptake-blocker were compared to the control responses and the
results are shown in Figure 5.12. While the histograms show little difference
in the peak increase in ivlAP following 0.5 mg kg-l of amitraz between non­
treated and DMI-treated dogs there was an indication that DMI reduced the
-1hypertensive stage when 1 mg kg of amitraz was given.
DISCUSSION 
It was shown in earlier experiments that the increase in blood pressure 
produced by amitraz persisted in the presence of hexamethonium (Chapter 3). 
Figure 5.11 Effects of 1(n=6), 2(n=7) and 5 mg kg-l (n=6) of amitraz on responses to histamine 
. -1 (0.5 and 2 µg kg ). Histograms show the time taken for the response to return at 
within 10% of the baseline. Symbols show the mean and vertical bars the SEM. 
A - amitraz 
• • Response before amitraz
0-- ---0 Response after amitraz 
* P<0.05.
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Table 5. 4 Changes in HR (bpm) produced by histamine comparing. the effects befor, 
amitraz (control, C) with those after 1, 2 and 5 mg kg-1 (Al,
Histamine 





A2, AS). Figures show mean (SEM). The number of dogs in each 
group showing HR changes in the direction indicated are given in 
italics. Some dogs showed a biphasic change. 
Direction of C Al C A2 C AS 
HR change 
Increase 16.8 9.8 20.1 9.5 20.6 5.2 
-1
(8.1) (2.4) (11.6) (6. 8) (10.2) (2. 8) 
6/6 6/6 3/7 7/7 6/6 5/6 
--------------- --------------- �--------------- ----------_,. _____
Decrease 3.1 - 5.6 - - -
(1. 3) (1. 9) 
3/6 3/7 
Increase 2.1 18.5 19.2 14.2 32.5 7.7 
(2.1) (2.7) (7. 4) (7.6) (14. 7) (3 .1) 
1/6 6/6 4/7 6/7 4/6 5/6 
- -------------- --------------- ., ____ -----------· ·----------------
Decrease 11.8 - 6.6 8.4 7.2 10.9 
(4.6) (1. 6) (8.4) (2. 7) (10. 9) 
6/6 6/7 1/7 3/6 1/6 
Figure 5.12 The top panel shows the dose response line for tyramine 
before (.e ...... --1e•) and after desipramine. The presence of 
uptake blocking activity both before C•---■) and after 
(0---0) ami traz was shown by the reduced responses to 
tyramine at 5 minutes and 20 minutes respectively. Symbols 
show mean and vertical bars the SEM (n=3). 
Lower panel shows the maximum effect of 0.5 and 1 mg kg-l of 
amitraz IV, given cumulatively, without (C) and in the 
-1presence of desipramine at a dose of 1 mg kg (D). Histo-
grams indicate mean increase in MAP and vertical bars the
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This finding indicated that the increase in blood pressure was not the result 
of a central action and did not arise from ganglionic stimulation. Since 
phentolamine prevented the pressor action it appeared that a-adrenoceptors 
were mediators in the response. 
Phentolamine was shown to prevent a secondary rise in blood pressure 
following chlordimeform administration, however hexamethonium also 
prevented the increase demonstrating that this effect had a central 
component (Lund et al, 1978; Hollingworth and Yim, 1980). Although arnitraz 
and chlordimeform belong to the same group of compounds this evidence 
suggests that their mechanisms of action are different. Hsu and Kakuk (1984) 
have also reported variation between the effects of arnitraz and chlordimeform 
. (Chapter 1). 
The stimulation of a-adrenoceptors following amitraz administration could 
arise from release of noradrenaline from the nerve terminals (an indirect 
syrnpathomimetic effect),prolonged action of noradrenaline or a direct effect 
on the receptor by the formamidine. 
The blood pressure responses to tyramine were increased in the presence of 
amitraz. This sympathomimetic amine releases noradrenaline from the nerve 
terminal before being metabolised by MAO, an enzyme inhibited by arnitraz 
(Chapter 1). The effects of syrnpathomimetic amines are potentiated by MAO 
inhibitors (Smith,. 1973; Bal.dessarini ., 1980) and Reiger et al (1980) have 
shown that amitraz increases the action of tyrarnine in rat liver, brain and 
lung in vitro by 27.5 ± 3.6, 38.1 ± 4.2 and 28.8 ± 3.4% respectively. 
The first indication that arnitraz did not have an indirect sympathomimetic 
effect came from the reduction in the presser responses to DMPP. Had these 
responses been increased after amitraz, then the possibility of both compounds 
stimulating the release of noradrenaline from the nerve ending to activate 
postjunctional receptors would have to be considered. Confirmation of this 
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absence of an indirect sympathomirnetic effect was made when peak pressor 
responses produced by arnitraz were shown to be similar before and after DMI. 
DMI blocks the neuronal uptake of noradrenaline (Langer and Raisman, 1983) and 
inhibits the actions of indirect syrnpathomimetic amines like tyrarnine 
(Baldessarini, 1980). Since DMI prolongs the action of noradrenaline at 
receptor sites in the central nervous system as well as peripherally 
(Baldessarini, 1980), then a central effect of the drug may be a contributing 
factor towards the difference in MAP peaks in non-treated and DMI-treated 
-1
dogs given 1 mg kg of amitraz. Results from the DMI study discount the
possibility that the presser action of amitraz is due to a change in the
outflow of transmitter from the nerve ending, but instead it favours the
mechanism of a direct effect on the a-adrenoceptor. Robinson (1979) showed
that BTS 27271, the first metabolite of arnitraz, contracted the central ear
artery of the rabbit in vitro by a direct action on a-adrenoceptors. The
possibility of an increase in noradrenaline release from the nerve ending was
eliminated by measuring the rate of efflux of 3H-noradrenaline from preloaded
strips. 
Hsu and Kakuk (1984) also showed that responses to amitraz in rats pretreated 
with a-methyl-p-tyrosine and reserpine (to deplete endogenous monoamines) 
were similar to those in non-treated animals. From these results the authors 
suggested that the formarnidine acted directly on the a-adrenoceptor. 
The inhibition of MAO is the most likely reason for an increase in blood 
pressure responses to tyrarnine in the presence of arnitraz. 
Prolongation of the action of noradrenaline at the receptor site was con­
sidered an unlikely cause of the increase in blood pressure produced by 
arnitraz because the responses to exogenous noradrenaline before and after the 
forrnamidine were not significantly different. 
It is probable that amitraz increases blood pressure by stimulating 
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a1-adrenoceptors but this would not explain the reduction in both the first 
and second pressor phases produced by DMPP. The presence of postjunctional 
a2-adrenoceptors in the cat and rat were suggested by Drew and Whiting (1979) 
and subsequently, evidence has been presented for a pressor effect following 
stimulation of these receptors in the dog (Constantine et al, 1980; Langer et 
al, 1980; Langer et al, 1981a,b). 
The most likely explanation for the pressor effect of amitraz and the reduced 
responses to DMPP is that amitraz stimulates a2-adrenoceptors. -Prejunctional 
a2-adrenoceptors regulate noradrenaline release from sympathetic nerve fibres 
(Langer, 1974; Langer, 1981) and acetylcholine release from preganglionic 
neurones (Starke, 1981). The first and second presser phases elicited by 
DMPP correspond to noradrenaline release from the nerve terminal and adrenal 
secretion, respectively. 
A few reports support the likelihood that presser responses to DMPP are 
reduced by stimulation of prejunctional a-adrenoceptors. The release of 
3H-noradrenaline from nerve terminals in preloaded tissues by electrical
stimulation was reduced by the a2-adrenoceptor agonist, clonidine, in mouse 
isolated vas deferens (Marshall, 1983) and canine isolated basilar, 
mesenteric and renal arteries (Sakakibara et al, 1982). Similarly, the 
a2-adrenoceptor agonist, oxymetazoline, also reduced 3H-noradrenaline 
released by DMPP in rabbit isolated hearts. However, oxymetazoline did not 
alter the release of noradrenaline produced by tyramine (Starke and Montel, 
1974). 
Results from the present experiments indicate that amitraz is an a2-adrenoceptor 
agonist, a finding in agreement with two other reports about the compound 
(Hsu and Kakuk, 1984; Hsu and Lu, 1984). This property means that amitraz 
resembles other a2-adrenoceptor agonists such as clonidine, xylazine, 
tramazoline, guanfacine, guanabenz, azepexole, oxymetazoline and naphazoline 
(Timmermans and van Zwieten, 1982; Goldberg and Robertson, 1983). 
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Acetylcholine and tyramine in vivo increase and decrease the heart rate 
respectively. These effects are secondary to the blood pressure changes and 
are mediated through baroreceptor reflexes (Taylor, 1980a; Weiner, 1980). 
Amitraz reduced the blood pressure responses to acetylcholine which suggests 
the possibility of an antimuscarinic action, and if this is the case, this 
effect may decrease those heart rate responses that are vagally mediated, 
including the bradycardia produced by tyramine and, occasionally histamine. 
Intravenous noradrenaline in vivo can slow the heart rate by a reflex effect 
(Weiner, 1980) which overrides any direct action of the catecholamine. After 
amitraz more dogs appeared to show an increase in heart rate in response to 
noradrenaline (Table 5.3). Mechanisms that may contribute to this effect 
are a direct action of amitraz on myocardial receptors, interference with the 
baroreceptor-heart rate reflex and a possible antimuscarinic effect. The 
presence of a weak action of amitraz on the heart has been suggested when 
enhanced tachycardia was seen after high doses of amitraz in the presence of 
propranolol (Chapter 3). 
Amitraz has been shown to be an a-adrenoceptor agonist and it has been 
reported that a-adrenoceptors, including the a2-subtype, can influence the 
function of the baroreceptor reflex (Huchet et al, 1981; Huchet et al, 1983; 
Harron et al, 1984). Consequently, further study of the actions of amitraz 
on these reflexes is indicated. 
These experiments have shown that amitraz had no significant effect on the 
hypotension produced by histamine. These results differed from those of 
Pass and Seawright (1982) who demonstrated an antihistamine action of 
amitraz in inhibiting the contractions of guinea-pig isolated ileum. Amitraz 
inhibited contraction in response to histamine and the histamine H1-agonists 
2-methylhistamine and 2-pyridylethylamine. Amitraz also reduced the
depressant effect of histamine although only weak, on the guinea-pig isolated 
atria (Pascoe, 1983). The metabolite of amitraz, BTS 27271, was also shown 
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to have a weak antihistaminic action (Robinson, 1979). 
Variations in the actions of amitraz may be attributed to the use of in vitro 
preparations and the study of the effects of histamine on different tissues. 
Histamine increases heart rate and myocardial contraction by a direct action 
but also there is an indirect effect through noradrenaline release from 
sympathetic nerves (Douglas, 1980). After amitraz, histamine decreased the 
heart rate in fewer dogs than before, however, there was a tendency for more 
dogs to show a histamine-induced tachycardia. In this complex �ituation it 
is hard to attribute these changes to one particular mechanism. While a 
possible antimuscarinic action has been suggested, other mechanisms that 
cannot be discounted are the a2-adrenoceptor agonist activity and the 
presser effect of amitraz that may oppose the vascular actions of histamine. 
Evidence so far indicates that amitraz lacks any effect at S-adrenoceptors. 
The hypotension and tachycardia produced by isoprenaline showed no 
significant difference before and after amitraz. The duration of the 
depressor response with isoprenaline was prolonged by amitraz, particularly 
after the lower doses, probably due to an increase in the baseline pressure 
level. The opposing forces of the vasopressor effect of amitraz and the 
vasodilator effect of isoprenaline became apparent at the two doses of 
isoprenaline used to assess the magnitude and duration of responses (Figure 
5. 8) .
These experiments have provided evidence that amitraz acts directly at 
peripheral a-adrenoceptors, both prejunctional and postjunctional. Further 
investigations studying the actions of amitraz in the presence of specific 
a1- and a2-adrenoceptor antagonists should reveal more information about its 
mechanism of action. Additional information about the actions is needed; in 
particular, support for an a2-adrenoceptor involvement in the reduction of 
pressor responses to DMPP. In addition, the function of the baroreceptor 
reflex in the presence of amitraz needs to be examined in some detail. 
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CHAPTER 6 
THE EFFECTS OF AMITRAZ ON THE RESPONSES TO BILATERAL 
CAROTID ARTERY OCCLUSION 
INTRODUCTION 
Earlier experiments have shown that arnitraz stimulates a-adrenoceptors, 
particularly the a2-subtype (Chapters 3 and 5). In addition, the blood 
pressure responses to acetylcholine were reduced by arnitraz which may 
indicate the presence of an antimuscarinic effect. In addition, an interest­
ing observation from the earlier studies was that higher doses of arnitraz 
produced less bradycardia than lower doses (Chapter 2). 
Tyrarnine and, frequently, noradrenaline reduce the heart rate in intact 
animals by a reflex effect following baroreceptor stimulation (Weiner, 1980). 
As amitraz was shown to change heart rate responses to tyrarnine and 
noradrenaline (Chapter 5) and to decrease responses to acetylcholine, which 
may attenuate vagal activity, a study of the baroreceptor reflexes in the 
presence of the formamidine was necessary. At the same time, a study of 
the effects of amitraz on the baroreceptor reflex may offer an explanation 
for the reduced heart rate changes seen after higher doses. Furthermore, the 
presence of a-adrenoceptors within the baroreceptor reflex arc has been re­
ported (Huchet et al, 1981; Huchet el al, 1983; Barron et al, 1984). 
The major baroreceptors in the circulatory system are found in the: 
(i) carotid sinus; (ii) aortic arch; (iii) left and right ventricular wall;
(iv) epicardium and (v) pulmonary artery (Korner, 1974).
Mechanoreceptors within the walls of the carotid sinus and aortic arch, two 
major baroreceptors, respond to longitudinal and circumferential stretch. 
Afferent nerve fibres carry information from these receptors via the 
glossopharyngeal (carotid sinus) and vagus (aortic arch) nerves to sensory 
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neurones located in the nucleus of the tractus solitarius, where the first 
synapse of the reflex is thought to lie (Kirchheim, 1976). From this 
nucleus, fibres connect with the reticular formation of the medulla and the 
supramedullary regions. Depending on whether hypotension or hypertension 
activates the baroreceptors, afferent impulses are integrated with those from 
other parts of the brain and either the sympathetic or parasympathetic 
effector neurones are stimulated. 
In the dog, bilateral occlusion of the common carotid arteries is considered 
to be a suitable method for eliciting a baroreceptor reflex and it is a 
relatively simple procedure. Occlusion for about 30 to 40 seconds produces 
a 45 to 50% fall in the mean blood pressure within the carotid sinuses before 
recovery to a new baseline about 20 to 30% below the original pressure 
(Kirchheim, 1976). This temporary reduction in pressure within the sinuses 
induces a reflex tachycardia and constricts the vessels in the renal, 
mesenteric, skin and muscle vascular beds by activation of the sympathetic 
nervous sytem. Increases in arterial blood pressure are recorded in regions 
below the carotid arteries. Similarly the vagal activity is reduced and, 
with sympathetic activation, heart rate is increased. In the anaesthetised 
dog baroreceptor function is likely to be altered by the anaesthetic 
(Korner et al, 1974; Prys-Roberts, 1980) and this may influence responses. 
The aim of these experiments was to investigate baroreceptor reflex function 
by bilateral occlusion of the carotid arteries and assess the effects of 
amitraz on this function. 
METHODS 
These experiments were performed using 47 clinically healthy mongrel dogs of 
either sex with a weight of 14.5 ± 0.8 kg (mean ± SEM). Dogs were 
anaesthetised and prepared for the recording of MAP and HR as described in 
Chapter 2. 
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An incision about 10 cm long was made in the ventral midline of the neck and 
the carotid arteries were exposed by separating the muscles. After 
separating the arteries from the vagosympathetic trunk a : "Mersilene'I: 
tie was placed loosely around each artery for easy identification. At the 
appropriate time both carotid arteries were occluded for 30 seconds using 
atraumatic serrefine bull dog clamps. Care was taken to avoid tension on the 
carotid sinus and the vagosympathetic trunk. 
For each carotid occlusion response (COR) the maximum increase in mean femoral 
artery blood pressure and HR were measured. 
-1
COR Following Amitraz at 1, 2 and 5 mg kg IV 
COR were recorded before and after DMSO, the vehicle used to dissolve 
amitraz, and again after amitraz at doses of 1, 2 and 5 mg kg 
-1 
IV. These
doses were on the linear portion of the dose response curve (Figure 2 .14) . 
Each dose of amitraz was studied in separate animals and the COR measured at 
least 10 minutes after injection. 
COR Following ICM and IV Amitraz 
COR were recorded 1, 3 and 5 minutes after each dose of amitraz given 
cumulatively. About 8 minutes elapsed between each injection. Doses of 
-1
5 and 15 µg kg of amitraz were administered ICM and, as a comparison,
-1
cumulative doses of amitraz of 5, 15 and 35 µg kg were given IV to a
separate group of animals. DMF was used to dissolve amitraz in these
experiments to facilitate the use of smaller volumes of injection (5 µl for
ICM injection and 20 µl for IV injection). The effects of DMF on the COR
were tested in each dog before amitraz was given.
A 19 gauge needle was inserted on the dorsal midline into the cisterna magna 
so that the point was in the subarachnoid space and there was a free flow of 
clear cerebrospinal fluid. Into the lumen of this needle, a 23 gauge needle, 
with a microsyringe attached, was inserted a predetermined length so that the 
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points of both needles were at the same depth. The microsyringe and 23 guage 
needle were filled with amitraz so that when in position an exact quantity 
was delivered. Once the injection was made the needles were left in position 
to prevent leakage of fluid into the tissues or to the exterior. 
COR and Threshold Doses of Amitraz 
Amitraz was given in cumulative doses either ICM or IV to determine the 
threshold dose required to depress the COR. The effects of amitraz at doses 
-1of 0.5, 1, 2 and 5 µg kg ICM were studied using the injection-technique
described above. -1The IV doses of amitraz used were 20, 40, 60 and 80 µg kg
allowing about 8 minutes between each injection in both studies. COR were
measured 1, 3 and 5 minutes after each injection.
COR After Pre-Treatment with Prazosin or Yohimbine 
Prior to giving cumulative doses of amitraz at 5, 15 and 25 µg kg -1 ICM
either prazosin, dose of 20 -1 or yohimbine, at a dose ofat a µg kg ' 
30 µg -1kg was given ICM. COR were measured initially and at 1, 3 and 5
minutes after injections of DMF, the a-adrenoceptor antagonist and then each
dose of amitraz. About 8 minutes elapsed between each injection. A lower
dose of yohimbine of 6 µg kg-l was also tested in 2 dogs.
Statistical Analysis 
The changes in MAP and HR produced by carotid occlusion before and after DMSO 
-1and after 1, 2 and 5 mg kg of amitraz were analysed using "Student's"
t test (Snedecor and Cochran, 1967). In subsequent experiments where
cumulative doses of amitraz were used and the COR were measured on 3
occasions after. each injection, the changes in MAP and HR were compared with
the control using Dunnett's t test (Dunnett, 1955).
Values that differed from the control at P<0.05 were considered significant. 
Values are expressed as mean ± SEM. 
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Drugs 
The drugs used were: prazosin hydrochloride (Pfizer Inc.), yohimbine 
hydrochloride (Sigma Chem. Co.). All dose rates were calculated· as a total 
salt. Drugs were made up fresh each day in sodium chloride (9 g 1-l) and a 
volume of 0.5 ml given. 
N, N-Dimethyl formamide (DMF) (Mallinckrodt Inc.) 0.942-0.946 g 1-l was used 
to dissolve amitraz. 
RESULTS 
Examples of COR before and after amitraz are shown in Figure 6.1. 
The vehicle used to dissolve amitraz (either DMSO or DMF) had no effect on 
the MAP and HR responses following carotid occlusion. 
COR Following Amitraz at 1, 2 and 5 mg kg-l IV
Amitraz at doses of 1, 2 and 5 mg kg-l IV (n=6 for each dose) reduced the 
MAP rises in response to carotid occlusion and the results are summarised in 
Figure 6.2. Details of statistical values are as follows: 
COR (MAP) COR (HR) 
Amitraz t value p t value p Dose 
1 -1 3.94 <0.05 0.19 N.S. mg kg 
2 
-1 2.99 <0.05 2.2 N.S. mg kg 
5 mg kg -1 2.85 <0.05 1.46 N .S. 
Although there was no difference statistically between the increase in HR 
before and after amitraz at each dose, there appeared to be greater 
-1depression after doses of 2 and 5 mg kg . The results, shown above, were 
close to statistical significance (Figure 6.2; t value for P<0.05 = 2.57). 
Figure 6.1 Examples of the increase in BP (upper trace) and the 
decrease in heart period (HP) in response to bilateral 
occlusion of the carotid artery for 30 seconds (COR) 
before (A) and after (B) amitraz ICM and IV. Duration 
of occlusion shown under each response as horizontal 
bars. 
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Figure 6.2 Increases in MAP and HR in response to occlusion of the carotid 
arteries before (C) and after amitraz at doses of 1, 2 and 
5 mg kg-l IV (Al, A2, AS). Histograms show mean and vertical bars
the SEM. 
* P<0.05 (n=6 in each case)
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COR Following Central and IV Amitraz 
The effects of amitraz given ICM (n=4) and IV (n=S) on the COR are 
summarised in Figure 6.3. There was a significant depression of COR 3 
minutes after 5 µg kg-l of amitraz ICM (n=4). Values are as follows: 
Time MAP Response 
(mmHg) 
Control 14.4 ± 1.2 
3 minutes 8.2 ± 0.6 
5 minutes 7.7 ± 0.5 
p p HR Response 
(b:em) 
7.4 ± 2.7 
4.8 ± 2.6 <0.01 N.S. 
2.5 ± 1.5 <0.05 
It appears from the upper panel in Figure 6.3 that amitraz had penetrated to 
the relevant parts of the brain to reduce MAP and HR responses to carotid 
occlusion after 3 minutes and after another dose further depression of the 
responses were minor. 
Amitraz was given to another group of dogs at doses of 5, 15 and 35 µg kg-l 
IV and the COR were compared to those when similar doses were given 
centrally (lower panel, Figure 6.3). 
There was no significant difference between the COR before and after IV 
-1 amitraz although the COR after 35 µg kg of amitraz showed some depression
-1which was close to significance (control 14.9 ± 3.1 mmHg; amitraz 35 µg kg
after 5 minutes 11.8 ± 3.1 mmHg).
COR and Threshold Doses of Amitraz ICM and IV 
Cumulative doses of amitraz were given ICM to determine the quantity that 
inhibited the COR (Figure 6.4, n=4). While there was a gradual decrease in 
-1 the MAP change after 1 and 2 µg kg of amitraz, the most consistent decrease
-1was seen after 5 µg kg . MAP responses and statistical significance are
shown in Table 6.1.
Similarly, the change in HR showed the most consistent reduction after 
Figure 6.3 The COR before (C) and after amitraz given ICM (n=4) 
or IV (n=S). Cumulative doses were given and responses 
were measured 1, 3 and 5 minutes after each injection. 
Points show the mean and vertical bars the SEM. 
* P < 0. 05; ** P<0.01. 
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amitraz at a dose of 5 µg kg-1, although, after 1 minute, 2 µg kg-l of amitraz
caused significant depression. HR response values and statistical 
significance are shown in .Table 6.1. These results indicate that the 
-1threshold quantity that inhibits the COR is between 2 and 5 µg kg of
amitraz ICM.
Table 6.1 COR before (control) and after amitraz ICM (n=4). Figures show 
mean± SEM. These values are taken from Figure 6.4. 
Time Amitraz MAP Response p HR Response p 
Dose (rnmHg) (bpm) 
Control - 16.4 ± 2.3 - 9.3 ± 1. 7
1 minute 2 -1 14.0 1.7 NS 5.3 1.4 µg kg ± ± 
5 minutes 2 -1 12.2 1.8 <0.05 6.4 1.3 µg kg ± ± 
1 minute 5 -1 12.7 1.7 NS 4.0 2.1 µg kg ± ± 
3 minutes 5 -1 10.2 1. 2 <0.01 3.5 1.7 µg kg ± ± 
5 minutes 5 -1 9.0 1.4 <0.01 2.25 1. 2 µg kg ± ± 
The MAP responses to carotid occlusion were consistently depressed by 







1 minute 15.5 ± 4.7 mmHg, P<0.01) and there was little difference between the
responses at 1, 3 and 5 minutes after each injection (Figure 6.5). The small
changes in HR responses appeared to be dose dependent but were not
statistically significant.
The decrease in the MAP response to carotid occlusion 5 minutes after 
40 µg kg-l (21.1%) of amitraz was similar to that produced by 35 µg kg-l 
(21.0%) in earlier experiments (Figure 6.3). The reason for the difference 
in the control responses is unknown, however depth of anaesthesia may have 
influenced the level of sympathetic activity. 
Figure 6.5 The COR before (C) and after amitraz given IV (n=4). Cumulative doses were 
given and responses measured 1, 3 and 5 minutes after each injection. Points 
show the mean and the vertical bars the SEM. 
· * P<O. 05 **P<0.01. 
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Figures 6.6 and 6.7 show dose response curves for amitraz in depressing COR. 
Percentage reduction of MAP or HR responses from the preamitraz control is 
plotted against the dose of the formamidine either ICM or IV. Results are 
taken from different experiments. Any fears about the accuracy of the 
technique used for injecting small doses and volumes ICM are allayed by 
-1
Figure 6.6 which shows that 5 µg kg of amitraz given either as a single
dose or cumulatively depressed the COR to a similar extent. The change in
MAP following IV amitraz is shown in Figure 6.7. There was no trend set by
the HR responses.
COR After Pretreatment with Prazosin or Yohimbine 
Figure 6.8 summarises the COR following different doses of amitraz after 
-1
20 µg kg of prazosin ICM. These results show that prazosin did not
antagonise the depressant actions of amitraz on the COR and the responses are
similar to those where no antagonists were given.
-1
Figure 6.9 summarises the results of the COR where yohimbine 30 µg kg ICM 
. 
-1 -1
(n=4) and 6 µg kg ICM (n=2) was given before amitraz (5, 15 ,and 25 µg kg 
ICM). Yohimbine at both doses prevented the depression of the COR produced 
by amitraz. 
Figure 6.10 shows the percentage change in COR after ICM amitraz, either alone 
or in the presence of prazosin or yohimbine. Responses are compared to the 
control. These graphs show that yohimbine, but not prazosin, inhibited the 
depressant actions of amitraz on the COR. 
DISCUSSION 
Bilateral occlusion of the common carotid arteries below the carotid sinuses 
reduces the mean arterial pressure within the sinuses and, despite the other 
baroreceptors not detecting any change in blood pressure, a response is 
elicited through the autonomic nervous system to constrict blood vessels and 
Figure 6.6 Cumulative dose response curves to ICM amitraz showing 
depression of COR. Different lines show data from 







































AMITRAZ JJg.kg- 1 ICM 
Figure 6.7 Cumulative dose response curves to IV amitraz showing depression of MAP response 
to carotid occlusion. Different lines show data taken from separate experiments 
where COR was recorded 5 minutes after injection. 
% 6 
















._ _ _ ....,_ _______ ....







Figure 6.8 The COR before (C) and after amitraz in the presence of prazosin 20 µg kg-l (n=4). All 
drugs given ICM. Cumulative doses of amitraz were given and responses were measured 
1, 3 and 5 minutes after each injection. Points show the mean and the vertical bars the 
SEM. 
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Figure 6.9 The COR before (C) and after amitraz in the presence of 
yohimbine 30 µg kg-l (n=4) (A) and 6 µg kg-l (n=2) (B). 
All drugs were given ICM. Cumulative doses of amitraz 
were given and responses·were measured 1, 3 and 5 minutes 
after each injection. Points show the mean and vertical 
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Figure 6.10 The COR expressed as a percentage of the control (C) after 
cumulative doses of amitraz ICM. -1 Yohimbine 30 µg kg or
-1 prazosin 20 µg kg were given ICM before amitraz. Points
show mean and the vertical bars the SEM. 
• �---•• control, no antagonist
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increase the heart rate. It has been shown that amitraz reduced this response 
to carotid artery occlusion. Attempts were made to keep these dogs in a 
light plane of anaesthesia to avoid greatly reducing the sympathetic 
activity. 
Depression of the COR followed both centrally and intravenously administered 
amitraz. The possibility of amitraz depressing the baroreceptors directly 
is unlikely in view of the low doses given centrally which depressed the 
COR. These same doses given intravenously had no effect. In £�ct, much 
higher doses had to be given intravenously to depress the COR. These 
-1experiments have shown that about 2 µg kg of amitraz ICM depressed the COR
in a similar way to 60 µg kg-l IV, although greater depression of the pressor
response was noted after 60 µg kg-l IV (60 µg kg-l IV, 38.0% depression;
-1 2 µg kg ICM, 25.3% depression). Although the results were not
significant, 40 µg kg-l of amitraz IV depressed the MAP response by 24.0%.
While amitraz is considered to act centrally to depress the COR, it should 
also be remembered that it is an a2 -adrenoceptor agonist and stimulates 
prejunctional receptors peripherally to regulate the release of neuro­
transmitters. This peripheral effect is likely to be more important when it 
is given intravenously and may also have played a role in these studies. 
Prazosin, a potent antagonist at a1-adrenoceptors (Cambridge et al, 1977;
U'Prichard et al, 1978), did not affect the actions of amitraz on the COR. 
On the other hand, yohimbine, the a2-adrenoceptor antagonist (Doxey et al,
1977; Shepperson et al, 1981; Paciorek and Shepperson, 1985) blocked the 
effects of amitraz and the responses appeared to be slightly increased 
(Figure 6.10). 
Carotid artery occlusion activates the sympathetic nervous system to increase 
blood pressure and heart rate. Amitraz depressed the COR and evidence 
favours the a2 -adrenoceptor as the central mediator. Other reports have 
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indicated that the a2-adrenoceptor modulates sympathetic output (Huchet et 
al, 1983), increases vagal activity (Huchet et al, 1981) and facilitates the 
transmission of afferent impulses from the baroreceptors to central 
autonomic neurones (Huchet et al, 1981). 
Huchet et al (1983) demonstrated that electrical stimulation of the carotid 
sinus nerve in bilaterally vagotomised dogs reduced the MAP by activating a 
sympathoinhibitory component of the baroreflex. Yohimbine (100 µg kg-1),
injected into the verterbral artery antagonised this effect. A-similarity 
exists between the study by Huchet et al (1983) and the present study with 
amitraz where the decrease in MAP response to carotid occlusion was 
antagonised by yohimbine suggesting that the same central a2-adrenoceptors 
were stimulated. 
Additional evidence to support the presence of a2 -adrenoceptors within the 
baroreflex arc in dogs was provided by Constantine et al (1982) who showed 
that 10 to 200 µg of yohimbine injected into the vertebral artery enhanced 
the responses, an affect that they attributed to the blockade of this 
receptor. 
Amitraz resembles other a2 -adrenoceptor agonists in its effect on the COR. 
Both clonidine (Robson and Antonaccio, 1976) and xylazine (Schmitt et al, 
1970; Antonaccio et al, 1973) reduced the hypertension and tachycardia seen 
following bilateral occlusion of the carotid artery in dogs and a similar 
effect was also produced by clonidine in cats (Bentley and Li, 1968; 
Tadepalli and Mills, 1978). Variations in the response from this technique 
do occur with different species because clonidine was also shown to 
potentiate the blood pressure response in rats following carotid occlusion 
(Bently and Li, 1968). Additional studies by Tadepalli and Mills (1978) 
using decerebrate cats and animals wh-ce:re clonidine was confined to the third 
cerebral ventricle indicated tha t this drug acted in the caudal brainstem. 
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Many similarities have been shown between amitraz and clonidine and its 
derivatives. As clonidine and related drugs lower sympathetic output 
centrally, then this may be a contributing factor for the decrease in the 
COR following the formamidine. Amitraz could also act on peripheral, pre­
junctional adrenoceptors to reduce these responses. 
Following on from this study on the COR, where pressure changes are 
recorded by the baroreceptors of only the carotid sinus, the effect of 
amitraz on all of the major baroreceptors needs investigation. _rn addition, 
an explanation for the heart rate changes seen following higher doses of 
amitraz (1., 2 and 5 mg kg-
1
) still cannot be given. 
Figure 6.1 shows examples of the depression of the COR by amitraz but at the 
same time suggests the presence of hypotension and bradycardia. In view of 
these changes in cardiovascular variables and the resemblance that amitraz 
has shown to other a2 -adrenoceptor agonists, like clonidine and analogues 
which are known to have a central action on the cardiovascular system 




THE ACTIONS OF AMITRAZ ON BARORECEPTOR FUNCTION 
INTRODUCTION 
It was shown in Chapter 6 that the cardiovascular responses to bilateral 
carotid artery occlusion were depressed by amitraz, an effect that was 
blocked by the a 2-adrenoceptor antagonist, yohimbine, but not by the 
a 1-adrenoceptor antagonist, prazosin. These results suggest that the 
a 2-adrenoceptor is the mediator of the depressant effects of arnitraz on the 
COR but do not explain the reduction in bradycardia seen after higher doses 
of the formamidine given intravenously. 
The a 2 -adrenoceptor agonist, clonidine, depressed the COR in dogs (Robson and 
Antonaccio, 1976) but enhanced the range and gain of the baroreceptor heart 
rate reflex in rabbits (Korner et al, 1974a). The baroreceptor function was 
studied by measuring the increase or decrease in heart rate in response to a 
transient fall or rise in blood pressure, respectively. 
It has been reported that a-adrenoceptors are important mediators in the 
central control of the baroreceptor-heart rate reflex (Huchet et al, 1981; 
Huchet et al, 1983; Harron et al, 1984). In view of these reports and the 
finding that clonidine, an a 2-adrenoceptor agonist with actions similar to those 
of arnitraz, enhanced baroreceptor function, a study of the actions of the 
formamidine on this reflex arc is indicated. 
Although the results of the depressant actions of amitraz on the COR provided 
much information about its central actions, a study of the baroreceptor 
function using a technique described by Korner et al (1972) where all 
baroreceptors are stimulated, is likely to be a more thorough study of the 
effects of the formamidine on cardiovascular reflexes. This technique 
measures reflex changes in heart rate in response to afferent impulses from 
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arterial, cardiac and pulmonary baroreceptors, and furthermore, changes in 
activity at the central effector neurones, the cardiac sympathetic and vagal, 
is reflected by the responses of the heart. The fact that vagal activity is 
assessed is another reason why this technique is more informative than 
carotid occlusion for assessing baroreceptor function. Studies will be made 
in anaesthetised dogs and it is expected that the anaesthetic may have an 
influence on the cardiovascular reflexes. 
METHODS 
Two techniques were used to vary blood pressure in the present study: 
alternate inflation of perivascular balloons around the aorta and posterior 
vena cava to partially obstruct blood flow and, in another group, alternate 
injections of a vasopressor and a vasodilator drug. 
1. Perivascular Balloons
These experiments were performed using 12 healthy mongrel dogs of either sex 
weighing 17.8 ± 0.9 kg (mean± SEM). Each dog was anaesthetised and a 
thorarotomy was performed by removing the seventh rib on the right side. 
Silastic rubber balloons were placed around the descending aorta and 
posterior vena cava (Figure 7.1). Balloons were constructed from an outer 
ring of polyvinyl chloride tubing (1 cm wide, 1.8 cm diameter) with an inner 
inflatable silicone segment of Silastic Medical Grade Tubing (Dow Corning 
Corp., Michigan, U.S.A.; Figure 7.1). The inflatable segment of the 
balloon was attached to a length of polyvinyl chloride tubing (Dural 
Plastics and Engineering, Dural, N.S.W.: SV 65, I.D. 0.86 mm, 0.D. 1.52 mm) 
which emerged from the thorax on the right side posterior to the thoractomy 
incision. 
Experimental Procedure - When the dogs had recovered from the thoracotomy, 
Figure 7.1 Upper diagram shows the position of the balloons (hatched 
areas over the aorta and posterior vena cava) in relation 
. to other structures in the thorax. 
0 oesophagus 
T - trachea 
Numbers show the ribs 
Lower diagram shows the design of the perivascular balloons. 
The balloon is placed around the blood vessel so that it 









approximately 3 to 4 days later, they were anaesthetised and the brachial 
artery and vein were cannulated in a similar way as was described in Chapter 
2. Pulsatile and mean arterial blood pressure and HP were recorded.
According to the method described by Korner et al (1972), increases and 
decreases in blood pressure were produced by partially obstructing blood 
flow for 30 seconds in the aorta and posterior vena cava respectively. 
Blood pressure changes of about 2.5, 5, 10, 15 and 20 and 30 mmHg were 
produced in random order and the direction of the change was alternated. 
Reflex changes in heart period, or pulse interval, were measured once a 
steady state had been reached (Figure 7.2). A sigmoid curve was generated 
from the change in HP in response to variations in MAP as described by 
Korner et al (1972) (Figure 7.3). From this data three parameters were 
assessed: the heart period range (HPR) between the upper and lower plateau 
levels; the median blood pressure (BPso), that is the MAP at half the heart 
period range, and the average gain (G) of the curve between +1 and -1 
standard deviations of the distribution function from the BP 50 (Figure 7.3). 
Eight dogs were given cumulative IV doses of amitraz to study the effects of 
-1 0.5, 2 and 5 mg kg . MAP-HP curves were generated and compared to the pre-
amitraz control curve. 
The e£fects on the MAP-HP curve of equivalent volumes of DMSO used to dissolve 
amitraz were studied in 4 dogs. The dose of DMSO te�ted was 31.9 ± 1.8 mg kg-l 
2. Baroreceptor Heart Rate Reflexes Using IV
Phenylephrine and Nitroprusside 
These experiments were performed on 6 healthy mongrel dogs of either sex 
weighing 15.3 ± 0.7 kg. Dogs were anaesthetised and the brachial artery and 
vein were cannulated as described in Chapter 2. Pulsatile and mean arterial 
pressure and HP were recorded. 
Figure 7.2 Examples of the change in heart period (HP) in response to 
controlled variations in MAP. The effects of small (A) and 
large changes (B) in MAP and the HP response �an be compared. 
Measurements taken from these MAP and HP recordings are 
plotted and form a sigmoid curve as shown in Figure 7.3. 
MAP changes in the top half of the figure are made by 
partially inflating balloons placed around the posterior vena 
cava (lowers MAP) or the thoracic aorta (increases MAP). 
Arrows indicate duration of balloon inflation. 
MAP changes in the lower half of the figure are made by IV 
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Figure 7.3 Sigmoid curve showing the reflex changes in the heart period 
(HP) in response to variation in MAP (MAP-HP curve). R, 
average resting value of MAP and HP. HPR, heart period 
range :(msec) between upper and lower plateau. BPso, the 
MAP at half of the heart period range (nunHg).. G, average 
gain or slope of curve between +1 and -1 standard 

































Using a similar technique to that described by Korner et al (1974b), 
MAP-HP curves were generated from data produced by alternate injections of 
the vasopressor, phenylephrine (IV doses of 0.25, 0.5, 1, 2 and 4 µg kg-
1
), 
and the vasodilator, sodium nitroprusside (IV doses of 0.3125, 0.625, 1.25, 
-1
2.5 and 5 µg kg ). Drug doses were given in random order and MAP and HP
measurements were taken at maximum responses (Figure 7.2). The three para­
meters, HPR, BP 50 and G, were calculated from the results.
MAP-HP curves were generated before and after cumulative IV doses of arnitraz 
-1
studying the effects of 25, 75 and 275 µg kg . The vehicle used to
dissolve amitraz, DMSO, was shown in the previous section to have no effect
on baroreceptor function.
Phenylephrine is a powerful a1-adrenoceptor agonist that increases blood 
pressure by vascular constriction. It has minimal direct cardiac effects 
and the bradycardia is a baroreceptor mediated reflex response (Weiner, 1980). 
Sodium nitroprusside relaxes arteriolar and venous smooth muscle lowering 
blood pressure and producing a reflex tachycardia. The half life is only a 
few minutes (Blaschke and Melman, 1980). 
Statistical Analysis 
MAP-HP curves were assessed for each treatment for each animal and the 
results collected for analysis by either Dunnett 1 s t test (Dunnett, 1955) 
or two-way analysis of variance (Snedecor and Cochran, 1967). Values that 
differed from the control at P<0.05 were considered significant. 
Results are expressed as a mean ± SEM. 
Drugs 
The drugs used in these experiments were: phenylephrine hydrochloride (Sigma 
Chemical Co.); sodium nitroprusside (Hoffman-La Roche and Co. Switzerland). 
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Technical grade amitraz was dissolved in dimethyl $Ulphoxide (DMSO, 
1.08 g ml-1, Ajax Chemical Labs).
RESULTS 
The MAP-HP curves before and after DMSO (n=4) are shown in Figure 7.4 and the 
values for the parameters are given in Figure 7.6. Although there was no 
difference between the values for HPR and G, the BP so was only small. The 
effect of DMSO was not taken into account when investigating the actions of 
amitraz on baroreceptor function. 
Baroreceptor - Heart Rate Reflex Using Balloons 
-1 IV doses of amitraz at 0.5, 2· and 5 mg kg increased the resting MAP and HP
(Table 7.1). The MAP-HP curves before and after amitraz (n=8) are shown in 
Figure 7.5 and the parameters in Figure 7.6. Both the HPR and G showed a 
significant decrease from the control values but there was no difference 






-1 The resting MAP and HP before and after 0.5, 2 and 5 mg kg of
amitraz IV. 
Amitraz (mg kg-1)
Control 0.5 2 5 
"MAP 
74.6 74.2 83.9 89.5 
HP 502 582 617 671 
These doses of amitraz flattened the lower portion of the curve from the 
resting values (where the heart rate increased) showing that there was no 
response to a decrease in blood pressure. Some cardiac slowing in response 
to blood pressure rises was present although reduced. 
Figure 7.4 MAP-HP curves determined before and after DMSO (n=4). 
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Figure 7.5 MAP-HP curves before (control) and after 0.5, 2 and 
-1
5 mg kg arnitraz (n=8). Vertical bars show SEM of the 
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Figure 7.6 Effect of DMSO and different doses of amitraz on the HPR, 
BPso and G taken from curves in Figures 7.4 and 7.5. 
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Baroreceptor-Heart Rate Reflexes Using IV Phenylephrine and Nitroprusside 
A rise in resting blood pressure and bradycardia were apparent after IV doses 






-1The resting MAP and HP before and after 25, 75 and 275 µg kg of 
amitraz IV. 
Amitraz (µg kg-1) 
Control 25 75 275 
MAP 104.1 119.1 124.7 119.4 
HP 567 651 857 1084 
The MAP-HP curves before and after each dose of amitraz are shown in Figure 
7.7. 
Figure 7.8 summarises details of the HPR, BPso and G. Amitraz at a dose of 
-125 µg kg had no significant effect on the parameters, however, there were
-1significant increases in HPR and BPso after 75 and 275 µg kg of amitraz.
-1The only G value that was significantly increased was after 275 µg kg of
amitraz.
The change in the upper part of the MAP-HP curves above the resting values was 
-1small when compared to the control after 75 and 275 µg kg of amitraz,
however, the lower part of the curve showed marked enhancement. This effect
was opposite to that seen after the higher doses of amitraz (0.5, 2 and
5 mg kg-l), as shown by the HPR and G. It is worthwhile mentioning that
while there was a small difference in the BPso values before and after DMSO,
which may be interpreted as an interference with baroreceptor function,
arnitraz produced marked differences in the MAP-HP curves. The only exception
-1was when 25 µg kg of amitraz was given.
Figure 7.7 MAP-HP curves showing the effects of 25, 75 and 
-1
275 µg kg of arnitraz (n=6). Vertical bars show SEM 
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Figure 7.8 Effect of different doses of amitraz on the HPR, BP 50
and G taken from curves in Figure 7.7. 





























Baroreceptor function was investigated after different doses of amitraz in 
separate experiments. Although the parameters, HPR and G, increased after 
-1 low doses of amitraz (75 and 275 µg kg ) and decreased after high doses
-1 (0.5, 2 and 5 mg kg ), the difference was considered to be attributable to 
the doses given rather than the experimental technique. Korner et al (1974b) 
have shown that similar MAP-HP curves can be derived using either perivascular 
balloons or vasoactive drugs. 
Both low and high doses of amitraz altered the shape of the MAP-HP curves and 
the parameters indicating that baroreceptor-dependent cardiac motor neurones 
were affected. When developing the technique, Korner et al (1973) 
demonstrated that changes in the shape of the sigmoid baroreflex curve and the 
parameters (HPR, BPso or G) followed interference with activity of the 
neurones within the baroreceptor-heart rate reflex arc. 
The finding that 25 µg kg-l of amitraz IV had no effect on baroreceptor
-1function is not surprising because an earlier study showed that 40 µg kg 
of the formamidine IV did not depress the carotid occlusion responses 
(Chapter 6). 
It was interesting to note that the total autonomic effector output, measured 
by the heart period range (Korner et al, 1974a) was enhanced by low doses of 
amitraz but reduced by the high doses. 
Stimulation of either vagal or sympathetic effector neurones will elicit 
changes in heart period, however, a reduction in effector neurone output can 
also alter the heart period (Korner et al, 1972). Increases and decreases in 
heart period were produced in the present study, however, this technique does 
not completely separate vagal and cardiac sympathetic activity. The upper 
part s of the MAP-HP curve is predominantly a vagally mediated effect and the 
lower part predominantly sympathetic (Korner et al, 1972) and one way of 
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separating these reflex responses is to repeat the experiments in animals 
given atropine, thereby eliminating effects transmitted by the vagal 
efferent pathway. Reflex responses would then be due to sympathetic 
activation or inhibition. 
Earlier evidence that amitraz had a central effect on the baroreceptor reflex 
was presented in Chapter 6 where it was shown that it significantly depressed 
-1 responses to bilateral occlusion of the carotid arteries after 2 µg kg · ICM
but a similar effect followed 60 µg kg-l IV. Stimulation of peripheral pre­
junctional a2 -adrenoceptors, particularly after intravenous administration, 
may also influence responses by reduction of transmitter release at the 
autonomic ganglia, cardiac and vascular effectors (Langer, 1981; Starke, 
1981). 
In conscious rabbits IV clonidine was shown to affect the baroreflex­
dependent cardiac motorneurones at a dose as low as 2.5 µg kg-l (with
-1 -1 infusion of 0.25 µg kg min ) (Korner et al, 1974a). While vagal activity
was shown to be increased by clonidine in cats (Haeusler, 1974) and dogs 
(Kobinger and Walland, 1971; Kobinger and Walland, 1972; Walland et al, 1974) 
and by oxymetazoline in dogs (Barron et al, 1984), evidence from the present 
studies suggested that vagal enhancement was not such an obvious feature of 
amitraz action. 
It has been hypothesised that a2-adrenoceptor stimulation increases vagal 
activity (Huchet et al, 1981) and inhibits sympathetic output (Huchet et al, 
1983) in dogs. a1-Adrenoceptor stimulation may inhibit the baroreflex 
function and the a2 -subtype facilitates the transmission of afferent baro­
receptor impulses to central sympathetic and vagal neurones (Huchet et al, 
1981). The a2 -adrenoceptor actions of amitraz have been demonstrated and 
although, at this stage, evidence is lacking for an a1-adrenoceptor action, 
a weak effect at the a1-subtype should not be discounted. If this is the case, 
then higher doses of the formamidine may elicit a significant a1-adrenoceptor 
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action which may offer an explanation for the difference in the effects 
between low and high doses of arnitraz on the baroreceptor reflex noticed in 
this study. 
It was interesting to notice from different experiments with similar doses 
intravenously that amitraz depressed the COR but enhanced the baroreceptor 
reflex. Clonidine has also been shown to depress the COR in cats (Bentley 
and Li, 1968) and dogs (Robson and Antonaccio, 1975) and increase baroreceptor 
activity (Komer et al, 1974a). At the same time, clonidine was _also shown 
to depress carotid sinus baroreceptor responses to pressure increases 
(Robson and Antonaccio, 1975). The COR activates baroreceptors in the walls 
of the carotid sinus whereas additional baroreceptors, including those in the 
aortic arch, are stimulated during baroreflex studies using perivascular 
balloons on major vessels. This difference offers an explanation for the 
actions that arnitraz has on the COR and baroreflex function. While the 
responses from the carotid and aortic baroreceptors are additive (Hainsworth 
et al, 1970) in maintaining cardiovascular homeostasis, the aortic baro­
receptors appear to act predominantly as an antihypertensive mechanism and 
play only a minor role inhypotension (Edis, 1971). In contrast, the carotid 
sinus baroreceptors are more sensitive to hypotension (Edis, 1971). 
Additional variation between the function of the baroreceptors of the carotid 
sinus and aortic arch was demonstrated when clonidine-induced enhancement of 
reflex bradycardia in dogs was prevented by aortic arch denervation but not 
by bilateral carotid sinusectomy (Robson and Antonaccio, 1975). 
The present study of amitraz was made in anaesthetised dogs and the 
anaesthetic drugs, thiopentone and methoxyflurane, may have influenced the 
results. Thiopentone (16 mg kg-l bolus + 0.8 mg kg-l min-l IV) in rabbits 
reduced the HPR and G and increased the BPso (Blake and Korner, 1981). 
Sympathetic activity and arterial pressure responses to electrical baro­
receptor nerve stimulation were shown to be unaffected by methcixyflurane in 
cats (Skovsted and Price, 1972). 
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Cumulative doses of amitraz of 0.5, 2 and 5 mg kg-l in these experiments pro-
gressively increased the heart period above control values which is an 
opposite effect to that reported in Chapter 2 where additional doses were 
given every 5 minutes and bradycardia diminished. When single doses of 
-1amitraz (1, 2 and 5 mg kg ) were given, a second phase of bradycardia slowly
developed after about 15 to 20 minutes (Figure 2.2). In the present study
subsequent doses of the forrnarnidine were given about 40 minutes after the
previous dose at a time when the second phase of bradycardia was present.
This may explain the difference in heart period values between the two
studies.
It is worthwhile making a few comments, at this stage, about the triphasic 
change in heart rate seen in experiments in Chapter 2 where 1, 2 and 
5 mg kg-l of arnitraz were given IV. Initial bradycardia was followed by a 
return of the heart rate towards the control reading and then bradycardia 
became more pronounced with time. Although evidence to show that arnitraz 
also stimulates a1 -adrenoceptors is lacking, the probability exists. The 
reduction in heart period range seen after higher doses of the formamidine 
was explained by an a1-adrenoceptor action, and following on from this, it is 
possible that higher doses may increase activity at this receptor and 
further inhibit baroreflex activity. This mechanism offers a likely 
explanation for the dose dependent return of heart rate towards the control 
reading (prearnitraz -resting value) at a time when the blood pressure showed a 
progressive rise. 
It is very likely that arnitraz acts centrally to affect the heart rate and 
therefore, it requires time to penetrate the CNS following IV injection. 
Thus, the transient reflex bradycardia is seen before the direct actions of 
the formarnidine on central neurones. 
No definite suggestions can be made to explain the gradual development of 
bradycardia 15 to 20 minutes after injection (Figure 2.2). This response 
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suggests that there is a change in activity at the central effector 
neurones that regulate the heart. The rate at which amitraz is metabolised 
in the dog and the subsequent tissue concentrations are unknown at this stage 
and variations in the blood and tissue levels could contribute towards the 
late onset of bradycardia. 
Results from these investigations have shown that amitraz interferes with the 
baroreceptor-heart rate reflex. Specific a-adrenoceptor antagonists were not 
used in these investigations but in the light of the carotid occlusion study 
where the a 2 -adrenoceptor was the major mediator for amitraz-induced 
depression, then it is likely that this receptor was also stimulated during 
this study. It is also highly likely that amitraz stimulated the a1-subtype. 
Further investigations into the central and peripheral actions of amitraz and 
its effect on a1- and a2 -adrenoceptors should clarify many of these points. 
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CHAPTER 8 
THE CENTRAL ACTIONS OF AMITRAZ 
INTRODUCTION 
Intravenous administration of amitraz increased blood pressure and lowered 
heart rate (Chapters 2 and 3) but in contrast, when the compound was given 
centrally to study the responses to carotid artery occlusion, there was 
evidence of the development of hypotension and bradycardia. Already amitraz 
has been shown to act centrally to depress COR, an action inhibited by 
yohimbine, an a2 -adrenoceptor antagonist. 
Some actions of amitraz resemble those of other a2-adrenoceptor agonists. 
Some drugs in this classification, clonidine, xylazine, azepexole and St 91 
(by injection into vertebral artery) act centrally to produce hypotension and 
bradycardia (Schmitt et al, 1970; Kobinger, 1978; van Zwieten and Timmermans, 
1980; Timmermans et al, 1981; Timmermans and van Zwieten, 1982; McLennan and 
Bentley, 1983). That these effects were antagonised by a2 -adrenoceptor 
antagonists, yohimbine, piperoxan and rauwolscine suggests that the 
a2 -receptor is the mediator of the response. 
These experiments aimed at studying the central actions ·of amitraz on blood 
pressure and heart rate. The formamidine was given by intracisterna magna 
injection and the responses compared to those when similar doses were given 
intravenously. The effects of prazosin, an a1 -adrenoceptor antagonist, and 
yohimbine, an a2 -adrenoceptor antagonist, on the responses were investigaged. 
METHODS 
These experiments were performed using 25 mongrel dogs of either sex that 
were clinically healthy and weighed 15.9 ± 1.3 kg (mean ± SEM). These dogs 
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were anaesthetised and prepared for the recording of femoral artery blood 
pressure and heart rate as described in Chapter 2. 
Intracisterna magna (ICM) injections of amitraz, prazosin or yohimbine were 
by the method described in Chapter 6. 
Responses to Amitraz ICM 
Prior to the administration of amitraz an equivalent volume of DMF (5 µl) that 
was used to dissolve each dose of the formamidine was given ICM to test its 
effects on MAP and HR. 
Cumulative doses of amitraz were given ICM to two groups of dogs to examine 
-1 1 the actions of 0.5, 1, 2 and 5 µg kg (n=4) and 5 and 15 µg kg- (n=4). After
each injection, readings of the change in MAP and HR from the preamitraz
control were made every 2 minutes. Additional injections of amitraz were
given every 8 to 10 minutes.
Responses to Amitraz IV 
For these experiments amitraz was dissolved in 20 µl of DMF and this volume 
was given alone initially to determine its actions on the MAP and HR. 
Cumulative doses of amitraz were given IV to study the effects of 5 and 
-1 -1 15 µg kg (n=4) and 20, 40, 60 and 80 µg kg (n=4). As in the previous
section, MAP and HR changes were measured every 2 minutes and subsequent
injections were given every 8 to 10 minutes.
Responses to Amitraz ICM in the Presence of Either Prazosin or Yohimbine ICM 
After the initial test volume of 5 µl of DMF ICM, prazosin at a dose of 
20 µg kg-l was given ICM before cumulative doses of amitraz of 5, 15 and 
25 µg kg-l ICM (n=4). This procedure was repeated in two other groups of 
-1dogs but instead of prazosin, yohimbine at a dose of either 30 µg kg (n=4)
-1or 6 µg kg (n=2) ICM was given.
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The time intervals for :MA.P and HR readings and subsequent injections were the 
same as for the previous experiments. 
Statistical Analysis 
Changes in :MA.P and HR after each ami traz injection were compared to 'the 
preamitraz control using Dunnett 1 s t Test (Dunnett, 1955). Treatment readings 
that differed from the control at P<0.05 were considered significant. 
Values are expressed as mean ± SEM. 
Drugs 
The drugs used were: prazosin hydrochloride (Pfizer Inc.) and yohimbine 
hydrochloride (Sigma Chem. Co.). All dose rates were calculated using the 
total salt. Drugs were made up fresh each day in sodium chloride (9 g 1-l) 
and a volume of 0.5 ml given. 
-1 N, N-Dimethyl formamide (DMF) (Mallinckrodt, Inc.) 0.942 - 0.946 g ml was 
used to dissolve amitraz. 
RESULTS 
DMF, given either ICM or IV, had no effect on MAP and HR. 
Figure 8.1 shows examples of the change in MAP and HR produced by amitraz 
given ICM or IV. 
Responses to Amitraz ICM 
Amitraz caused a dose dependant fall in both MAP and HR. A summary of the 
results from the two experiments with ICM amitraz are shown in Figure 8.2. 
-1 In experiment I 0.5 µg kg of amitraz ICM produced a time. dependant decrease 
Figure 8.1 Examples of BP (upper trace) and heart period changes in a dog given amitraz ICM 
(A) and IV (B).
Hypotension and bradycardia developed soon after 5 µg kg-l of amitraz ICM (A). 
Trace shown every 5 minutes. 
Hypotension and bradycardia developed after 40 µg kg-l of amitraz IV (B). Note 
the transient hypertension and bradycardia following each injection of amitraz. 
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Figure 8.2 The decrease in MAP and HR following cumulative doses of amitraz ICM in experiment I 
(n=4) and II (n=4). Points shown mean and vertical bars the SEM. 
C = control; A = amitraz. 
* P<0.05 ** P<0.01. All points to the right of the double asterisk are 
significant at P<0.01. 
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in MAP and HR (n=4). -1A dose of amitraz as low as 0.5 �g kg caused
significant hypotension and bradycardia (Figure 8.2) and MAP and HR both
continued to fall with additional doses. There is some suggestion in
-1experiment II that the effect of amitraz may plateau after 15 µg kg 
A comparison of the decrease in MAP and HR 8 minutes after 5 µg kg-l of
amitraz ICM in the two experiments showed that the MAP was reduced by 
18.6 mmHg and the HR by 25.7 bpm in experiment I and by 18.7 mmHg and 
18.0 bpm in experiment II. Thus cumulative doses of the formamidine appeared 
to have a similar effect on the MAP and HR as a single dose. 
Results from these experiments showed that significant changes in cardio- • 
vascular variables occurred between 2 and 4 minutes after injection of amitraz 
which correlated closely to the time taken (3 to 5 minutes) for amitraz 
(5 µg kg-l ICM) to depress the COR (Chapter 6, Figure 6.4).
Responses to Amitraz IV 
As in the ICM experiments, amitraz again reduced MAP and HR at low doses. 
A summary of the results from the effects of cumulative doses of amitraz IV 
in two groups of animals is presented in Figure 8.3. There was no significant 
effect on MAP following 5 and 15 µg kg -1 of amitraz (experiment I, n=5) and
20 µg kg -1 (experiment II, n=4) but after 40 µg kg -1 a significant reduction
in MAP_ was recorded (control 121.1 ± 4.4 mmHg; amitraz 40 -1 after 2µg kg 
minutes 110.7 ± 6.3 mmHg, P<0.01). This depressant effect appeared to 
plateau at about 80 µg kg-l when the MAP was between 101.7 and 102.5 nunHg, a
decrease of 18.6 to 19.4 mmHg. A corresponding plateau in the MAP was seen 
after about 15 µg kg-l of amitraz ICM, a decrease of 24.7 mmHg. It should be
pointed out that the plateau effect applied only to the doses tried and do not 
indicate a maximum response produced by amitraz. 
Although there was no significant difference between the control HR values and 
Figure 8.3 The decrease in MAP and HR following cumulative doses of amitraz IV in experiment I (n=S) 
and II (n=4). Points show mean and vertical bars the SEM. 
C = control: A =  amitraz. 
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those after 5 µg kg-l of amitraz IV, there .was a significant difference when 
-1 -1 15 µg kg was given (control 127.9 ± 8.2 bpm, amitraz 15 µg kg after 2
minutes 119.6 ± 9.6 bpm, P<0.01, n=S). One dog within this group had a lower
resting HR (99.0 bpm) than the other four animals (135.1 ± 5.0 bpm). This
animal also showed more extensive bradycardia following amitraz (10 minutes
after 15 µg kg-l of amitraz the HR in four dogs was reduced by 7.1 ± 2.3 bpm
and 24.3 bpm in the fifth animal). This variation between the dogs accounted
for the large standard errors.
Analysis of the results from 4 dogs, omitting the one with the slower HR, 
showed that there was no significant difference between the control HR 
(135.1 ± 5.0 bpm) and that following 5 µg kg-l of amitraz. However, there 
was significant bradycardia after 15 µg kg-l (after 2 minutes 128.7 ± 4.0 bpm, 
P<0.01; after 10 minutes 128.0 ± 3.4 bpm, P<0.01). 
In experiment II there was a significant reduction in HR after 60 µg kg-l 
of amitraz IV (control 137.9 ± 6.1 bpm; amitraz, 2 minutes 130.8 ± 4.1 bpm, 
-1P<0.01) and after 80 µg kg the reduction appeared to plateau to a level of
12.1 bpm below control. After central injections of amitraz HR values
plateaued at 24.7 bpm below the control. The depressant effects of ICM and
IV amitraz on MAP and HR (showing percent change from control using the 8
minute points) are compared in Figure 8.4. The dose response curve for IV
amitraz is to the right of the ICM curve; the difference for MAP depression
is a factor of 40 and for HR depression, a factor of 80.
It was shown that 0.5 µg kg-l of amitraz ICM significantly lowered MAP and 
HR (Figure 8.2) and it is apparent that a considerably higher intravenous 
dose is required to produce a similar effect. 
When cumulative doses of amitraz were given IV using increments of 5, 10 or 
20 µg kg-l, each injection produced a small initial transient increase in MAP 
and a decrease in HR; the blood pressure change was thought to be due to 
Figure 8.4 The depressant effects of increasing doses of amitraz on 
MAP and HR. Points show the percent depression from control 
8 minutes after injection in separate experiments. 
• ...----•• Amitraz ICM (experiment I) 
01-----0 Amitraz ICM (experiment II) 
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a peripheral effect and the HR change, a reflex action. These changes, 
which were dose related, lasted about 1 minute (Figure 8.5) and were 
followed by hypotension. 
Responses to Amitraz ICM in the Presence of Either Prazosin or Yohimbine 
ICM 
-1The effects of ICM injections of prazosin, 20 µg kg (n=4) and yohimbine, 
30 µg kg-l (n=4) and 6 µg kg-l (n=2), on the MAP and HR are shown in 
Figure 8.6. There was no significant effect of these drugs on either MAP 
or HR. 
A swnmary of the changes in MAP and HR produced by amitraz alone (Figure 
8.2, experiment II) and with pretreatment using either prazosin or 
yohimbine is presented in Figure 8.7. Prazosin failed to antagonise the 
depressant effects of amitraz on the MAP but appeared to partly antagonise 
the bradycardia. 
Yohimbine at a dose of 30 µg kg-l ICM (n=4) reversed the hypotension 
produced by amitraz at -1doses up to 25 µg kg , however the bradycardia
persisted to some extent (Figure 8.9) in the presence of this antagonist.
Amitraz alone at a dose of 15 µg kg-l (8 minute point), reduced HR by
24.0 bpm (control 90.6 ± 1.0 bpm) but in the presence of yohimbine the
decrease was 13.0 bpm (control 101.3 ± 12.4 bpm) and with prazosin the
decrease was 9.3 bpm (control 139.0 ± 3.9 bpm).
Yohimbine at a dose of 6 µg kg-l ICM (n=2) prevented thehypotension and 
also the HR appeared to show little change from the control (Figure 8.8). 
As only two dogs were given yohimbine at 6 µg kg-l no definite conclusions 
can be drawn. 
MAP and HR changes following amitraz alone and in the presence of either 
Figure 8.5 The·increase in MAP and HR produced by 5, 10 and 
-1
20 µg kg of amitraz IV. 
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Figure 8.6 The effects of prazosin (20 µg kg-l ICM, n=4), P and yohimbine (30 µg kg-l ICM, n=4 
and 6 µg kg-l ICM, n=2), Y30 and Y6 respectively, on the MAP and HR. Points show 
mean and the vertical bars the SEM. 
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Figure 8.7 The changes in MAP and HR following amitraz alone (n=4) and in the presence of either 
prazosin (20 µg kg-l ICM, n=4) or yohimbine (30 µg kg-l ICM, n=4). Points show the 
mean and vertical bars the SEM. 
C = control, A = amitraz, * P<0.05 ** P<0.01. All points to the right of 
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Figure 8.8 The changes in MAP and HR following amitraz in the presence of yohimbine 30 µg kg-l ICM (n=4) 
and 6 µg kg-l ICM (n=2). Points show the mean and vertical bars the SEM. 
C = control A = Amitraz ** P<0.01. 
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Figure 8.9 Percentage change from control of MAP and HR induced by amitraz alone (n=4) or in the presence of 
prazosin (20 µg kg-l ICM, n=4) or yohimbine (30 µg kg-l ICM, n=4). Points show mean and the 
vertical bars the SEM. 
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prazosin or yohimbine are expressed as a percentage change from control 
(Figure 8.9). Yohimbine but not prazosin prevented the hypotension 
following amitraz, however, bradycardia persisted in the presence of 
both antagonists. After 15 µg kg-l of amitraz alone, the HR decreased 
by 21.3 ± 2.1% whereas HR depression was only 10.8 ± 2.6% in animals 
-1given yohimbine (30 µg kg ) and 6.1 ± 1.9% following prazosin.
DISCUSSION 
These results indicate that amitraz lowers blood pressure and heart rate 
by a central action. Amitraz given intravenously at low doses also 
produces a similar effect on the cardiovascular variables but as the dose 
required was much higher than when given intracisternally, it is likely 
that a central action is being studied. Evert if the highest dose given 
intracisternally had escaped from the central nervous system then the 
peripheral effects would have been negligible (Figure 8.4). The 
transient hypertension seen initially after IV amitraz is likely to be a 
peripheral effect preceding the central action. 
For a compound to have central actions following intravenous administration 
it must have lipophilic properties (Kobinger, 1978; van Zwieten, 1980) 
and from the results shown in Figures 8.2 and 8.3, together with those 
from the carotid occlusion studies, there is every reason to believe 
that amitraz penetrates the central nervous system. 
Since yohirnbine and not prazosin prevented hypotension produced by arnitraz 
given ICM, it appears that the a 2 -adrenoceptor is mediating this response. 
The extent of hypotension in the presence of prazosin approached that produced 
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by amitraz alone. 
This central hypotensive action of amitraz is a property also shown by other 
a2 -adrenoceptor agonists. Hypotension produced by centrally administered 
clonidine was inhibited by either yohimbine or another a2 -adrenoceptor 
antagonist, piperoxan, in rabbits (Kim et al, 1982), cats (Hamilton et al, 
1980) and rats (Borkowski and Finch, 1979). As well as clonidine, centrally 
administered B-HT 933 (azepexole) (van Zwieten and Timmermans, 1980) and St 91 
(McLennan and Bentley, 1983) in cats and rats caused hypotensio� that was 
antagonised by piperoxan. 
Unlike the above reports, McLennan and Bentley (1983) showed that prazosin, 
a preferential a1-adrenoceptor antagonist, also inhibited the hypotension 
produced by a clonidine analogue, St 91, in cats (both drugs were given into 
the vertebral artery). The central hypotensive action of clonidine was also 
shown to be inhibited by prazosin in the cat (Timmermans et al, 1979). 
In a subsequent report, Timmermans et al (1981) described the antagonism of 
the central hypotensive actions of clonidine in cats by yohimbine and 
rauwolscine, both a
2
-adrenoceptor antagonists, and corynanthine, a preferential 
a1-adrenoceptor antagonist. Timmermans et al (1981) regarded the evidence 
from this study and their earlier one (Timmermans et al, 1979) as favouring 
the a2 -adrenoceptor as the mediator for the central hypotensive action of 
clonidine. In addition, these authors considered that while both prazosin and 
corynanthine were selective antagonists at a1-adrenoceptors they also had 
measurable affinity for the a2-subtype. Another factor which may be 
important is that the classification of these drugs was made following 
experiments on receptors in peripheral tissues and not receptors in the central 
nervous system (Timmermans et al, 1981). Furthermore, they proposed that there 
may be discrimination between the antagonists, prazosin and corynanthine on 
one hand and yohimbine and rauwolscine on the other for pre- and postsynaptic 
az-adrenoceptors in the central nervous system. 
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After citing reports showing that clonidine and prazosin do not compete for 
the same binding site in the brain, McLennan and Bentley (1983) suggested 
that different central pathways rather than central a-adrenoceptors may be 
involved in the production of hypotension and bradycardia by clonidine and 
St 91. The antagonism of the St 91-induced hypotension by prazosin may take 
place elsewhere on the pathway, perhaps distally to the site of action of 
St 91 and clonidine. 
The central actions of amitraz on the heart rate are not as clear cut. 




yohimbine (30 µg kg ) but the extent was not as marked as when amitraz was
given alone. Dogs given prazosin had less bradycardia than those given
yohimbine (Figure 8.9). It should be pointed out that despite indications
that amitraz is an a2-adrenoceptor agonist, it may also stimulate
a1-adrenoceptors, as suggested by the present study. The central actions of
amitraz in producing bradycardia suggest that both a1- and a2-adrenoceptors
may be important in the central control of the heart rate.
Central receptors in the dog that control blood pressure appear to be 
different from those that control heart rate, a suggestion also made by 
Timmermans et al (1979) for the cat and rat. These authors described the 
blockade by prazosin of centrally-induced hypotension and not bradycardia 
following clonidine. 
McLennan and Bently (1983) used the equal inhibition of hypotension and 
bradycardia, responses to the central actions of St 91, by piperoxan as an 
indication of similar receptor types for blood pressure and heart rate. This 
type of response was not 'seen with dogs in the present study which adds 
support to the possibility of different receptors controlling blood pressure 
and heart rate. 
Specific a2-adrenoceptor antagonists inhibited bradycardia produced by clonidine 
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in cats (Hamilton et al, 1980) and rats (Borkowski and Finch, 1979) and St 91 
in cats (McLennan and Bentley, 1983). Because of the likelihood of variation 
in central receptors between different species care is required when 
comparing responses (Kobinger, 1978). 
The mechanism of the central action of clonidine, either pre- or post­
synaptically, has been discussed by van Zwieten (1980) and Johansson (1984) 
and as yet no definite conclusions can be made. Clonidine is an 
a2-adrenoceptor agonist and receptors of this type have been lo�ated in those 
parts of the brain associated with cardiovascular control and the baro­
receptor reflex. These areas include the nucleus of the tractus solitarius, 
the dorsal nucleus of the vagus nerve and the ventrolateral medulla 
oblongata (Probst et al, 1985; Young and Kuher, 1979). The hypothalamus has 
also been suggested as a site of action for clonidine to produce hypotension 
(Struyker-Boudier et al, 1974a). In a recent report intracerebroventricular 
injections of either yohimbine or prazosin prevented bradycardia elicited by 
electrical stimulation of the hypothalamus in the rabbit (Evans, 1985). From 
this, the author suggested that an a-adrenergic pathway existed between the 
cardioinhibitory zone in the rabbit hypothalamus and the baroreceptor refl�x 
pathway in the caudal brainstem. Both a 1- and a2-adrenoceptor antagonists 
have this inhibitory effect suggesting that both receptors are involved. 
The central regulation of blood pressure and heart rate is extremely complex 
and from the many studies undertaken, researchers have proposed a number of 
theories to explain their results, as discussed above. Amitraz-induced 
hypotension appears to be mediated by central a 2-adrenoceptors while there is 
evidence that stimulation of both a 1- and a 2-adrenoceptors produces bradycardia. 
The finding that prazosin partly antagonised the amitraz-induced bradycardia is 
unusual, though clonidine - and St 91-induced hypotension have been 
antagonised by prazosin (Timmermans et al, 1979; McLennan and Bentley, 1983). 
U'Pritchard et al (1978) used receptor binding techniques in peripheral 
tissues and brain and suggested that prazosin may act at two separate sites. 
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The central actions of amitraz, particularly with respect to its effect on 
the heart rate, requires further study in an attempt to elucidate its 
mechanism of action. 
Hypotension and bradycardia, caused by the central actions of clonidine and 
related drugs, is predominantly due to reduction in peripheral sympathetic 
tone (Kobinger > 1978; Timmermans and van Zwieten, 1982). Arnitraz has been 
shown to have many actions similar to clonidine and also appears to be an 
a2 -adrenoceptor agonist. Hence, it is possible that the central actions of 
the formamidine may be attributable, to some extent, to a reduction in 
peripheral sympathetic tone. 
In a previous study where phentolamine antagonised the hypertensive actions 
of amitraz, given cumulatively (Chapter 3), an hypotensive effect was 
revealed along with the reduced pressor response (Figure 3.2). It is likely 
that the pressor effect was produced by initial stimulation of peripheral 
vascular a-adrenoceptorsbefore a central hypotensive action developed. 
Phentolamine has difficulty in penetrating the central nervous system 
(van Zwieten, 1980) and may have been unable to inhibit the central actions 
of amitraz. 
If the peripheral actions of amitraz predominate and mask the hypotensive 
effect this would explain the finding in earlier investigations that hypo­
-1 
tension was inconsistent after doses of 0.5, 1, 2, 5 and 10 mg kg IV. 
-1
Arnitraz at a dose of 0.5 µg kg ICM produced hypotension and bradycardia 
-1
which was a lower dose than that (2 µg kg ICM) required to depress the
COR. The intravenous dose of amitraz necessary for COR depression and
-1
hypotension was between 40 and 60 µg kg .
It was noticed in these experiments that there was greater variation in the 
heart rate than the blood pressure responses, particularly after 15 and 20 
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-1
µg kg of amitraz IV (experiments I and II). This may be related to the 
time needed for arnitraz to penetrate to those parts of the brain, producing 
bradycardia. 
In conclusion, previous experiments indicated that amitraz was an 
a2-adrenoceptor agonist and this was further supported when yohimbine blocked 
the amitraz-induced depression of the COR. While yohimbine blocked the 
central hypotensive actions of amitraz, bradycardia persisted in the presence 
of either prazosin or yohimbine, although it was reduced. Thus� it appears 
that arnitraz activates central a2-adrenoceptors to lower blood pressure and 
both a1- and a2-subtypes to reduce heart rate. One aspect that could be 
investigated in the future is the effect of combined yohimbine and prazosin 
on arnitraz-induced bradycardia. 
The likelihood of amitraz stimulating a1-adrenoceptors, as well as the 
a2-subtype, in the peripheral vasculature also needs investigation. 
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CHAPTER 9 
THE ACTIONS OF AMITRAZ ON THE AUTOPERFUSED HINDLIMBS OF THE DOG 
INTRODUCTION 
Evidence has been presented to show that amitraz is an a2-adrenoceptor 
agonist. In addition, investigations into the central actions of amitraz 
have shown that it can also stimulate the a1 -subtype because prazosin partly 
reduced the bradycardia caused by the formamidine. 
As well as producing hypotension and bradycardia by a central action, amitraz 
depresses baroreceptor reflex function and the COR. 
Hypertension and reflex bradycardia follow the intravenous administration of 
ami traz. The pressor responses are inhibited by phentolamine, how eve�, the 
peripheral actions of amitraz have not been studied using specific· 
a-adrenoceptor antagonists. The design of experiments investigating
peripheral actions must take into consideration the likelihood that this 
compound penetrates the CNS, as shown by' hypotension and depression of the COR 
when given intravenously. 
In the intact animal the direct effect of a substance on the vascular system 
can be examined by intra-arterial injections into autoperfused tissues. The 
use of an autoperfused vascular bed will allow separation of both direct 
effects of the drug and reflex changes. The perfusion of tissues using a 
constant flow technique gives accurate and reliable information about the 
interaction between substances and vascular receptors (Beck, 1961). With 
constant flow, change in vascular resistance is reflected in the perfusion 
pressure. 
The aim of these experiments was to study the peripheral actions of amitraz 
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in the autoperfused hindlimbs of the dog taking blood from the aorta through 
a delay circuit and then pumping it back into the aorta. This preparation was 
also used to test effects of several a-adrenoceptor antagonists on amitraz 
responses; phentolamine, an a1- and a 2 -adrenoceptor antagonist (Drew, 1976; 
Cavero et al, 1977); prazosin, an a1-subtype antagonist (Cambridge et al, 
1977; U'Prichard et al, 1978) and yohimbine, an a 2 -subtype antagonist (Doxey 
et al, 1977; Shepperson et al, 1981; Paciorek and Shepperson, 1985). 
METHODS 
These experiments were performed using 31 mongrel dogs that were clinically 
healthy and weighed 20.3 ± 0.9 kg (mean± SEM). These animals were 
anaesthetised as described in Chapter 2. 
Blood was taken from the aorta posterior to the kidneys through a delay 
circuit (4.65 metres long, approximate volume 110 ml), made of clear vinyl 
and silastic rubber tubing (Dow Corning Corp., Michigan, U.S.A.), and 
returned to the aorta before the bifurcation into the iliac arteries (Figure 
9.1). This delay circuit allowed time for separation between the reflex 
responses to intravenous drugs and their direct effect on reaching the hind­
limbs. The circuit was filled with isotonic dextrose-saline solution 
containing 15 IU heparin per ml. A constant blood flow through the circuit 
was maintained with a peristaltic pump (Watson-Marlow, Ltd., England) and 
perfusion pressure distal to the pump recorded with a Gould Statham P23 ID 
pressure transducer. Part of the circuit passed through a water bath at 
38 ° C to maintain the perfusion fluid at body temperature. 
All major vessels were left intact and care was taken not to damage any nerves 
in order to preserve reflex function. 
The right brachial artery was cannulated for the recording of pulsatile and 
mean arterial blood pressure and heart period as described in Chapter 2. 
Figure 9.1 Diagramatic representation of the delay circuit used for 
the autoperfusion of the hindlimbs of the dog. 
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Intravenous injections were made through a cannula in the .brachia1 vein and 
intra-arterial (IA) injections were made into a rubber segment of the delay 
circuit before it entered the aorta distally. 
The speed of the perfusion pump was adjusted so that perfusion pressure was 
equivalent to MAP before injecting amitraz. Changes in the perfusion pressure 
reflected changes in vascular resistance of the hindlimbs. 
The Effects of IA Amitraz 
Cumulative doses of amitraz were given IA at intervals of 5 minutes studying 
-1
the effects of 0.125, 0.25 and 0.5 mg kg (actual doses given were 0.125,
-1
0.125 and 0.25 mg kg , n=5). Readings of the change in MAP, HR, peak
perfusion pressure (A in Figure 9.2) and new baseline perfusion pressure
(Bin Figure 9.2) were made after each injection. 
In another series of experiments the same protocol was used to study the 
-1
effects of 6.25, 12.5 and 25 µg kg of amitraz IA (n= 3) (actual doses given 
-1
were 6.25, 6.25 and 12.5 µg kg ). 
Responses to IV Vasoactive Substances 
The changes in MAP, HR and peak perfusion pressure produced by acetylcholine, 
-1 -1 -1
1 µg kg IV; noradrenaline, 0.2 µg kg IV and isoprenaline, 0.2 µg kg IV 
-1 -1
were m�asured before and after amitraz at doses of 0.5 mg kg and 25 µg kg .
Amitraz was given IA and as its actions were shown in previous studies to 
persist for some time (Chapter 2), it was expected to have distributed 
around all tissues of the body by the time injection of vasoactive substances 
was repeated. The delay circuit in the hindlimbs enabled the reflex responses 
to the vasoactive substances given intravenously to be separated from the 
direct effect. 
Amitraz was dissolved in 10 µl of DMF and the effects of the vehicle on the 
perfusion pressure and the responses of the vasoacti ve substances ¼:�re tested at 
Figure 9.2 Examples of BP, HP and perfusion pressure (PP) changes 
-1 1 
produced by 0.125 mg kg (upper panel) and 6.25 µg kg-
(lower panel) of amitraz IA. 
Peak perfusion pressure is the maximum pressure reached 
immediately following injection (A). Baseline perfusion 
pressure is the new resting perfusion pressure after amitraz 
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the start of the experiments. 
Dose Response Curves for Amitraz and Effects of a�Adrenoceptor Antagonists 
Measurements were made of the maximmn increase in perfusion pressure, from 
the preamitraz control, following IA doses of amitraz at 0.25, 0.5, 1, 2, and 
-15 µg kg . Dose response curves were drawn. These doses were actual doses
given and not cmnulative doses.
As such small doses of amitraz were used its actions were probably terminated 
rapidly by redistribution and metabolism but despite the use of small 
quantities, some accmnulation of the compound in the body was expected. 
A noradrenaline dose response curve was made using 0.01, 0.02, 0.08, 0.32 and 
0.64 µg kg-l IA and this was compared to that for amitraz. 
Increasing doses of amitraz were given IA after IV injections of either 
-1 -1 
-
-1 phentolamine, 0.5 mg kg ; prazosin, 35 µg kg ; prazosin, 150 µg kg ;
yohimbine, 10 µg kg-l or prazosin 35 µg kg-l plus yohimbine 10 µg kg-l
In order to monitor a-adrenoceptor blockade, responses to noradrenaline were
recorded before and after the antagonists and again. at the completion of 
the experiment. The concentration of 3H-yohimbine in the blo.od of mice was
reported to be about 66% of the total tritiated material 45 minutes after 
intraperitoneal injection (Ho et al, 1971), and the doses given to the dogs 
-1in the present study were low (10 µg kg IV). Thus, test doses of
noradrenaline were not given immediately following the antagonist but amitraz
was given as soon as MAP and HR reached a new resting level while yohimbine
concentrations were maximmn. Noradrenaline was repeated 38 to 40 minutes after
yohimbine.
Statistical Analysis 
The mean changes in all cardiovascular variables following 0.125, 0.25 and 
185. 
• 0.5 mg kg-l of amitraz IA were compared to the control values using
Dunnett's t test (Dunnett, 1955). Responses to IV vasoactive substances
before and after amitraz were compared using "Students" t test (Snedecor and
Cochran, 1967). Dose response curves for IA amitraz before (control) and
after each adrenoceptor antagonist were compared using a parallel line assay
technique which tested for parallelism, linearity and for a shift in the line
(Colquhoun, 1971). The same analysis compared the noradrenaline and amitraz
dose-response curves.
Values are expressed as mean ± SEM. The SEM at any dose was calculated as 
described in Chapter 2. Results differing from the control at P<0.05 were 
considered significant. 
Drugs 
The agonist drugs used in these experiments were, acetylcholine chloride 
(Sigma Chem. Co.), noradrenaline hydrochloride (Sigma Chem. Co.), isoprenaline 
sulphate (Sigma Chem. Co.). These drugs were made up fresh each day in 
1 -1 catecholamine vehicle (9 g 1- sodium chloride, 0.19 g 1 sodium 
dihydrogen phosphate, 30 mg 1-l ascorbic acid) and volumes of 0.1 ml were 
given. 
The antagonist drugs used were, prazosin hydrochloride (Pfizer Inc.), 
yohimbine hydrochloride (Sigma Chem. Co.), phentolamine mesylate (Ciba 
Pharmaceuticals). Prazosin and yohimbine were made up fresh each day in 
sodium chloride (9 g 1-1) and phentolamine was used directly from the
commercial solutio.n in ampoule. 
All dose rates were calculated using the total salt. N, N-dimethyl formamide 
-1 (DMF, Mallinckrodt Inc.) 0.942-0.946 mg ml was used to dissolve the amitraz.
186. 
RESULTS 
Test doses of IA DMF had no effect on the MAP, HR, perfusion pressure or the 
responses to the vasoactive substances. 
The Effects of IA Amitraz 
Figure 9.2 demonstrates typical actions of amitraz on MAP, HR and perfusion 
pressure. 
The changes in MAP, HR, peak perfusion pressure and baseline perfusion 
-1 pressure produced by IA doses of 0.125, 0.25 and 0.5 mg kg (n=S) and
-1 6.25, 12.5 and 25 µg kg of amitraz (n=3), given cumulatively, are shown in
Figure 9.3.
All doses produced a significant increase in peak perfusion pressure and 
baseline perfusion pressure. Initial values that showed statistical 
significance are: 
Peak Perfusion p · Baseline Perfusion p 
Pressure (mmHg) Pressure (mmHg)
Control 100.4 ± 2.0 100.4 ± 2.0 
Amitraz 0.125 182.6 ± 14.6 <0.01 134.8 ± 6.4 <0.01 
mg kg-l 
-1 A significant hypotension and bradycardia developed after 0.25 mg kg of 
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The lower doses of amitraz, 6.25, 12.5 and 25 µg kg-l (n=3) produced similar 
changes to the higher doses except that baseline perfusion pressure was little 
affected. -1After 25 µg kg the MAP and HR decreased by 9.2 mmHg and 8.4 bpm,
Figure 9.3 Mean changes in MAP, HR, peak perfusion pressure(•■------■•) 
and baseline perfusion pressure (.ti:•--:Aa ) produced by IA 
amitraz given cumulatively. Injections given every 5 
minutes (left panel, n=S; right panel, n=3). Vertical 
bars show the SEM at any dose. 
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respectively, while the peak perfusion pressure and ba�eline perfusion 
pressure increased by 74.8 mmHg and 9.1 mm Hg, respectively. 
Responses to IV Vasoactive Substances 
-1
Figures 9.4 and 9.5 show examples of the cardiovascular responsesto 1 µg kg 
1 -1
acetylcholine IV, 0.2 µg kg
-
noradrenaline IV and 0.1 µg kg isoprenaline 
IV. A summary of the changes in MAP, HR and perfusion pressures produced by
-1 -1
these substances before and after 25 µg kg and 0.5 mg kg of amitraz is 
presented in Figures 9.6 and 9.7. 
Acetylcholine and isoprenaline decreased while noradrenaline increased the 
MAP. Pressor and depressor reflex responses were seen respectively in the 
hindlimbs before the direct actions of the drugs were produced as they reached 
the vascular beds (Figures 9.4 and 9.5). 
The MAP and HR responses following acetylcholine were depressed by the higher 
amitraz dose (Figure 9.7) as was seen in a previous study (Chapter 5). 
Amitraz had no significant effect on the blood pressure responses or the 
direct and reflex perfusion pressure responses to noradrenaline at either 
dose. 
The vascular responses produced by acetylcholine, noradrenaline and 
-1
isoprenaline showed little change before and after 25 µg kg amitraz 
(Figure 9.6). 
The high dose of amitraz increased the baseline perfusion pressure by 56.2 mmHg 
to 156 ± 7.1 mmHg when the second dose of noradrenaline was given. 
The isoprenaline-induced fall in MAP was reduced after amitraz but this was 
in the presence of a concomitant decrease in blood pressure (control response, 
-1
20.5 ± 2.4 mmHg; after amitraz 0.5 mg kg , response 6.2 ± 2.5 mmHg; P<0.05).
The MAP at the peak of the isoprenaline response was 73.S ± 3.4 mmHg before and
Figure 9.4 BP
> 
perfusion pressure (PP) and HP responses to 
t 1 h 1. 1 0 k -l IV d 1· 0 2 µg kg-l IV ace y c o  1ne . µg g , nora rena 1ne . 
and isoprenaline 0.1 µg kg-l IV before (A) and after (B) 
-1amitraz at a dose of 25 µg kg . Closed arrows indicate
the time at which the vasoactive substance was administered
and open arrows show reflex responses in the hindlimbs.
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Figure 9.5 BP� perfusion pressure (PP) and HP responses to 
acetylcholine 1.0 µg kg-l IV, noradrenaline 0.2 µg kg-l 
IV and isoprenaline O .1 µg kg -l IV- before (A) and after 
-1(B) amitraz at a dose of 0.5 mg kg . Closed arrows
indicate the time at which the vasoactive substance was 
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Figure 9.6 Responses of the MAP, HR and perfusion pressure (PP) to IV 
acetylcholine, noradrenaline and isoprenaline before and 
-1
after amitraz 25 µg kg (A). Histograms show the mean change 
and vertical bars the SEM. Shaded histograms show reflex 
effects in the hindlimbs and the unshaded histograms the 
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Figure 9.7 Responses of the MAP, HR and perfusion pressure (PP) to IV 
acetylcholine, noradrenaline and isoprenaline before and 
-1
after amitraz 0.5 mg kg (A). Histograms show the mean
change and vertical bars the SEM. Shaded histograms show
reflex effects in the hindlimbs and the unshaded histograms
the direct effect of the agonist drug.
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55.7 ± 2.5 mmHg after amitraz. The difference in baseline is a probable 
reason for variation in the isoprenaline blood pressure responses. 
The direct effect of isoprenaline on the hindlimbs was to lower the 
perfusion pressure. The control response was 12.0 ± 2.9 mmHg (baseline 
-1
pressure 100.4 ± 2.9 mmHg) but after 0.5 mg kg of amitraz the response was 
49.5 ± 10.2 rnmHg, P<0.05 (baseline pressure 156.6 ± 7.1 mmHg, Figure 9.7). 
While the reflex responses in the hindlimbs to intravenous acetylcholine and 
isoprenaline in this study were reduced significantly by amitraz, it should 
be pointed out that the systemic actions of these agonists on the MAP were 
also reduced and, therefore, no conclusions can be made about the action of 
amitraz on the vascular reflexes from these results. 
Dose Response Curves for Amitraz 
The dose response curves for IA noradrenaline and amitraz are shown in Figure 
9.8. Responses to amitraz were taken from three different experiments. 
The amitraz dose response curve did not differ significantly from parallelism 
to the noradrenaline curve (F=12.19, P<0.005, amitraz doses used 0.25 to 
-1 
5 µg kg ) and was shifted 151.5 fold to the right, i.e., noradrenaline was
151.5 times more potent than amitraz in increasing perfusion pressure. 
Dose Response Curves for Amitraz Following a-Adrenoceptor Antagonists 
The changes in MAP and HR produced by phentolamine, prazosin and yohimbine 
are shown in Table 9.1. The perfusion pump speed was adjusted so that the 
perfusion pressure and MAP were equivalent before antagonists reduced MAP and 
increased HR. 
Figure 9.8 The dose response curve for IA noradrenaline (e------) and amitraz (0----0). Points 
marked� and □ show effects of amitraz taken from another two experiments. 



















































Table 9.1 The decrease in :MAP and increase in HR.produced by 
a-adrenoceptor antagonists. Figures show mean ± SEM.
Antagonist Decrease in MAP In�rease in 
(given IV) (mmHg) (bpm) 
Phentolamine 0.5 
-1
23.5 3.1 23.9 8.5 mg kg ± ± 
Prazosin 35 µg kg
-1
19.2 ± 4.1 6.2 ± 1.6 
Prazosin 150 µg kg
-1
21.7 ± 1.7 14.8 ± 4.1 
Yohimbine 10 
-1
2.8 ± 1.5 6.6 3.0 µg kg ± 
HR 
The responses to noradrenaline were inhibited between 7 and 9 minutes 
(before amitraz) after prazosin and phentolamine and again between 43 and 45 
minutes after these antagonists, at the end of each experiment. 
Noradrenaline was not given immediately after yohimbine but between 38 and 
40 minutes later. A summary of the responses to noradrenaline before and 
after the antagonists is shown in Figures 9.9 and 9.10. 
Figure 9.11 shows the dose response curves for IA amitraz alone and in the 
presence of a-adrenoceptor ant:a:gonists. 
Prazosin, yohimbine and phentolamine all antagonised the peripheral actions 
of amitraz and shifted the dose response curve to the right in a parallel 
manner. The dogs that received both prazosin and yohimbine were given the 
a2 -adrenoceptor antagonist after the effects of prazosin on amitraz were 
investigated. 
Table 9.2 gives details of the statistical analysis comparing the dose 
response curves for amitraz alone and after the antagonists. 
Figure 9.9 Responses to noradrenaline before (-e--e-), 7 to 9 
minutes after (.A----,&) and 43 to 45 minutes (a-----11) 
after prazosin, 35 µg kg-l IV (A); prazosin, 150 µg kg-l IV 
-1 (�) and phentolamine 0.5 mg kg IV (C). Points show mean 
increase in MAP or PP (perfusion pressure). Vertical bars 
show the SEM. 
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Figure 9.10 Responses to noradrenaline before Ce e) and 38 to 40 minutes after C•----■) yohimbine
-110 µg kg IV (A). Panel B shows responses to IA noradrenaline before Ce e) and 43
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Figure 9.11 Dose response curves for IA amitraz alone (•e..--�e-, n=4) and
-1 -1after prazosin 35 µg kg C•---■, .n=5), yohimbine 10 µg kg 
(Ar---4i., n=5), phentolamine 0.5 mg kg-l (0---0, n=4),
1 -1prazosin 150 µg kg - (0-···-0 , n=5) and prazosin 35 µg kg 
plus yohimbine 10 µg kg -l (D;.·········�, n=5). Points show mean
increases in peak perfusion pressure and vertical bars show 
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Table 9.3 Results of statistiGal analysis comparing the effect of 
a-adrenoceptor antagonists on IA amitraz. Despite the apparent
difference between the shape of the control amitraz dose response
curve and that after prazosin plus yohimbine, statistical analysis
indicated that they were both parallel, probably due to the scatter
of the points.




Phentolamine 0.5 mg kg 
-1
3.43 ** 





50.89 ** µg kg 
Yohimbine 10 
-1
30.68 ** µg kg 
Prazosin 35 µg kg 
-1
PLUS 16.61 ** 
--
Yohimbine 10 µg kg 
-1
Deviation from Potency Ratio 
Parallelism EDs o (Antag.) / 
(F Value) EDso(Amitraz) 
0.63 10.87 * 
0.25 2.34 * 
6.37 * 10. 88 *
0.026 5.05 * 
2.84 36.37 * 
There was little consistent change in baseline perfusion pressure after 
amitraz alone and in the presence of yohimbine, prazosin and phentolamine. 
DISCUSSION 
These experiments have provided extra evidence for the vasopressor action of 
amitraz. Earlier it was shown that phentolamine antagonised the increase in 
blood pressure following intravenous injections of amitraz (Chapter 3). In 
addition blood pressure increased concurrently with a dose dependant rise in 
vascular resistance (Chapter 4). 
Amitraz acts centrally to lower blood pressure and heart rate (Chapter 8) 
and it can be expected that a central effect was responsible for the 
reduction in these variables in the present study. It was shown that an IV 
-1
dose of 60 µg kg of amitraz significantly lowered MAP and HR by a central 
action (Chapter 8) but in the present studies a significant decrease in MAP 
2:0:0 .. 
-1followed 0.25 mg kg of amitraz IV. The reason for this .difference in dose 
rates is unknown but one possibility is that a proportion of amitraz is held 
in the vasculature and tissues of the hindlimbs thereby lowering the quantity 
that returns to the heart and is available to penetrate the CNS. 
Amitraz acted like a partial agonist in the autoperfused hindlimbs when it 
was compared to noradrenaline. Phentolamine, prazosin (35 µg kg
-1
) and
yohimbine competitively antagonised the peripheral actions of amitraz on the




The higher dose of prazosin (150 µg kg ) produced a non-
which indicates non-competitive antagonism.
In view of the antagonism of amitraz by yohimbine in these experiments, the 
formamidine has now been shown to have a2 -adrenoceptor agonist actions both 
centrally and peripherally. Indications of an action at a1-adrenoceptors 
became apparent during the study of the central actions of the formamidine 
when prazosin reduced the degree of bradycardia. Peripherally, prazosin also 
antagonised the presser actions of amitraz demonstrating the involvement of 
a1-adrenoceptors. 
-1
An IV dose of between 40 and 60 µg kg of amitraz acted centrally to lower 
both the blood pressure and heart rate (Chapter 8). In some of the present 
experiments with antagonists, sufficient am1traz was administered and this may 
have exceeded the intravenous threshold dose for a central effect. 
Experiments in which high cumulative doses of amitraz were given were those 
-1
with phentolamine, prazosin 150 µg kg and prazosin plus yohimbine. Weak
central actions of amitraz may have been sufficient to interfere with its
peripheral actions and alter the shape of the dose-response curve. In those
experiments where antagonism at the a2-adrenoceptor was predominantly absent
-1
(prazosin 150 µg kg ) or weak (prazosin plus yohimbine) the dose-response
curve was obviously flattened. Phentolamine, an a1- and a 2 -adrenoceptor
antagonist (Drew, 1976; Cavero et al, 1977), may have either penetrated the
201. 
nervous system in sufficient quantities to antagonise the central actions of 
amitraz or, masked any hypotensive actions of the formamidine peripherally. 
One way of eliminating the possibility of a secondary central action of 
amitraz is to study its effects in spinal animals and this is a study which 
could be performed in the future to clarify this point. 
Many reports have described postjunctional a-adrenoceptors of both subtypes 
in the blood vessels of dogs (Constantine et al, 1980; Langer et al, 1980; 
Sullivan and Drew, 1980; De Mey and Vanhoutte, 1981; Langer et al, 1981a; 
Langer et al, 1981b; Horn et al, 1982; Sakakibara et al, 1982; Polonia et al, 
1985). 
Evidence has been presented for the presence of a1- and a 2-adrenoceptors in 
isolated canine femoral and saphenous veins (De Mey and Vanhoutte, 1981), 
saphenous veins (Sullivan and Drew, 1980; Polonia et al, 1985) and the renal 
and femoral vasculature in intact animals (Horn et al, 1982). While equal 
concentrations of both a1- and a2 -adrenoceptors were shown to be present in 
the canine basilar artery, the a 1-subtype predominated in the mesenteric and 
renal arteries (Sakakibara et al, 1982), femoral and splenic arteries (De Mey 
and Vanhoutte, 1981) and renal, splenic, cranial mesenteric, jejunal and 
femoral arteries (Polonia et al, 1985). From these studies it appears that 
higher concentrations of the a2 -subtype exist in veins of dogs (De Mey and 
Vanhoutte, 1981), a finding that was also made in a study of postjunctional 
a-adrenoceptors in human femoral arteries and veins (Glusa and Markwardt,
1983). 
Clonidine had a variable effect on canine arteries in vitro: it contracted the 
basilar artery in a similar way to noradrenaline but the responses in the 
mesenteric and renal arteries were less than those to noradrenaline 
(Sakakibara et al, 1982). Clonidine failed to contract isolated preparations 
of canine splenic artery (De Mey and Vanhoutte, 1981; Hieble and Woodward, 
1984), however, tramazoline was shown to contract the artery (De Mey and 
202. 
Vanhoutte, 1981). Both prazosin and rauwolscine antagonised noradrenaline­
induced contractions in splenic vessels (Hieble and Woodward, 1984). 
Vascular resistance in the renal and femoral vascular beds, reflected by 
changes in regional blood flow to these areas, has been studied in 
anaesthetised dogs. Vasoconstriction of the femoral bed by intra-arterial 
injections of clonidine was inhibited by yohimbine while prazosin had little 
effect. Clonidine was equipotent with noradrenaline as a pressor agent on 
femoral but less potent on renal vessels (Horn et al, 1982). 
Variation in the distribution of a-adrenoceptor subtypes was demonstrated in 
a number of isolated canine veins by comparing the contraction elicited by 
the a1-agonist, phenylephrine, and the a 2-agonist, clonidine (Shoji et al, 
1983). The saphenous, cephalic, femoral and external jugular veins were more 
sensitive to clonidine while the portal vein and the posterior vena cava, at 
the junction of the portal vein, were more sensitive to phenylephrine. · The 
mesenteric vein showed a similar response to both agonists and the 
brachiocephalic, azygos, pulmonary and splenic veins and anterior vena cava 
and two sections of the posterior vena cava (thoracic section and posterior 
to renal veins) were only contracted by phenylephrine. 
Again these reports favour the a1-adrenoceptor as being most important in 
arteries while the a
2
-subtype is found predominantly in veins. However, there 
appears to be variation in response to a 2 �adrenoceptor agonists in different 
veins. 
Because the posterior aorta supplies blood to the muscles of the hindlimb and 
the skin the increased perfusion pressure produced by amitraz may be due to 
action on the blood vessels in either or both areas. While there is little 
evidence for arteriovenous anastomoses in muscle, they are present in the 
circulation of the skin and sympathetic vasoconstrictor fibres .are present in 
these anastomoses (Guyton, 1981). The presence of a 2 -adrenoceptors has been 
203. 
reported in canine femoral vessels (De Mey and Vanhoutte, 1981; Horn et al, 
1982) and stimulation of this receptor type will constrict the vessel but the 
action of amitraz on the blood vessels to the skin is not known at this stage. 
As this compound stimulates a 1-adrenoceptors and there are sympathetic 
vasoconstrictor fibres ii the skin (Guyton, 1981) it can be speculated that 
some degree of vasoconstriction may occur in the cutaneous circulation. The 
important factor to point out is that in view of the current knowledge that 
there is extreme variation between the types of a-adrenoceptors and their 
concentration in the vasculature of different tissues, it can he expected 
that the response to amitraz in separate tissues may differ. 
The intravenous injection of the vasoactive substances acetylcholine, 
noradrenaline and isoprenaline demonstrated that the surgical preparation of 
these autoperfused dogs did not interfere with vascular reflexes. The reflex 
response, reflected in the change in perfusion pressure, was apparent before 
the direct effect of the agonist. Despite the reduction in the reflex 
responses after amitraz, conclusions about their function cannot be made 
because the blood pressure responses to acetylcholine and isoprenaline were 
decreased. A study of these reflexes requires the presence of a similar 
blood pressure response before and after amitraz. 
The increase in baseline perfusion pressure produced by amitraz is the 
likely reason for the marked increase in isoprenaline responses 
after amitraz (Figure 9.7). At the peak of the response the perfusion 
pressure was 88.4 mm Hg for the control and 107.1 mm Hg after amitraz. A 
previous study showed that amitraz had no effect on the responses to IV 
isoprenaline (Chapter 5). 
While amitraz was shown to be a partial agonist at a-adrenoceptors in the 
autoperfused hindquarters of the dog there was no convincing evidence to 
suggest the presence of any antagonistic properties at these receptors. 
Admittedly, noradrenaline was given only intravenously after amitraz in 
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these experiments, and those described in Chapter 5, whereas a more accurate 
assessment of antagonism could be made by injecting the catecholamine 
intra-arterially and comparing responses. 
Not only were clonidine, oxymetazoline, naphazoline and St 91 (drugs with 
some similarities to amitraz) partial agonists in rat autoperfused kidneys, 
hindquarters and mesentry but also they were shown to be partial a-antagonists. 
St 91 had a variable effect as an agonist and antagonist (Hepburn and 
Bentley, 1982) and the extent of the antagonism appeared to vary between 
tissues within species and tissues between species because clonidine was a 
marked antagonist in autoperfused hindquarters and kidneys in the rabbit but 
only a moderate antagonist in the rat (Hepburn and Bentley, 1982). Further 
studies are required using the same tissue preparation to examine more closely 
the possibility of amitraz having a-adrenoceptor antagonist properties and 
comparing them with imidazoline derivatives known to have these properties. 
This study has provided further evidence that amitraz activates both 
a1- and a 2-adrenoceptors, particularly the vascular receptors. 
205. 
CHAPTER 10 
THE ACTIONS OF AMITRAZ ON THE RAT VAS DEFERENS'PREPARATION 
INTRODUCTION 
Experimental evidence from anaesthetised dogs has shown that amitraz 
predominantly activates a 2 -adrenoceptors. Pressor responses to the 
ganglion stimulant, DMPP, were decreased by amitraz, an effect that was 
attributed to a prejunctional a 2 -adrenoceptor agonist action of -the 
formamidine (Chapter 5). In later experiments, the a 2 -adrenoceptor 
antagonist, yohimbine, inhibited amitraz-induced central and peripheral 
cardiovascular responses (Chapters 8 and 9). 
Despite this evidence confirmation of the a 2 -adrenoceptor actions of the 
formamidine was considered necessary using an·in vitro preparation. Various 
methods have been used to study the actions of a 2 -adrenoceptor agonists and 
antagonists. Measurement of the release of 3H-noradrenaline from preloaded 
tissues following electrical nerve stimulation and radioligand binding are 
two methods that have been used but a simple and effective technique is the 
measurement of depression of evoked contractions following transmural 
electrical stimulation of the• vas deferens of the rat, guinea-pig or mouse 
(Doxey and Roach, 1980). Noradrenaline is released from the sympathetic 
nerve fibres by the electrical stimulation and contraction of the smooth 
muscle of the vas deferens ensues. 
Because the twitch response has been shown to be resistant to blockade by 
prazosin (Docherty et al, 1979) and phentolamine (Swedin, 1971), three 
theories have been proposed to explain the role of noradrenaline in the 
contraction of the vas deferens following electrical stimulation. These have 
been summarised by Drew (1977) and Doxey and Roach (1980). One theory suggests 
that nerve terminals are deeply embedded in muscle cells and are poorly 
accessible to exogenously applied drugs while another suggestion is that 
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noradrenaline and a second unknown transmitter are �eleased by stimulation 
and noradrenaline then acts presynaptically to inhibit its own release and 
release of the second transmitter. Finally, it was suggested that when 
·noradrenaline was released•it activated-receptors on non-noradrenergic nervf}."
terminals to inhibit the release of an unknown transmitter. Despite these
differing theories, presynaptic.a. 2 -adrenoceptors are located on the motc,,:_t>
terminals making the vas deferens a suitable end-organ to study the actions of
presynaptic a
2
-adrenoceptor agonists and antagonists (Doxey and Roach, 1980).
Vizi·et al (1973) showed that presynaptic a.-adrenoceptor stimulation by 
xylazine (BAY-1470) or clonidine reduced transmitter output following electrical 
stimulation of the rat isolated vas deferens and consequently, the evoked 
contractions were decreased. The reduction in transmitter release was con-
firmed by measuring 3H-noradrenaline output from preloaded nerve terminals. 
The aim of this study was to assess the a.
2
-adrenoceptor action of amitraz 
using the rat vas deferens preparation. 
METHODS 
The vasa deferentia were removed from Wistar rats (300-350 g) and suspended 
-1
in a bath (12.8 ml) of modified Krebs solution (concentration in rnmol 1 :
NaC1=120, KCl=S, MgS04=1, NaHC0 3 =25, NaH2 P0 4= l, CaC12 =2.5, glucose 10)
maintained at 37 ° C. A mixture of 5% carbon dioxide in 95% oxygen was bubbled
through the bath and a tension equivalent to 1 g weight was applied
longitudinally to the tissue. Contractions of the vas deferens were recorded
isometrically with a Grass FT-03C force displacement transducer and displayed
on a Grass Model 7D polygraph (Figure 10.1).
Stainless steel electrodes were placed as shown in Figure 10.1 and 
supramaximal, square wave electrical stimuli (duration 0.5 .. msec), at a 
frequency of 0.1 Hz, were applied transmurally using a Grass S88 stimulator. 
Figure 10.1 Diagram showing the method by which the vas deferens was 
suspended in the tissue bath of modified Krebs solution. 






Each electrical stimulus produced a contraction of the tissue recorded as a 
twitch response. Stimulation voltage was adjusted to 15% above that which 
produced a maximal twitch. 
The Effects of Amitraz 
In separate experiments the effects of an equivalent volume of DMF, the vehicle 
used to dissolve amitraz, were tested on twitch responses of the vas deferens. 
After at least 30 minutes and when the twitch height became constant amitraz 
was added to the bath. Subsequent quantities of the formamidine were added at 
intervals of 3 to 5 minutes and from the results a cumulative dose response 
curve was made. 
By adopting the same protocol the effects of yohimbine, at concentrations of 
10- 7M, 10- 6 M and Sx10- 6 M; and prazosin, at concentrations of 10- 7M and 10- 6 M, 
were studied in separate experiments on the actions of amitraz. The 
antagonists were incorporated in the bath fluid while an amitraz dose response 
curve was constructed. 
The Effects of Phenylephrine 
The same preparations were used to test the response to phenylephrine but were 
not stimulated electrically. Phenylephrine was added to the bath and when 
tissue contraction had reached a maximum the bath was washed with Krebs 
solution to remove the agonist. The effects of different concentrations of 
phenylephrine were tested and a dose response curve was constructed. 
Phenylephrine dose response curves were constructed before and after the 
addition of DMF, amitraz (10- 5 M), yohimbine and prazosin. The concentrations 
of the antagonists were the same as those used with amitraz. Dose response 
curves were compared with those when phenylephrine was tested alone. 
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Statistical Analysis 
Statistical analysis of the central linear portions of the dose response 
curves were made using a parallel line assay to determine if curves were 
parallel and shifted significantly from control curves- (Colquhoun, 1971). 
The pA2 value was calculated as described by Arunlakshana and Schild (1959). 
The SEM at any dose was calculated as described in Chapter 2. 
Drugs 
The drugs used were: prazosin hydrochloride (Pfizer Inc.); yohimbine 
hydrochloride (Sigma Chem. Co.) and phenylephrine hydrochloride (Sigma 
Chem. Co.�. Drugs were made up fresh each day in the modified Krebs 
solution. 
N ,N-Dimethyl formamide: 
to dissolve amitraz. 
The Effects of Amitraz 
-1
(DMF) (Mallinckrodt) 0.942-0.946 g ml was used
RESULTS 
DMF did not interfere with the electrically-induced twitch responses of the 
rat vas deferens preparation. 
Amitraz reduced the twitch responses of the rat vas deferens preparation in a 
dose dependent manner. A 10- 8M concentration reduced twitches by 6.3 ± 1.04% 
and a 3x10- 5M concentration reduced them by 90.99 ± 1.9% (n= lS) (control lines 
Figure 10.2). 
Prazosin at concentrations of 10-7M (n=S) and 10
- 6M (n=2) had no effect on 
twitch height or on the actions of amitraz. Both dose response curves were 
parallel to and showed no significant shift from the control (Figure 10.2). 
In contrast, yohimbine inhibited the reduction in twitch height produced by 
Figure 10.2 Depression of twitch height by increasing concentrations of 
amitraz C••t---�e-) (control, n=lS). Upper panel shows the 
effects of prazosin and lower panel the effects of 
yohimbine on amitraz actions. 
(..tr----.6.) Prazosin 10-
7M (n=S) 
C•-----11) Prazosin 10- 6M (n=2) 
(II-----•) Yohimbine 10-
7M (n=S) 
C•----A) Yohimbine 10- 6M (n=4) 
(0-----0) Yohimbine Sxl0-
6M (n=4) 
Points show mean values and the vertical barsthe SEM at any 
dose. Ami traz concentration is exp,r,e,s,sed as the -negative log
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amitraz (Figure 10.2) while not affecting twitch height per se. Details of 
the effects of yohimbine are as follows: 
Yohimbine n Effect on Amitraz Dose 
Concentration Response Curve 
10- 7M 5 Parallel. Significant 
shift ( 4.39 fold) 
10- 6M 4 Not parallel . Significant 
shift (6 .98 fold) 
Sx10- 6M 4 Parallel. Significant 
shift (69.04 fold) 
The pA2 value for yohimbine against amitraz was 7. 53. 
The Effects of Phenylephrine 
DMF was shown not to interfere with the phenylephrine -induced contractions
of the tissue preparation. 
Increasing concentrations of phenylephrine (3xl0- 6M to 10-•3) contracted the 
vas deferens (control lines Figure 10.3). The presence of 10- 5M amitraz had 
no effect on phenylephrine
-
induced contractions . The dose response lines 
before and after amitraz were parallel and showed no significant shift (n=13), 
(Figure 10.3). 
Prazosin, at 10-7M (n=S) and 10- 6M (n=2) concentrations, inhibited the 
phenylephrine responses . The lower concentration produced a parallel 3.45 
fold shift of the dose response curve to the right while the higher 
concentration depressed phenylephrine responses markedly (Figure 10.3). 
Yohimbine had a varied effect on the phenylephrine responses as tabulated 
below: 
Figure 10.3 Contraction of the vas deferens by increasing concentrations 
of phenylephrine C••t----••) (control). 
Upper panel shows the effects of amitraz C•----11) on 
phenylephrine responses (n=13). 
Middle panel shows the antagonism of phenylephrine responses 
by prazosin 10- 7M C•----■, n=S) and 10- 6M (.,._·--.&., n=2). 
Lower panel shows the effects of yohimbine on 
phenylephrine responses. 
(0------0) Yohimbine 10- 7M (n=6) 
(._·--•) Yohimbine 10- 6M (n=8) 
(Ill-- -II) Yohimbine Sx10- 6M (n=4) 
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'Effect on Phenylephrine 
Dose Response Curve 
Parallel. No significant shift. 
Parallel. Significant shift 
(1.83 fold) 
Not Parallel. Significant shift 
(2.24 fold) 
This study has shown that arnitraz reduced the height of electrically-
induced twitches in the rat isolated vas deferens. This technique was 
similar to that described by Doxey et al (1977) and Drew (1977) for studying 
the actions of a-adrenoceptor agonists, particularly those compounds that have 
a predominant action on the presynaptic receptor. 
It has been pointed out by Doxey et al (1977) and Doxey and Roach (1980) that 
there are mechanisms of reducing twitch height of the isolated vas deferens 
other than stimulating presynaptic a-adrenoceptors. The possibility of 
arnitraz antagonising the_actions of noradrenaline, as a transmitter, was 
eliminated when it was shown that phenylephrine responses were not affected 
by the forrnamidine. · Yohimbine, a potent antagonist at the presynaptic 
a2-adrenoceptor (Doxey et al, 1977) produced a parallel shift to the right of 
the amitraz dose response curve whereas prazosin, which usually acts as an 
antagonist at the postsynaptica 1-adrenoceptor (Doxey et al, 1977) had no 
effect. A direct effect of the antagonist on the smooth muscle of the tissue 
was eliminated when twitch heights remained constant. In accordance with the 
points raised by Drew (1977), Doxey et al (1977) and Doxey and Roach (1980) it 
can be concluded that arnitraz is acting at the presynaptic a-adrenoceptor. 
As discussed in Chapter 9, arnitraz has been shown not to antagonise the actions 
of noradrenaline, a property not shared by another a2-adrenoceptor agonist, 
clonidine. This absence of an inhibitory action at the postsynaptic 
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a-adrenoceptor is supported by results from the present study whereby amitraz
had no effect on the phenylephrine responses. 
The effects of the antagonists, at the same concentrations used against 
amitraz, were assessed against phenylephrine, a potent postsynaptic 
a-adrenoceptor agonist (Weiner, 1980). Prazosin had no effect on the actions
of amitraz but significantly reduced phenylephrine responses. Results from 
the present study using isolated vas deferens preparations have thus 
indicated that amitraz lacked a1-adrenoceptor agonist activity. - Yohimbine, 
on the other hand, significantly shifted the amitraz dose response curve to 
the right but had a much reduced effect on the phenylephrine responses. These 
results provide extra support for an a2-adrenoceptor action of amitraz. 
The pA 2 value for yohimbine against amitraz on the vas deferens was 7.53 and 
this compares favourably to reports for the same antagonist against other 
agonists using similar preparations: 
Agonist pA 2 Vas Deferens Reference 
Preparation 
Amitraz 7.53 rat Present study. 
Detomidine 8.0 mouse Virtanen and Nyman, 
Clonidine 8.2 rat Doxey et al, 1977. 
Clonidine 7.4 rat Drew, 1977. 
The pA 2 value for yohimbine/amitraz indicates that it has a high 
specificity for a2-adrenoceptors, in this tissue. 
1985. 
Drew (1977) showed that 1.76x10
- 9M clonidine and 6.9x10
- 9M xylazine, in
separate experiments, reduced the twitch response in rat isolated vas deferens
by 50%. In comparison, the present study showed that 4x10
- 7M amitraz produced
a similar effect suggesting that it is less potent than the other two
compounds. Hsu and Kakuk (1984) also described the same order of potency for
these three a2-adrenoceptor agonists. Hsu and Kakuk (1984) studied the
quantities of compounds that produced the same degree of bradycardia and
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mydriasis in rats. 
Detomidine is a new sedative analgesic recently released for veterinary use 
and was shown to be more potent than clonidine or xylazine. This comparison 
was made using direct a2-adrenoceptor binding techniques in rat brain 
membranes (Virtanen and Nyman, 1985). 
Evidence from the present study has confirmed that amitraz is an 
a2-adrenoceptor agonist. Initially, reduced responses to DMPP �ere 
attributed to a presynaptic action (Chapter 5) and then the antagonism by 
yohimbine of both central and peripheral cardiovascular actions of amitraz 
(Chapters 6, 8 and 9) were discovered. Despite the predominantly 
a2-adrenoceptor action of amitraz it has been shown in earlier investigations 
to have a weak action at the a1-receptor subtype, however, this effect was not 




This study of the pharmacology of the formamidine, amitraz, has shown it to 
have -both peripheral and central actions in stimulating a-adrenoceptors. 
Research into a-adrenergic receptor function has been extensive in recent 
years and an indication of this is given by a selection of articles that have 
appeared reviewing knowledge of the central and peripheral prejunctional and 
postjunctional a-adrenoceptors, particularly with regard to their role in 
cardiovascular function (Langer, 1981; Starke, 1981; Timmermans and Van 
Zwieten, 1981; Langer and Shepperson, 1982a, b; McGrath, 1982; Timmermans and 
Van Zwieten, 1982; McGrath, 1983; Johansson, 1984; Ruffolo, 1985). 
a-Adrenoceptors that regulate the cardiovascular system can be found in the
brain, heart and circulation. The a2-adrenoceptor appears to be an important 
receptor subtype that modulates heart rate and blood pressure centrally. 
The prejunctional a2-adrenoceptor is postulated to regulate the release of 
important neurotransmitters like noradrenaline, at peripheral and central 
neurones; acetylcholine, at central and preganglionic autonomic neurones and 
postganglionic parasympathetic nerve endings and 5-hydroxytryptamine, 
centrally. Peripherally, a mixed population of both a1- and a2-adrenoceptors 
is located postjunctionally in arteries and veins and constrict the 
vasculature when stimulated. The a 1-subtype is predominantly junctional in 
arteries, that is, in the adrenergic neuroeffector junction, and extra­
junctional in veins while the a2-subtype is predominantly extrajunctional and 
junctional in arteries and veins, respectively (Ruffolo, 1985). 
The a-adrenoceptor in the myocardium is of the postjunctional a 1-subtype 
which increases the force of contraction (Ruffolo, 1985) and cardiac 
acceleration (Flavahan and McGrath, 1981; McGrath, 1982). 
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Due to the wide distribution and varied eff_e�ts mediated by c1.-adrenoceptors, 
they are characterised and defined by _relative affinities of agonist and 
antagonist drugs for them (Langer, 1981; Ruffolo, 1985). In the present 
study, actions of amitraz on adrenoceptors were determined by studying 
responses in the presence of cardiovascular agonists and antagonists, 
initially in the anaesthetised dog and then using rat vas deferens in vitro. 
The first indication that a-adrenoceptors were mediators of amitraz responses 
came from the antagonism of amitraz by phentolamine and the reduction by 
amitraz of responses.to DMPP. The latter effect was explained by an action 
of the prejunctional a2-adrenoceptor. Subsequently, the use of specific 
antagonists, either centrally or peripherally, confirmed these findings, 
however, some action at the a1-subtype was also found. Final confirmation of 
the a2-adrenoceptor agonist properties of amitraz was made using rat vas 
deferens in vitro, although a1-adrenoceptor activity was not apparent in 
this preparation. 
The central actions of amitraz lower blood pressure and heart rate while its 
peripheral effects increase the blood pressure and cause a transient reflex 
bradycardia. Elevated blood pressures persisted after 1, 2 and 5 mg kg-l of
amitraz IV suggesting that, at these doses, the peripheral actions pre­
dominated over the central effect. 
Amitraz had a contrasting and dose related effect on the baroreceptor-heart 
rate reflexes. -1 Enhancement was seen afte-r doses of 75 and 275 µg kg IV.
This effect was attributed to a predominant a2-adrenoceptor action on 
autonomic neuroeffectors and facilitation of baroreceptor afferent inputs to 
central sympathetic and vagal neurones in a similar way to that seen with 
clonidine (Korner et al, 1974a). Inhibition of the baroreceptor-heart rate 
reflexes may result from a1-adrenoceptor stimulation when doses of amitraz 
-1 of 0.5 mg kg and higher were given. Since this study on the baroreflexes,
an a1-adrenoceptor agonist action has been confirmed which supports the 
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explanation for the inhibition of reflexes after high doses. Apart from the 
predominantly central actions of amitraz on cardiovascular reflexes, some 
peripheral effects of the compound may modulate efferent impulses to effector 
cells. Modulation of impulse transmission to the heart may occur followin� 
stimulation of prejunctional a2-adrenoceptors and a possible antimuscarinic 
effect was demonstrated in Chapter 5. 
In the light of evidence for an a2-adrenoceptor agonist action of amitraz, its 
overall effects resemble those of other a2-agonists such as clonidine, xylazine, 
trarnazoline, guanfacine, guanabenz, azepexole, oxyrnetazoline, naphazoline and 
other derivatives. All of these compounds are pressor agents when given 
systemically but a centrally mediated hypotensive action frequently follows. 
Oxyrnetazoline, naphazoline and a clonidine derivative, St 66, differ in that 
there is no hypotensive phase following intravenous administration (Kobinger, 
1978). Bradycardia also accompanies the hypotension with those drugs that have 
a biphasic blood pressure response (Kobinger, 1978). 
A very recent article, only the title of which has been sighted, indicates 
that amitraz produces bradycardia in dogs, an effect antagonised by yohimbine 
(Hsu and McNeel, 1985). A similar effect was seen in the present study. 
Although the drugs mentioned above are predominantly a2-adrenoceptor agonists, 
weak a1-adrenoceptor agonist actions have also been reported. A summary of 
comparative potencies at both receptors is given by Langer (1981), Timmermans 
and Van Zwieten (1982) and Ruffolo (1984). In common with these drugs arnitraz 
has been shown to activate both receptor types. However, affinities of this 
compound for both receptor subtypes cannot be assessed fully from the present 
data and, furthermore, comparisons between the potency of arnitraz and other 
a2-adrenoceptor agonists was not carried out directly. Hsu and Kakuk (1984) 
did make a comparison from drug-induced bradycardia .and mydriasis in the rat 
and showed that arnitraz was a weaker a2-adrenoceptor agonist than 
clbnidine or xylazine. A comparison between amitraz and other drugs with 
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similar affinity for the a2-adrenoceptor awaits further investigation. 
Future studies could also make use of recently discovered and more specific 
a2-adrenoceptor antagonists such as rauwolscine, idazoxan (RX 781094) 
(Ruffolo, 1984) and selected benzoquinolizines (Wy 2S309, Wy 26392 and 
Wy 26703) (Paciorek et al, 1984). 
Molecular Structure 
Figure 11.1 compares the molecular structure of amitraz with other drugs that 
have similar properties. Many a2-adrenoceptor agonists have an amidine 
moiety (Figure 11.1) where X can be atoms of C, N, 0 or S. Oxymetazoline 
and naphazoline differ slightly in that the left hand N atom of the amidine 
moiety is substituted for a C atom (Kobinger, 1978). Although the amitraz 
molecule does not have the amidine moiety it does share the -N=C-N­
configuration with clonidine and xylazine. 
Differences in molecular structure have been suggested as being important in 
determining whether central or peripheral a2-adrenoceptors are activated. A 
-N= bridge between phenyl and imidazoline moieties was considered important
for a central action, while a -C- bridge favoured peripheral receptor action 
(Struyker-Boudier et al, 1974b; Struyker-Boudier et al, 1975). Oxymetazoline 
and naphazoline show only central depression of cardiovascular function after 
intracisternal injection (Kobinger and Pichler, 1976). 
Amitraz Metabolites 
The first metabolite of amitraz, BTS 27271, which is formed by cleavage of 
the parent molecule, is about four times as toxic to animals as amitraz. 
Further metabolism destroys the formamidine nucleus and the potential to 
produce toxic signs (Seawright, 1982). The liver has been shown to be the 
major organ where amitraz is metabolised (Knowles and Benezet, 1981), however, 
high levels of BTS 27271 are produced in acid environments, particularly the 
stomach following amitraz ingestion (Seawright, 1982). 

























In these studies technical grade amitraz, that was supplied, was injected 
into dogs and the responses were measured. While it was considered that all 
responses resulted from the actions of amitraz, it should be remembered that 
metabolism of the compound continued during the experiment and the metabolite, 
BTS 27271, may also have contributed to the cardiovascular changes. It has 
been shown that BTS 27271 is an a-adrenoceptor agonist, similar to the parent 
compound (Robinson, 1979). 
The Effects of Amitraz on the Respiratory System 
Much has been written about the actions of a-adrenoceptor agonists on the 
cardiovascular system but information about the effects of these drugs on the 
respiratory system is very limited. The present studies have concentrated on 
the actions of amitraz on the cardiovascular system and restricted the 
respiratory actions to changes in tidal volume, respiratory rate and 
respiratory minute volume. Amitraz may act either directly or indirectly, by 
way of its monoamine oxidase inhibiting properties or by altering neuro­
transmitter concentrations in the brain to depress respiratory function 
(Chapter 3). A central action on the respiratory system is highly likely as 
other evidence indicates that amitraz penetrates the central nervous system. 
a2-Adrenoceptors have been reported in high concentrations in the nucleus of
the tractus solitarius in the medulla (Kirchheim, 1976; Young and Kuhar, 1979; 
Probst et al, 1985). Stimulation of these receptors inhibited cardiovascular 
reflexes and lowered blood pressure. In addition, the locus coeruleus in the 
pons has h1gh concentrations of this receptor (Young and Kuhar, 1979; 
Probst et al, 1985). Cells within the nucleus of the tractus solitarius are 
also thought to regulate the frequency of the respiratory cycle, although there 
is still doubt about this (Mueller et al, 1982). Furthermore, the locus 
coeruleus has cells containing 5-hydroxytryptamine and noradrenaline which 
are regarded as being important for respiratory function (Mueller et al, 
1982). 
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In view of the fact that amitraz is an a2-adrenoceptor agonist and these 
receptors lie in close proximity to cells which regulate respiratory function, 
it is possible that this receptor may have a role in the control of 
respiration. 
a2-Adrenoceptor Distribution and the Effects of Amitraz 
The present studies have investigated the effects of amitraz on the 
adrenoceptors of the cardiovascular system. 
Rats were shown to be sedated after either intracerebroventricular injections 
with clonidine, xylazine and naphazoline or intraperitoneal injections with 
clonidine (Drew, 1978) while mice and chickens showed a similar effect 
following xylazine (Hsu, 1981). These effects were antagonised by 
a2-adrenoceptor antagonists suggesting that the response was mediated by 
this receptor. Observations made during experiments reported in this thesis 
support these findings. The level of anaesthesia appeared to deepen a few 
-1
minutes after IV amitraz injections of 1, 2 and 5 mg kg . As well, animals
that showed eyelid closure in response to corneal touch before amitraz lost
this reflex soon after injection.
These observations indicating possible sedative effects of amitraz in dogs 
are inconclusive, however, they are consistent with sedation occasionally 
described in dogs and calves that have been washed in the formamidine 
(Chapter 1). 
Acetlycholine release from Auerbach's plexus in intestinal longitudinal 
muscle is inhibited by stimulation of presynaptic a2-adrenoceptors (Vizi, 
1979). Furthermore, a-methylnoradrenaline, adrenaline, clonidine and 
xylazine were shown to be more potent than noradrenaline in antagonising 
the release of acetylcholine from Auerbach 1 s plexus. Twitch responses in 
guinea-pig isolated ileum following cholinergic nerve stimulation were 
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reduced by clonidine, xylazine and oxymetazoline and these effects were 
reversed by piperoxan (Drew, 1978). Further evidence of a2-adrenoceptor 
inhibition of contractions in the intestine were shown when clonidine 
reduced small intestinal transit time in the rat (Ruwart et al, 1980) and 
xylazine delayed transit in the small intestine of mice (Hsu, 1982). These 
responses were reversed by a2-adrenoceptor antagonists, either yohimbine or 
phentolamine in rats and yohimbine, piperoxan or tolazoline in mice. 
Atropine did not alter the effects of either clonidine or xylazine in these 
experiments. In addition, the title of a recent article indicated that 
amitraz reduced transit time in the gastrointestinal tract of dogs, an 
effect also antagonised by yohimbine (Hsu and McNeel, 1985). 
This evidence for the a2-adrenoceptor in the intestine and the actions of 
amitraz on this receptor offers a possible explanation for the reduced or 
absent intestinal sounds and the abnormal electrical activity of horse 
intestine in vitro in animals washed with amitraz (Roberts and Seawright, 
1979; Sellars et al, 1982). Pass and Seawright (1982) have also reported 
that the H1 histamine-stimulated contractions in guinea-pig ilewn sections 
are reduced by amitraz. However, the present studies with dogs have shown 
that amitraz has no significant effect on the blood pressure responses to 
histamine. 
The antihistaminic and the a-adrenergic effects of amitraz are two possible 
reasons for slowing of gastrointestinal motility in horses. This action has 
also been shown in mice where the amitraz actions were reversed by yohimbine, 
piperoxan and tolazoline (Hsu and Lu, 1984). Finally, yohimbine (0.2 mg kg-l 
given into the ileo-colic artery) prevented the pressure changes in the 
large colon of ponies seen after amitraz (0.1 mg kg-l intra-arterially) 
inferring that a2-adrenoceptors are stimulated (Sellers et al, 1985). 
Drew et al (1979) reported that the a-adrenoceptor agonists, clonidine, 
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xylazine, naphazoline, methoxamine and phenylephrine ,. lowered body 
temperature in rats. Although no conclusions of the receptor type 
responsible for mediating hypothermia were made, it was interesting to note 
that a side effect seen in dogs washed with arnitraz was hypothermia 
(Seawright, 1982). 
a2-Adrenoceptors have also been reported in adipose tissue, pancreatic 
islets and platelets (Langer, 1981; Timmermans and van Zwieten, 1982) but 
at this stage there is no evidence to indicate what affects amitraz has at 
these sites. It is not known if amitraz has any analgesic actions but both 
xylazine and clonidine have an antinociceptive action in rats and mice and 
these effects are reversed by yohimbine (Schmitt et al, 1974a,b). The 
actions of amitraz on a2-adrenoceptors other than those associated with the 
cardiovascular system require investigation. 
Finally, this study has revealed much information about the pharmacology of 
amitraz, particularly as it applies to the cardiovascular and respiratory 
systems in the dog. Already most of the toxicological effects of the 
formarnidine, described in Chapter 1, can be explained by its action on 
a-adrenoceptors, particularly the a2-subtype. Now that some details of the
pharmacology of the formamidine are available, additional studies into its 
toxicological effects can be considered. Due to its depressant effects on 
the respiratory system, one likely cause of death in dogs given high doses 
of arnitraz (about 5 to 10 mg kg-l IV and higher) is respiratory failure,
however, this point is made following results from anaesthetised animals 
given intravenous injections of the formamidine. It can be expected that 
circulating blood levels of amitraz from transcutaneous or oral intake in 
dogs washed in the substance will rise less rapidly than when given intra­
venously, but the potential for danger exists. Attempts could be made to 
reverse severe arnitraz-induced side-effects by administering a2-adrenoceptor 
antagonists such as yohimbine, now available as an antagonist for the 
sedative/analgesic xylazine, also an a2-adrenoceptor agonist. 
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